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5TIIVISTELMÄ
Tausta: Ylipainosta on tullut vakava kansanterveydellinen ongelma länsimaisessa 
nyky-yhteiskunnassa. Lihavuus ja vähän liikuntaa sisältävä elämäntapa ovat kiinteäs-
ti yhteydessä metaboliseen oireyhtymään, sen osakomponentteihin ja eriasteisiin 
glukoosiaineenvaihdunnan häiriöihin. Nämä ovat hyvin tunnettuja sydän- ja veri-
suonitautien riskitekijöitä, ja ne on liitetty myös varhaisiin valtimotautimuutoksiin. 
Näiden riskitekijöiden itsenäinen merkitys valtimotaudin kehittymisessä on kuiten-
kin vielä epäselvä. Tiedetään, että tyypin 2 diabetes lisää sydän- ja verisuonitauti-
en riskiä naisilla miehiä enemmän. Tämän vuoksi on luontevaa esittää hypoteesi, 
että myös lievempien glukoosiaineenvaihdunnan häiriöiden ja metabolisen oireyh-
tymän yhteydet varhaiseen valtimotautiin voisivat olla samalla tavalla sukupuoli-
riippuvaisia. Tutkimustieto on kuitenkin tältä osin vähäistä.
Perintötekijöiden vaikutus sydän- ja verisuonitautiriskiin on toinen runsaasti huo-
miota viime vuosina saanut osa-alue alan tutkimuksessa. Suuret koko genomin katta-
vat analyysit ovat paljastaneet useita geenipolymorfi smeja, jotka assosioituvat sydän- 
ja verisuonitautiriskiin. Useissa eri tutkimuksissa on todettu kromosomissa 9p21.3 
sijaitsevan geneettisen lokuksen vaikuttavan sepelvaltimotaudin riskiin. Vahvimmin 
sepelvaltimotautiin tässä kromosomissa on assosioitunut rs1333049-niminen geeni-
variantti. IL6−174 G>C -nimellä tunnettua polymorfi smia, joka sijaitsee interleu-
kiini-6 -geenin välittömässä läheisyydessä kromosomi 7:ssä, on tutkittu lukuisissa 
kandidaattigeenitutkimuksissa. Tämä polymorfi smi on yhdistetty mm. sydäninfark-
tin riskiin ja useisiin sydän- ja verisuonisairauksien riskitekijöihin, mutta aiemmat 
tulokset ovat ristiriitaisia. Interleukiini-6 on tärkeä välittäjäaine tulehdusprosessissa, 
jonka ajatellaan nykyisin olevan metabolisen oireyhtymän, tyypin 2 diabeteksen ja 
myös itse valtimotautiprosessin taustalla. Näiden kahden yllä mainitun genotyypin 
rooli varhaisessa valtimotaudissa on epäselvä.
Tavoitteet: Tässä tutkimuksessa tutkittiin metabolisen oireyhtymän ja eriasteisten 
glukoosiaineenvaihdunnan häiriöiden itsenäisiä yhteyksiä varhaisiin valtimotau-
timuutoksiin. Erityisesti selvitettiin mahdollisia sukupuolieroja näissä yhteyksis-
sä. Toinen tutkimustavoite oli selvittää joidenkin potentiaalisten geenimuuttujien 
yhteyksiä sydän- ja verisuonitautien riskitekijöihin ja varhaisiin valtimotautimuu-
toksiin. Tutkimuskohteiksi valittujen geenien valinnassa käytettiin kahta lähesty-
mistapaa: tarkemman arvioinnin kohteeksi valittiin polymorfi smi, joka assosioituu 
koko genomin kattavissa tutkimuksissa kaikkein vahvimmin sepelvaltimotautiin, ja 
toisaalta polymorfi smi, joka assosioituu kandidaattigeenitutkimuksissa vahvasti sy-
6dän- ja verisuonitautien riskitekijöihin ja sepelvaltimotautiin. Polymorfi smi kromo-
somissa 9p21.3 (rs1333049) ja IL6−174 G>C -genotyyppi edustavat näitä kahta 
lähestymistapaa tässä tutkimuksessa.
Menetelmät: Terveys 2000 -tutkimus on suuri suomalainen terveystutkimus (toteu-
tettiin vuosina 2000–2001), jonka alaotos muodosti tämän tutkimuksen pääasial-
lisen tutkimuspopulaation (otoksen koko 1353). Tässä populaatiossa tutkimushen-
kilöt olivat yli 45-vuotiaita (ikäjakauma 46–76 vuotta). Lasten sepelvaltimotaudin 
riskitekijät (LASERI) -tutkimus on monikeskustutkimus, missä selvitetään valtimo-
taudin riskitekijöitä lapsilla ja nuorilla aikuisilla. Tämän tutkimuksen populaatio-
ta käytettiin toisena kohorttina selvitettäessä rs1333049-polymorfi smin yhteyttä 
varhaiseen valtimotautiin. LASERI-aineistossa tutkittavat olivat 24–39 vuotiai-
ta (otoksen koko 2251). Molemmissa populaatioissa tutkittaville tehtiin fyysinen 
tutkimus ja lukuisia mittauksia, joita käytetään varhaisten valtimotautimuutos-
ten arvioinnissa. Ultraäänellä mitattuja kaulavaltimon intima-median paksuutta, 
kaulavaltimon elastisuutta ja olkavarsivaltimon endoteelitoimintaa sekä impe-
danssikardiografi alla mitattua pulssiaallon etenemisnopeutta käytettiin tässä tut-
kimuksessa. Molemmissa populaatioissa sairaushistoria, lääkitykset ja elämänta-
paan liittyvät tekijät selvitettiin haastattelututkimuksella, ja lisäksi tehtiin edustava 
joukko verikoemäärityksiä mukaan lukien genotyypitykset kiinnostuksen kohteena 
olevien geenipolymorfi smien osalta. Sokeritasapaino arvioitiin esitietojen ja soke-
rirasituskokeen perusteella, ja luokittelussa käytettiin ADA:n (American Diabetes 
Association) kriteerejä. Metabolinen oireyhtymä luokiteltiin käyttämällä NCEP:n 
(National Cholesterol Education Program) ja IDF:n (International Diabetes Fede-
ration) luokituksia. Pääosin analyyseissä käytettiin NCEP-luokitusta.
Tulokset: Metabolinen oireyhtymä oli itsenäisesti, muista sydän- ja verisuonitauti-
en riskitekijöistä riippumatta, yhteydessä kohonneeseen pulssiaallon etenemisno-
peuteen ja kaulavaltimon lisääntyneeseen intima-median paksuuteen molemmilla 
sukupuolilla. Tämä yhteys vaikutti kuitenkin olevan voimakkaampi naisilla erityi-
sesti kaulavaltimon seinämäpaksuuden osalta. Kun metabolisen oireyhtymän osa-
komponentit otettiin huomioon, yhteys kaulavaltimon intima-median paksuuden 
ja metabolisen oireyhtymän välillä säilyi merkitsevänä naisilla mutta ei miehillä. 
Miehillä perinteiset sydän- ja verisuonitautien riskitekijät olivat vahvasti yhteydes-
sä kaulavaltimon seinämäpaksuuteen, eikä metabolinen oireyhtymä vaikuttanut 
antavan oleellisesti lisäinformaatiota kokonaisriskistä. Naisilla vastaavasti metabo-
liseen oireyhtymään liittyi lisäriski kaulavaltimon intima-median paksuuden suu-
rentumiselle erityisesti silloin, kun perinteisten riskitekijöiden perusteella määritet-
ty riski oli suhteellisen matala.
Kaulavaltimon intima-median paksuus lisääntyi ja kaulavaltimon elastisuus vä-
hentyi molemmilla sukupuolilla trendinomaisesti glukoosiaineenvaihdunnan häiriön 
7vaikeutuessa. Tämä trendi heikentyi merkittävästi, kun muut sydän- ja verisuo-
nitautien riskitekijät otettiin huomioon. Glukoositoleranssin yhteys kaulavaltimon 
elastisuuteen säilyi merkitsevänä vain naisilla muiden riskitekijöiden huomioinnin 
jälkeen. Kaulavaltimon intima-median paksuuden ja glukoositoleranssin yhteys ei 
ollut merkitsevä kummallakaan sukupuolella muista riskitekijöistä riippumattomana.
Yhden nukleotidin polymorfi smi kromosomissa 9p21.3 (rs1333049) ei ollut yh-
teydessä kaulavaltimon intima-median paksuuteen kummassakaan tutkimuskohor-
tissa eikä olkavarsivaltimon endoteelitoimintaan nuorilla aikuisilla.
IL6−174 G>C -genotyyppi ei ollut yhteydessä kaulavaltimon intima-median 
paksuuteen. Se assosioitui kuitenkin kokonaiskolesteroli-, LDL-kolesteroli- ja paas-
tosokeritasoihin sekä painoindeksiin ja systoliseen verenpaineeseen miehillä.
Johtopäätökset: Metabolinen oireyhtymä on yhteydessä varhaiseen valtimotautiin 
molemmilla sukupuolilla. Tämä yhteys vaikuttaa olevan voimakkaampi naisilla 
erityisesti silloin, kun sydän- ja verisuonitautiriski perinteisten riskitekijöiden pe-
rusteella arvioituna on matala. Varhaiset valtimotautimuutokset lisääntyvät glu-
koosiaineenvaihdunnan häiriön vaikeusasteen kasvaessa sekä miehillä että naisilla. 
Tämä yhteys on ainakin osittain riippuvainen muista riskitekijöistä, ja se vaikuttaa 
naisilla voimakkaammalta kuin miehillä. Yhden nukleotidin polymorfi smi kromo-
somissa 9p21.3 (rs1333049) ei ole yhteydessä varhaisiin valtimotautimuutoksiin, 
mikä viittaa siihen, että sen vaikutusmekanismi on jokin muu kuin suoraan ateros-
kleroosimuutosten edistäminen valtimoiden seinämissä. IL6−174 G>C -genotyy-
pin vaikutus sydän- ja verisuonitautien riskitekijöihin saattaa olla erilainen miehillä 
ja naisilla. Tämä voi osittain selittää aiemmat ristiriitaiset tulokset koskien tämän 
genotyypin yhteyttä sydän- ja verisuonitautiriskiin. IL6−174 G>C -genotyypin 
vaikutus voi olla myös riippuvainen kehon rasvapitoisuudesta ja toisaalta elimistön 
metabolisesta ja infl ammatorisesta tilasta. Väestötasolla tällä polymorfi smilla näyt-
tää olevan merkitystä geneettisenä riskitekijänä, mutta lisätutkimuksia tarvitaan 
sen vaikutuksen selvittämiseksi erilaisissa populaatioissa.
Monet tämän tutkimuksen tuloksista korostavat sitä tosiseikkaa, että sydän- ja 
verisuonitautien kokonaisriskiä arvioitaessa on tärkeää huomioida yksilön suku-
puoli kuten myös muut yksilölliset tekijät. Monet tunnetuista riskitekijöistä saat-
tavat vaikuttaa eri tavoin riippuen näistä tekijöistä. Tällainen lähestymistapa on 
tulevaisuudessa erittäin tärkeä myös sydän- ja verisuonitautien tieteellisessä tutki-
muksessa. Jopa monien perinteisten riskitekijöiden vaikutuksia voidaan joutua ar-
vioimaan uudelleen tietyissä populaatioissa.
 

9ABSTRACT
Background: Overweight has become a major health issue in modern Western 
society. Obesity and a sedentary lifestyle are closely related to metabolic syndrome, 
its components and different stages of  glucose metabolism impairment. These are 
well-known cardiovascular risk factors and they have also been related to early 
stages of  atherosclerosis. The independent roles of  these particular risk factors in 
the development of  atherosclerosis are not, however, fully understood. It is known 
that type 2 diabetes has a more pronounced effect on cardiovascular risk in women 
than in men. Therefore, it is reasonable to hypothesize that milder impairment in 
glucose metabolism and metabolic syndrome might also have similar sex-related 
differences in their relationships to early atherosclerosis. This has not been studied 
extensively
Genetics is another field in cardiovascular research that has gained a 
tremendous amount of  attention in recent years. Large genome-wide association 
studies have revealed several gene polymorphisms relating to cardiovascular risk. 
Several different studies have identifi ed a genetic locus on chromosome 9p21.3 
that has an infl uence on the risk of  coronary heart disease. The single nucleotide 
polymorphism on chromosome 9p21.3 showing the strongest association with 
coronary heart disease is known as rs1333049. A polymorphism located in the 
promoter region of  infl ammatory cytokine interleukin-6, known as IL6−174 G>C, 
has been studied in a number of  candidate gene studies. It has been associated 
with the incidence of  cardiovascular events, such as myocardial infarction, and 
several risk factors for cardiovascular disease. Interleukin-6 is closely related to 
infl ammation, which is believed to be the driving force behind metabolic syndrome, 
type 2 diabetes and the atherosclerosis process in general. Overall, the results 
regarding IL6−174 G>C genotype and its associations with cardiovascular risk 
have been very controversial. The role of  these two above-mentioned genotypes in 
the early stages of  atherosclerosis is not clear.
Aims: In the present study, the independent associations of  metabolic syndrome 
and different stages of  glucose intolerance with the markers of  early atherosclerosis 
were studied. Specifi cally, possible sex-related differences in these associations 
were investigated. Another study aim was to evaluate the associations of  some 
contemporary candidate genes with cardiovascular risk factors and the markers 
of  early atherosclerosis. Two approaches were used in the selection of  the genetic 
variants of  interest: the polymorphism showing the strongest association with 
coronary heart disease in genome-wide association studies and a polymorphism 
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strongly associating with cardiovascular risk factors and coronary heart disease in 
candidate gene studies were selected to be studied in detail. A single nucleotide 
polymorphism on chromosome 9p21.3 (rs1333049) and IL6-174 G>C genotype 
represent these two approaches in the present study. 
Subjects and Methods: A subpopulation of  the Health 2000 Survey, which is 
a large Finnish cross-sectional health examination survey carried out in 2000–
2001, formed the main population of  the current study (sample size 1,353). The 
subjects were over 45 years old (age range 46–76 years). The population of  the 
Cardiovascular Risk in Young Finns Study, a multi-centre study of  atherosclerotic 
risk factors in children and young adults, was used as a second cohort in the 
investigation regarding the association of  the rs1333049 polymorphism and early 
atherosclerosis. Subjects in the Young Finns Study were 24–39 years old (sample 
size 2,251). In both cohorts subjects underwent a physical examination and a 
variety of  measurements used as markers for early atherosclerosis. Carotid artery 
intima-media thickness, carotid artery elasticity and brachial artery fl ow-mediated 
dilatation measured by ultrasound as well as pulse wave velocity measured by 
whole-body impedance cardiography were used in this study. Medical history, 
medication and lifestyle-related factors were evaluated with questionnaires, and a 
comprehensive selection of  blood sample measurements, including genotyping for 
the genetic variants of  interest, was carried out for both cohorts. Glucose tolerance 
status was evaluated using medical history and the oral glucose tolerance test, 
and it was defi ned using the American Diabetes Association criteria. Metabolic 
syndrome was defi ned using the National Cholesterol Education Program criteria 
(used in most of  the calculations) and the International Diabetes Federation 
criteria.  
Results: Metabolic syndrome was associated with increased pulse wave velocity and 
carotid artery intima-media thickness independently of  other cardiovascular risk 
factors in both sexes. This association, however, appeared to be stronger in women, 
which was seen especially regarding carotid artery intima-media thickness. After 
the components of  metabolic syndrome were taken into account, the association 
between metabolic syndome and carotid artery intima-media thickness remained 
signifi cant in women but not in men. In men, traditional cardiovascular risk 
factors were strongly associated with carotid artery intima-media thickness, and 
metabolic syndrome seemed to offer little additional information. In women, 
however, metabolic syndrome was associated with an additional risk of  increased 
intima-media thickness, especially when the risk according to the traditional risk 
factors was relatively low.
There was a trend of  increasing carotid artery intima-media thickness and 
decreasing carotid artery elasticity according to the worsening of  glucose tolerance 
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in both sexes. This trend was weakened markedly after the adjustment for other 
cardiovascular risk factors. The association of  glucose tolerance status and carotid 
artery elasticity remained signifi cant in women but not in men after the other risk 
factors were taken into account. The association of  glucose tolerance status and 
carotid artery intima-media thickness was not signifi cant in either sex after these 
adjustments. 
The rs1333049 polymorphism was not associated with carotid artery intima-
media thickness in either of  the study cohorts, and it was not associated with 
brachial artery fl ow-mediated dilatation in the Young Finns Study cohort either. 
IL6−174 G>C genotype was not associated with carotid artery intima-media 
thickness. It was, however, associated with the levels of  total cholesterol, LDL 
cholesterol and fasting plasma glucose as well as with body mass index and systolic 
blood pressure in men.
Conclusions: Metabolic syndrome is associated with early atherosclerosis in both 
sexes. This association seems to be stronger in women, especially if  the risk for 
cardiovascular disease defi ned by traditional risk factors is low. There is a trend of  
increasing early atherosclerosis according to the worsening of  the glucose tolerance 
in both sexes. This association is at least partly mediated by other risk factors and 
may be stronger in women than in men. The rs1333049 polymorphism is not 
related to the markers of  early atherosclerosis, suggesting that its effect on the 
risk of  coronary heart disease might be mediated by different mechanism than 
simply promoting atherosclerotic changes in the vascular wall. The association 
of  IL6−174 G>C genotype with cardiovascular risk factors seems to be different 
in men and women. This may partly explain the previous controversial results 
regarding its effect on cardiovascular risk. The effect of  this genotype may also 
depend on factors such as body fat mass as well as the metabolic and infl ammatory 
state. At the population level, this polymorphism seems to have an impact as a 
genetic risk factor. However, future research is needed to evaluate its effect in 
different populations. 
Many of  the results of  the present study emphasize the fact that in the 
evaluation of  overall cardiovascular risk, it is important to take the subjects’ sex 
as well as other characteristics into account. Many of  the known risk factors may 
act differently depending on these characteristics. This kind of  approach will be 
extremely important in the future cardiovascular research as well. Some of  the 
traditional risk factors may even have to be re-evaluated in specifi c populations.

13
CONTENTS
TIIVISTELMÄ  5
ABSTRACT  9 
CONTENTS  13 
LIST OF ORIGINAL PUBLICATIONS  17
ABBREVIATIONS  19 
1 INTRODUCTION  21
2 REVIEW OF THE LITERATURE  23
2.1 Pathophysiology of  atherosclerosis ........................................................  23 
2.2 Markers of  early atherosclerosis ............................................................  25
 2.2.1 Endothelial function ...................................................................  25
 2.2.2 Arterial intima-media thickness ..................................................  25
 2.2.3 Arterial stiffness and elasticity ....................................................  26
2.3 Risk factors for atherosclerosis ..............................................................  27
 2.3.1 Lipid risk factors .........................................................................  27
  2.3.1.1 Low-density lipoprotein cholesterol ..............................  27
  2.3.1.2 High-density lipoprotein cholesterol .............................  28
  2.3.1.3 Triglycerides .................................................................  28
  2.3.1.4 Other lipid risk factors ..................................................  29
 2.3.2 Smoking ......................................................................................  29
 2.3.3 Hypertension ..............................................................................  30
 2.3.4 Diabetes, insulin resistance, and metabolic syndrome ...............  30
  2.3.4.1 Diabetes ........................................................................  30
  2.3.4.2 Insulin resistance and metabolic syndrome ..................  32
 2.3.5 Obesity  ......................................................................................  35
 2.3.6 Markers of  infl ammation ...........................................................  36
  2.3.6.1 High-sensitivity C-reactive protein ...............................  36
  2.3.6.2 Other markers of  infl ammation ...................................  37
 2.3.7 Genetic risk factors .....................................................................  38
  2.3.7.1 Genome-wide association approach: the coronary 
   heart disease risk variant on chromosome 9p21.3 
   (rs1333049) ...................................................................  39
  2.3.7.2 Candidate gene approach: IL6−174 G>C genotype ...  39
 2.3.8 Other risk factors ........................................................................  40
14
3 AIMS OF THE STUDY  43
4 SUBJECTS AND METHODS  45
4.1 Subjects..................................................................................................  45
 4.1.1 The Health 2000 Survey ............................................................  45
 4.1.2 The Cardiovascular Risk in Young Finns Study ........................  45
4.2 Methods .................................................................................................  47
 4.2.1 Physical examination and questionnaires ...................................  47
  4.2.1.1 The Health 2000 Survey ..............................................  47
  4.2.1.2 The Cardiovascular Risk in Young Finns Study...........  48
 4.2.2 Blood collection and analyses .....................................................  48
 4.2.3 Genotyping .................................................................................  49
 4.2.4 Metabolic syndrome, glucose tolerance, and Framingham risk    
  scoring ........................................................................................  49
 4.2.5 Ultrasound examinations ...........................................................  50
  4.2.5.1 The Health 2000 Survey ..............................................  50
  4.2.5.2 The Cardiovascular Risk in Young Finns Study...........  52
 4.2.6 Pulse wave velocity measurements .............................................  52
 4.2.7 Statistical methods ......................................................................  54
5 RESULTS  57
5.1 Characteristics of  the study populations ...............................................  57
5.2 Association of  glucose tolerance and early atherosclerosis 
 (original publication V) ..........................................................................  57
5.3 Association of  metabolic syndrome and early atherosclerosis 
 (original publications I and III)..............................................................  63
 5.3.1 Metabolic syndrome, its components, and carotid 
  intima-media thickness (original publication  III).......................  63
 5.3.2 Metabolic syndrome, its components, and arterial pulse wave 
  velocity (original publication I) ...................................................  69
5.4 Coronary heart disease-associated locus on chromosome 9p21.3 and 
 subclinical atherosclerosis (original publication II) ................................  75
5.5 Association of  IL6−174 G>C genotype with the risk factors and 
 markers of  early atherosclerosis (original publication IV) .....................  78
6 DISCUSSION  81
6.1 Study populations ..................................................................................  81
 6.1.1 The Health 2000 Survey ............................................................  81
 6.1.2 The Cardiovascular Risk in Young Finns Study ........................  81
6.2 Methodological considerations ..............................................................  82
 6.2.1 Ultrasound measurements ..........................................................  82
  6.2.1.1 Carotid artery intima-media thickness .........................  82
  6.2.1.2 Carotid artery elasticity ................................................  83
  6.2.1.3 Brachial fl ow-mediated dilatation .................................  84
15
 6.2.2 Pulse wave velocity measurement ...............................................  84
6.3 Glucose tolerance and early atherosclerosis ..........................................  84
6.4 Metabolic syndrome and early atherosclerosis ......................................  88
 6.4.1 Metabolic syndrome as an independent risk factor ....................  88
 6.4.2 Metabolic syndrome as a risk factor beyond the Framingham 
  risk score .....................................................................................  92
6.5 Coronary heart disease-associated locus on chromosome 9p21.3 and 
 early atherosclerosis ...............................................................................  93
6.6 Association of  IL6–174 G>C genotype with the risk factors and 
 markers of  early atherosclerosis ............................................................  95
 6.6.1 IL6-174 G>C genotype and the risk factors for atherosclerosis ...  96
 6.6.2 IL6-174 G>C genotype and the markers of  early atherosclerosis ..  97
 6.6.3 Clinical characteristics and the effects of  the IL6-174 G>C 
  genotype .....................................................................................  98
6.7 Clinical implications and future research needs ....................................  99
7 SUMMARY AND CONCLUSIONS  103
8 ACKNOWLEDGEMENTS  105
9 REFERENCES  107
10 ORIGINAL COMMUNICATIONS  129

17
LIST OF ORIGINAL PUBLICATIONS
This thesis is based on the following original publications:
I  Sipilä K, Koivistoinen T, Moilanen L, Nieminen T, Reunanen A, Jula 
A, Salomaa V, Kaaja R, Kööbi T, Kukkonen-Harjula K, Majahalme S, 
Kähönen M. Metabolic syndrome and arterial stiffness: the Health 2000 
Survey. Metabolism. 2007 Mar;56(3):320–6.
II Samani NJ, Raitakari OT, Sipilä K, Tobin MD, Schunkert H, Juonala M, 
Braund PS, Erdmann J, Viikari J, Moilanen L, Taittonen L, Jula A, Jokinen 
E, Laitinen T, Hutri-Kähönen N, Nieminen MS, Kesäniemi YA, Hall AS, 
Hulkkonen J, Kähönen M, Lehtimäki T. Coronary artery disease-associated 
locus on chromosome 9p21 and early markers of  atherosclerosis. Arterioscler. 
Thromb. Vasc. Biol. 2008 Sep;28(9):1679–83. Epub 2008 Jul 3.
III Sipilä K, Moilanen L, Nieminen T, Reunanen A, Jula A, Salomaa V, Kaaja 
R, Kukkonen-Harjula K, Lehtimäki T, Kesäniemi YA, Koivistoinen T, 
Nieminen MS, Tuomilehto J, Kähönen M. Metabolic syndrome and carotid 
intima media thickness in the Health 2000 Survey. Atherosclerosis. 2009 
May;204(1):276–81. Epub 2008 Sep 4.
IV Riikola A, Sipilä K, Kähönen M, Jula A, Nieminen MS, Moilanen 
L, Kesäniemi YA, Lehtimäki T, Hulkkonen J. Interleukin-6 promoter 
polymorphism and cardiovascular risk factors: the Health 2000 Survey. 
Atherosclerosis. 2009 Dec;207(2):466–70. Epub 2009 Jun 11.
V Sipilä K, Kähönen M, Salomaa V, Päivänsalo M, Karanko H, Varpula 
M, Jula A, Kaaja R, Kesäniemi YA, Reunanen A, Laakso M, Moilanen L. 
Carotid artery intima-media thickness and elasticity in relation to glucose 
tolerance. Submitted.
The final publication is available at http://www.springerlink.com/openurl.asp?
genre=article&id=doi:10.1007/s00592-011-0291-z. 

19
ABBREVIATIONS
AASI  ambulatory arterial stiffness index
ADA American Diabetes Association
ADC  arterial diameter change
AGE  advanced glycation end product
AHA American Heart Association 
AIx  augmentation index
apo  apolipoprotein
BMI body mass index
CAC  carotid artery compliance 
CAS carotid artery stiffness
CCA  common carotid artery 
CHD coronary heart disease
CIMT carotid artery intima-media thickness
CRP C-reactive protein
CVD cardiovascular disease
DAD  diastolic arterial diameter
DBP diastolic blood pressure
DM diabetes mellitus
EGIR  European Group for the Study of  Insulin Resistance
Ep Peterson’s elastic modulus
FFA free fatty acid
FMD  fl ow-mediated dilatation 
FRS  Framingham Risk Score 
HDL  high-density lipoprotein 
HDL-C  high-density lipoprotein cholesterol
hsCRP  high-sensitivity C-reactive protein
ICGWB whole-body impedance cardiography
IDF International Diabetes Federation 
IFG impaired fasting glucose
IL-6 interleukin-6
IMT intima-media thickness
IGT  impaired glucose tolerance 
LDL low-density lipoprotein 
LDL-C low-density lipoprotein cholesterol
MetS metabolic syndrome
NCEP  National Cholesterol Education Program 
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NGT  normal glucose tolerance
NHLBI  National Heart, Lung, and Blood Institute 
NO  nitric oxide
OGTT oral glucose tolerance test
PAI-1 plasminogen activator inhibitor-1 
PP  pulse pressure
PWV  pulse wave velocity
SAD  systolic arterial diameter
SBP systolic blood pressure
SI  beta stiffness index
SNP single nucleotide polymorphism 
T2DM  type 2 diabetes 
TNF-α  tumour necrosis factor alpha 
VLDL  very-low-density lipoprotein
WHO World Health Organization
YEM Young’s elastic modulus
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1  INTRODUCTION
A sedentary lifestyle and obesity have become an epidemic in modern Western 
society. Striking evidence suggests that even childhood obesity is a strong 
predictor for mortality (Franks et al. 2010). There is a clear relationship between 
atherosclerosis, cardiovascular disease (CVD) and obesity (Poirier et al. 2006). 
Abdominal obesity is strongly related to insulin resistance, type 2 diabetes (T2DM) 
and a cluster of  risk factors known as metabolic syndrome (MetS) (Eckel et al. 
2010). These are major mediators of  increased CVD risk in overweight subjects 
(Poirier et al. 2006). Atherosclerosis is now considered an infl ammatory disease, 
and insulin resistance and MetS have been shown to be proinfl ammatory states 
(Eckel et al. 2005). It is known that T2DM is a greater CVD risk factor in women 
than in men (Beckman et al. 2002), and it has been suggested that this would also 
be the case with MetS (Iglseder et al. 2005). The latter has not, however, been 
consistently proven. MetS predisposes to T2DM (Lorenzo et al. 2003), which is 
one of  the major CVD risk factors (Ridger and Libby 2008), as well as coronary 
heart disease (CHD) (Bonora et al. 2003) and mortality (Isomaa et al. 2001, Lakka 
et al. 2002, Malik et al. 2004). However, its independent role in the pathogenesis of  
atherosclerosis has raised controversy. It has been debated whether the syndrome 
as an entity offers additive information apart from its components and traditional 
CVD risk factors (Kahn et al. 2005).    
In addition to the modifi able risk factors, such as obesity, genetic factors play 
a key role in the pathogenesis of  atherosclerosis and CVD. It has been estimated 
that roughly 50% of  the CVD risk is based on inheritance (Zdravkovic et al. 2002). 
However, the genetic basis of  atherosclerosis has not been clearly characterized to 
date. Major genome-wide association studies have identifi ed several genetic loci 
associated with CHD. A common variant located on chromosome 9p21.3 is the 
one with the strongest association with CHD in these studies (Burton et al. 2007, 
Helgadottir et al. 2007, McPherson et al. 2007, Samani et al. 2007, Schunkert 
et al. 2008). However, the exact role of  this genetic locus in the disease process 
is not clear. Another approach in genetic studies investigating CVD risk is to 
study a gene associated with a known or suspected risk factor – i.e., a candidate 
gene study. As an infl ammatory disease, atherosclerosis has been associated with 
infl ammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-
6). Genes that are associated with the production of  such markers have been 
studied as possible risk factors for atherosclerosis. A single G>C base exchange 
polymorphism in the promoter region of  the IL-6 gene has been associated with 
IL-6 production (Fishman et al. 1998, Burzotta et al. 2001, Hulkkonen et al. 2001) 
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and atherosclerosis (Georges et al. 2001, Humphries et al. 2001, Chiappelli et al. 
2005), but the results have been inconsistent. Some studies have suggested that 
allele G is the risk allele (Fernandez-Real et al. 2000, Huth et al. 2006), while other 
studies have associated allele C with increased CVD risk (Georges et al. 2001, 
Humphries et al. 2001, Chiappelli et al. 2005). 
Atherosclerotic changes are usually present years or even decades before the 
onset of  the clinical disease (Enos et al. 1953, McNamara et al. 1971, Tuzcu et al. 
2001). Subclinical atherosclerotic lesions can be studied with several techniques. 
Arterial endothelial function is usually impaired very early in the disease process 
(Ross 1999) and it can be evaluated with ultrasound (Corretti et al. 2002). 
Thickening and stiffening of  the arterial walls is another typical feature of  early 
atherosclerosis (Pignoli et al. 1986). Wall structure and elasticity can be evaluated 
with ultrasonic methods (Pignoli et al. 1986), and arterial stiffness may also be 
estimated by measuring the movement of  the pulse wave along the arterial tree 
(Oliver and Webb 2003).
The specifi c aims of  this thesis were to study the independent associations of  
MetS and glucose intolerance with early atherosclerosis, in addition to possible 
sex differences in these associations. Another major study aim was to evaluate the 
associations of  contemporary candidate genes with cardiovascular risk factors and 
early atherosclerosis. Two approaches were used in the selection of  the genetic 
variants of  interest: a polymorphism with the strongest association with CHD in 
genome-wide association studies, and a polymorphism strongly associating with 
cardiovascular risk factors and CHD in candidate gene studies. Therefore, the 
roles of  a single nucleotide polymorphism on chromosome 9p21.3 (rs1333049) 
and IL6−174 G>C genotype in the early stages of  atherosclerosis were evaluated. 
These aims were investigated in a sub-population of  a large Finnish health 
examination survey, the Health 2000 Survey. The polymorphism on chromosome 
9p21.3 was also studied in the population of  the Cardiovascular Risk in Young 
Finns Study, a multi-centre study of  atherosclerotic risk factors in children and 
young adults.
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2  REVIEW OF THE LITERATURE
2.1  Pathophysiology of atherosclerosis 
Atherosclerosis is a progressive disease. It typically leads to arterial wall thickening 
by the accumulation of  lipids, leukocytes, smooth muscle cells and fi brous material 
(Lusis 2000). Symptomatic CHD, stroke and peripheral arterial disease appear in the 
late stages of  this process. Asymptomatic lesions in the arterial wall are present years 
or even decades before the onset of  clinical disease (Enos et al. 1953, McNamara et 
al. 1971, Tuzcu et al. 2001). Atherosclerosis usually begins in the abdominal aorta 
and then progresses to coronary and carotid arteries (McGill 1968). 
A normal arterial wall consists of  three layers. The innermost layer facing the 
lumen is called the intima. It has a monolayer of  endothelial cells on the luminal 
side and a sheet of  elastic fi bres, the internal elastic lamina, on the peripheral 
side. Normally, the intima is a very thin region consisting mainly of  extracellular 
connective tissue matrix, primarily proteoglycans and collagen. The middle layer, 
media, consists of  smooth muscle cells. The outermost layer is called the adventitia, 
consisting primarily of  smooth muscle cells, fi broblasts and connective tissue (Lusis 
2000). Morphology of  a normal arterial wall is illustrated in Figure 2.1.
FIGURE 2.1 Morphology of  a normal arterial wall. Reprinted by permission from Macmillan Publishers 
Ltd: Nature, copyright (2000) (Lusis 2000). 
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Atherosclerosis is now widely considered to be an infl ammatory process. This 
is based on a hypothesis known as the response-to-injury theory. A dysfunctional 
endothelium is believed to play an important role in the initiation of  the process 
(Ross and Glomset 1973, Ross 1999). In very early stages of  atherosclerosis, low-
density lipoprotein (LDL) particles are deposited in the intima. These particles 
are subsequently modifi ed to induce cytokine production. This, in turn, causes 
leukocytes (macrophages and lymphocytes) to enter the intima. Macrophages then 
uptake the modifi ed lipoprotein particles and begin to transform into so called foam 
cells. These cells further promote the infl ammatory process and the production of  
cytokines. The infl ammatory process continues with an increase in the amount of  
smooth muscle cells in the intimal layer. Smooth muscle cells produce extracellular 
FIGURE 2.2 Schematic of  the evolution of  the atherosclerotic plaque. 1, Accumulation of  lipoprotein 
particles in the intima. The modifi cation of  these lipoproteins is depicted by the darker colour. The 
modifi cations include oxidation and glycation. 2, Oxidative stress including products found in modifi ed 
lipoproteins can induce local cytokine elaboration. 3, The cytokines thus induce increased expression of  
adhesion molecules for leukocytes that cause their attachment and chemoattractant molecules that direct 
their migration into the intima. 4, Blood monocytes, on entering the artery wall in response to chemoattract-
ant cytokines such as monocyte chemoattractant protein 1 (MCP-1), encounter stimuli that can augment 
their expression of  scavenger receptors. 5, Scavenger receptors mediate the uptake of  modifi ed lipoprotein 
particles and promote the development of  foam cells. Macrophage foam cells are a source of  mediators such 
as more cytokines and matrix metalloproteinases. 6, SMCs in the intima divide, and other SMCs migrate 
into the intima from the media. 7, SMCs can then divide and elaborate extracellular matrix, promoting 
extracellular matrix accumulation in the growing atherosclerotic plaque. In this manner, the fatty streak 
can evolve into a fi bro-fatty lesion. 8, In later stages, calcifi cation can occur (not depicted), and fi brosis 
continues, sometimes accompanied by SMC death (including programmed cell death, or apoptosis), yielding 
a relatively acellular fi brous capsule surrounding a lipid-rich core that may also contain dying or dead cells 
and their detritus. IL-1 = interleukin-1; LDL = low-density lipoprotein, SMCs = smooth muscle cells. 
Reprinted from Braunwald’s Heart Disease: A Textbook of  Cardiovascular Medicine, 8, Libby P, The 
vascular Biology of  Atherosclerosis, 989, Copyright Elsevier (2008) (Libby 2008).
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material, and the fi bro-fatty lesion entitled an atherosclerotic plaque begins to 
form. Cellular death and apoptosis also take place in these lesions. Atherosclerotic 
plaques may produce symptoms by reducing blood fl ow. However, acute myocardial 
infarction is often caused by thrombosis after superfi cial erosion or rupture of  the 
plaque (Libby 2008). The pathogenesis of  atherosclerosis is depicted in Figure 2.2.
2.2  Markers of early atherosclerosis
2.2.1  Endothelial function
The endothelium and its function have been recognized as key factors in the 
pathogenesis of  atherosclerosis. Endothelial cells have a wide variety of  functions 
maintaining homeostasis in the vessel wall. It is believed that endothelial 
dysfunction is one of  the earliest steps in the initiation of  atherosclerosis (Ross 
1999). The dilatation of  blood vessels in response to increased fl ow and shear 
stress is known as fl ow-mediated dilatation (FMD). This phenomenon is mainly 
mediated by endothelium-derived nitric oxide (NO). Non-invasive measurement 
of  brachial FMD by ultrasound has been used to evaluate endothelial function 
(Corretti et al. 2002). It has been shown to correlate well with coronary FMD 
(Takase et al. 1998), and reduction in brachial FMD has been related to an 
increased risk of  cardiovascular events (Gokce et al. 2002, Yeboah et al. 2007).
2.2.2  Arterial intima-media thickness
Thickening of  the arterial intima is an early sign of  atherosclerosis. Atherosclerotic 
lesions often evolve progressively into plaques that protrude into the vessel lumen 
(Libby 2008). This process can be evaluated by measuring the intimal + medial 
thickness (intima-media thickness) with ultrasound (Figure 2.3). The measurement 
of  carotid artery intima-media thickness (CIMT) has become a widely utilized 
non-invasive marker for subclinical atherosclerosis. It has been shown to relate 
closely to microscopically measured intima-media thickness (Pignoli et al. 1986). 
Increased CIMT has been reported to associate with prevalent CVD (Salonen et 
al. 1994, Burke et al. 1995), and CIMT also correlates with the angiographically 
measured extent of  CHD (Lekakis et al. 2000, Kablak-Ziembicka et al. 2004). 
Several trials have found an increased risk of  myocardial infarction or stroke in 
subjects with increased CIMT (Bots et al. 1997, Chambless et al. 1997, O’Leary 
et al. 1999, Chambless et al. 2000). CIMT is also commonly used as a surrogate 
marker in studies evaluating the effect of  drugs on myocardial infarction risk, 
26
and in a recent meta-analysis a decrease in CIMT was reported to associate with 
reduced event risk. However, in some studies CIMT has not appeared to be a 
useful surrogate marker for the risk of  myocardial infarction. The authors of  the 
meta-analysis concluded that statin therapy, for example, might lower the risk via 
mechanisms that are not refl ected in changes in CIMT (Goldberger et al. 2010).
FIGURE 2.3 Intima-media layers (arrows) of  the common carotid artery in an ultrasound image.
2.2.3  Arterial stiff ness and elasticity
Thickening of  the arterial wall tends to reduce elasticity and increase stiffness 
in the vessel wall. Age and systolic blood pressure (SBP) are major determinants 
of  arterial stiffness. It may also be the result of  increased intima-media thickness 
associated with atherosclerosis (Cohn 2006). Therefore, arterial stiffening is 
not considered merely a marker of  age and elevated blood pressure but rather 
a product of  multiple pathological mechanisms affecting the arterial tree 
(Cruickshank et al. 2002). Measurements of  arterial stiffness and elasticity have 
been used as surrogates in evaluating atherosclerosis.
The ejection of  blood from the heart initiates an arterial pressure wave 
travelling towards the periphery. The velocity of  this pressure wave refl ects the 
elastic properties and stiffness of  the arteries (Oliver and Webb 2003). Arterial 
stiffness can therefore be evaluated by measuring pulse wave velocity (PWV) 
along the arterial tree. PWV has been shown to be an independent predictor of  
coronary events (Boutouyrie et al. 2002) and cardiovascular mortality in several 
patient groups (Blacher et al. 1999, Laurent et al. 2001, Cruickshank et al. 2002). 
Previously, PWV measurements have been performed mostly with methods 
utilizing Doppler ultrasound or mechanoelectrical pulse transducers (Lehmann et 
al. 1992, Wilkinson et al. 1998). PWV can also be measured by means of  whole-
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body impedance cardiography (ICGWB). This method is highly repeatable and 
reproducible (Kööbi et al. 2003). 
Ultrasonically measured carotid artery elasticity has also been used as a marker 
of  arterial stiffness. On the basis of  ultrasound measurements and blood pressure, 
several different elasticity indices have been derived. Carotid artery compliance 
(CAC) measures the ability of  the carotid artery to expand as a response to pulse 
pressure (PP) caused by cardiac contraction and relaxation (Juonala et al. 2005). 
The beta stiffness index (SI) is a marker of  arterial elasticity that is considered to be 
relatively independent of  blood pressure (Hirai et al. 1989). Young’s elastic modulus 
(YEM), on the other hand, is a measure of  arterial wall stiffness that is independent 
of  intima-media thickness (Salomaa et al. 1995). Carotid artery stiffness (CAS) has 
been related to CVD mortality (Blacher et al. 1998, Stork et al. 2004).
Other methods that have been used to estimate arterial stiffness include the 
ambulatory arterial stiffness index (AASI) and indices derived from pulse wave 
analysis. AASI is a recently proposed marker of  arterial stiffness (Dolan et al. 2006) 
that is based on 24-h ambulatory blood pressure measurements. This is a rather 
simple and inexpensive method, but it has been reported to be only moderately 
reproducible (Stergiou et al. 2010). Pulse wave analysis is a method that employs 
aplanation tonometry to record arterial waveforms. These can be measured 
from, for example, the carotid and brachial arteries. It has been suggested that 
the measurements are relatively easily assessed (Wilkinson et al. 1998). Several 
indices used as surrogates for arterial stiffness have been derived from pulse wave 
analysis. These include the augmentation index (AIx), carotid-brachial pressure 
amplifi cation and central pulse pressure. A recent analysis with the population 
of  the Framingham Heart Study compared PWV, AIx, carotid-brachial pressure 
amplifi cation and central pulse pressure in their ability to predict CVD events, 
and PWV was the only method signifi cantly associating with increased risk for a 
fi rst CVD event (Mitchell et al. 2010). The sensitivity of  AIx in assessing arterial 
stiffness has also been questioned (Cheng et al. 2007).
2.3  Risk factors for atherosclerosis
2.3.1  Lipid risk factors
2.3.1.1  Low-density lipoprotein cholesterol
LDL particles are the main carriers of  cholesterol in humans. Their accumulation 
and modifi cation in the intima play an important role in the initiation of  
endothelial dysfunction and atherosclerosis (Lusis 2000). LDL modifi cation 
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includes oxidation, and oxidized LDL, in turn, promotes foam cell formation as 
well as infl ammation (Steinberg 1997). These deleterious processes are enhanced 
by raised LDL levels in plasma (Lusis 2000). Subjects suffering from familial 
hypercholesterolaemia have a markedly elevated LDL cholesterol (LDL-C) level, 
and they are at high risk of  developing CHD early in life (by the third to fourth 
decade of  life for men and 8 to 10 years later for women) (Genest and Libby 2008). 
It has been convincingly shown that lowering the LDL-C level reduces the CHD 
risk (Grundy et al. 2004a). These facts underline the importance of  LDL as a risk 
factor for atherosclerosis. LDL-C level has been associated with increased CIMT 
(Salonen et al. 1988, Raitakari et al. 2003) and arterial stiffness (Smilde et al. 1998, 
Juonala et al. 2005).
2.3.1.2  High-density lipoprotein cholesterol
It has been shown in epidemiological studies that high-density lipoprotein 
cholesterol (HDL-C) level has an inverse relationship with CVD. A process 
known as reverse cholesterol transport has been suggested to be at least partly 
responsible for this protective effect of  HDL-C. According to this theory, high-
density lipoprotein (HDL) moves cholesterol away from the vessel wall and from 
the peripheral tissues (Brewer 2004). HDL also has the ability to protect LDL 
from oxidation (Navab et al. 2002). Another protective mechanism is probably 
the ability of  HDL to decrease the amount of  endothelial-cell adhesion molecules 
that promote leukocyte migration into the vessel wall (Barter et al. 2002). A low 
HDL-C level has been linked to increased CIMT (Salonen et al. 1988) and arterial 
stiffness (Havlik et al. 2001).
2.3.1.3  Triglycerides
The major proportion of  ingested fat consists of  triglycerides, which are used for 
the transportation and storage of  energy (Genest and Libby 2008). The triglyceride 
concentration in the blood is highly diet dependent and also has an inverse 
relationship with the HDL-C concentration. The role of  the triglyceride level as 
an independent risk factor for atherosclerosis has, therefore, been controversial 
(Ridger and Libby 2008). One recent meta-analysis, however, concluded that 
an elevated triglyceride level is associated with CHD independently of  HDL-C 
and this association is similar in fasting and non-fasting participants (Sarwar et 
al. 2007). Another meta-analysis in subjects from the Asia-Pacifi c region also 
suggested that the serum triglyceride level is an independent risk factor for 
CHD and stroke (Asia Pacifi c Cohort Studies Collaboration 2004). One possible 
mechanism explaining these associations is that the exposure of  the arterial wall 
to triglyceride-rich lipoproteins, such as very-low-density lipoprotein (VLDL), 
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may promote atherosclerosis (Ridger and Libby 2008). However, the mechanisms 
are not fully understood. An increased triglyceride level has been linked to early 
atherosclerosis (Li et al. 2004).
2.3.1.4  Other lipid risk factors
Smaller size and increased density in LDL particles has been connected with a 
high atherosclerosis risk in particular (Gardner et al. 1996), although this concept 
has been questioned (Sacks and Campos 2003).  The high atherogenity of  these 
particles may be a result of  low binding affi nity for the LDL receptor, prolonged 
plasma half-life and low resistance to oxidative stress (Tribble et al. 1992, 
Chapman et al. 1998). Small dense LDL particles have been linked to increased 
CIMT (Skoglund-Andersson et al. 1999).
Apolipoproteins (apo) are structural components of  lipoprotein molecules. 
Different apolipoproteins are associated with different lipoprotein molecules. For 
example, apoA-I and apoA-II are associated with HDL, and apoB is a component 
of  atherogenic lipoproteins such as VLDL and LDL (Genest and Libby 2008). It 
has been suggested that measurements of  apoA-I and apoB levels may be better 
in predicting CVD risk than the LDL-C level (Walldius et al. 2001). In a study 
by Pischon et al. apoB turned out to be a stronger predictor for CHD in men 
than did any of  the cholesterol measurements (Pischon et al. 2005). In women, 
however, apoB was not superior in predicting CHD when compared to non-HDL 
cholesterol (total cholesterol-HDL cholesterol) (Ridker et al. 2005).  ApoB has 
been related to increased CIMT (Sharrett et al. 1994).
Lipoprotein (a) is a particle resembling LDL in which apoB is connected with 
a certain glycoprotein, apoprotein(a) (Ridger and Libby 2008). High levels of  
lipoprotein (a) have been linked to an increased risk of  coronary events and stroke 
(Danesh et al. 2000, Suk Danik et al. 2006, Kiechl et al. 2007). The mechanisms 
by which lipoprotein (a) promotes atherosclerosis may include its local actions in 
the atherosclerotic lesions, and it may also have prothrombotic features (Ridger 
and Libby 2008). In studies by Raitakari et al. and Grebe et al., increased CIMT 
and lipoprotein (a) were not signifi cantly associated (Raitakari et al. 1999, Grebe 
et al. 2007), although some authors have suggested that such an association exists 
(Schreiner et al. 1996).
2.3.2  Smoking
Smoking is one of  the most important risk factors for CHD (Ridger and Libby 
2008). It has also been shown to increase mortality from cerebrovascular disease, 
although not to the same extent as in the case of  CHD (Ezzati et al. 2005). It is a 
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well-known risk factor for peripheral arterial disease as well (Ambrose and Barua 
2004). Smoking promotes atherosclerosis by several different mechanisms. It may 
cause endothelial dysfunction by reducing nitric oxide synthesis in the endothelial 
cells (Barua et al. 2003) and by increasing LDL oxidation (Heitzer et al. 1996). 
Smoking has also been linked to increased infl ammation (Bazzano et al. 2003). 
Smokers have an adverse lipid profi le compared to non-smokers, and it has been 
suggested that insulin resistance, promoted by smoking, is the key factor behind 
this phenomenon (Reaven and Tsao 2003). Both active and passive smoking 
have been associated with increased CIMT (Howard et al. 1994b) and decreased 
arterial compliance (Li et al. 2005).
2.3.3  Hypertension
Hypertension is one of  the most signifi cant risk factors for CVD (Stamler et al. 
1993), especially for stroke (Lawes et al. 2004). It has an important and complex 
role in the pathogenesis of  atherosclerosis. Sustained elevation in blood pressure 
causes endothelial changes such as increased permeability, decreased endothelium-
dependent vasodilatation, increased leukocyte adherence to the endothelial 
surface and subsequent macrophage accumulation in the intima. Hypertension 
also increases smooth muscle cell proliferation and enhances infl ammation in 
the arterial wall (Chobanian 1990, Chobanian and Alexander 1996). On the 
other hand, infl ammation and endothelial dysfunction may play an important 
role in the development of  hypertension (Savoia and Schiffrin 2006). Isolated 
systolic hypertension and elevated pulse pressure are signs of  increased vascular 
wall stiffness and can thus be considered markers of  existing atherosclerosis. It 
is therefore not surprising that hypertension has been linked to increased CIMT 
and arterial stiffness (Riley et al. 1986, Gariepy et al. 1993, Zanchetti et al. 2001, 
Czernichow et al. 2005).
2.3.4  Diabetes, insulin resistance, and metabolic syndrome
2.3.4.1  Diabetes
Diabetes (DM) is a powerful risk factor for CVD morbidity and mortality. CVD 
event rates are roughly 2- to 4-fold in diabetic subjects in relation to their age-
matched non-diabetic counterparts (Ridger and Libby 2008). In a large Canadian 
population-based cohort study, DM was found to increase CVD risk as much as 
ageing of  15 years (Booth et al. 2006). Interestingly, T2DM increases the risk for 
CVD events more in women than in men (Beckman et al. 2002). 
31
As many as 90 percent of  diabetic patients suffer from T2DM (Beckman, et 
al 2008). It has been proposed that atherosclerosis and T2DM have a similar 
infl ammatory basis (Eckel et al. 2005). There have been several trials investigating 
the effect of  glycaemic control on CVD events and mortality. These studies have 
yielded some support for the hypothesis that strict glycaemic control reduces CVD-
related morbidity and mortality (Beckman, et al 2008). The fi ndings, however, 
suggest that hyperglycaemia per se is not the only factor contributing to the CVD 
risk in diabetics.
Excess adipose tissue is usually present in T2DM. It is believed that adipose 
tissue in obese subjects secretes an increased amount of  proinfl ammatory agents 
such as tumour necrosis factor-alpha (TNF-α) and IL-6 (Berg and Scherer 2005), 
which play an important role in initiating infl ammatory processes. Visceral 
fat that is associated with abdominal obesity has been shown to be more active 
than subcutaneous fat in this regard (Shoelson et al. 2006). Excess adipose tissue 
also secretes an increased amount of  free fatty acids (FFAs). This inhibits insulin 
function, especially in muscle tissue, promoting so-called insulin resistance (Belfort 
et al. 2005). This is an important mechanism linking obesity and hyperglycaemia. 
Elevated blood glucose and increased FFA concentrations may induce a 
decrease in endothelial nitric oxide (NO) production, leading to vasoconstriction, 
hypertension and smooth muscle cell proliferation. They also enhance 
infl ammation and increase the production of  cytokines contributing to endothelial 
dysfunction. Hyperglycaemia promotes thrombosis by platelet activation and 
increases the production of  potentially atherogenic advanced glycation end 
products (AGEs). Part of  the proinfl ammatory action of  hyperglycaemia is caused 
by the increased AGE production (Creager et al. 2003). 
The American Diabetes Association (ADA) (Genuth et al. 2003) and World 
Health Organization (WHO) (Alberti and Zimmet 1998) diagnostic criteria for 
DM recognize two intermediate metabolic states between normal glucose tolerance 
(NGT) and DM. These pre-diabetic states, known as impaired fasting glucose 
(IFG) and impaired glucose tolerance (IGT), represent two distinct subgroups of  
abnormal glucose metabolism. It has been shown recently that impaired insulin 
release is a predominant feature in IFG, whereas peripheral insulin resistance is 
characteristic of  IGT (O’Rahilly et al. 1994, Stancakova et al. 2009). There is 
also evidence that even these milder abnormalities in glucose metabolism increase 
the risk for all cause and CVD mortality (Barr et al. 2007). Hu et al. reported 
that women who eventually developed diabetes had a threefold relative risk of  
myocardial infarction before the actual diagnosis of  DM (Hu et al. 2002). 
A deteriorating trend in CIMT (Wagenknecht et al. 1998, Bonora et al. 2000, 
Henry et al. 2004, Sigurdardottir et al. 2004, Mohan et al. 2006) and CAS (Henry 
et al. 2003) according to the worsening of  glucose tolerance has been reported. 
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It is also well known that subjects with T2DM have increased CIMT (Kawamori 
et al. 1992, Folsom et al. 1994, Pujia et al. 1994, Niskanen et al. 1996, Bonora et 
al. 1997) in comparison to subjects without impairment in glucose metabolism. 
Some (Hanefeld et al. 1999a, Mohan et al. 2006, Zhang et al. 2006, Faeh et al. 
2007), but not all (Niskanen et al. 1996, Tuomilehto et al. 1998, Wagenknecht et 
al. 1998), previous studies have found signifi cantly higher CIMT also in subjects 
with IGT when compared to those with NGT. In a recent meta-analysis Brohall 
et al. concluded that subjects with IGT have slightly increased CIMT compared 
to subjects with normal glucose metabolism (Brohall et al. 2009). Non-diabetic 
glucose intolerance and increased stiffness of  the carotid arteries have also been 
related previously (Salomaa et al. 1995, van Popele et al. 2000). Most of  the 
previous studies have not reported a difference in carotid atherosclerosis between 
subjects with IFG and NGT (Bonora et al. 1999, Hanefeld et al. 1999b, Tropeano 
et al. 2004, Faeh et al. 2007), although some studies have suggested increased 
CIMT (Zhang et al. 2006) or CAS (van Popele et al. 2006) in IFG when compared 
to normal glucose metabolism. Some reports have suggested that the effect of  
glucose metabolism impairment on early carotid atherosclerosis would be greater 
in women than in men (Salomaa et al. 1995, Kawamoto et al. 2007b). The data 
regarding sex-related differences is limited, however, and other studies have not 
confi rmed this hypothesis (Folsom et al. 1994, Bonora et al. 2000).
2.3.4.2  Insulin resistance and metabolic syndrome
Obesity-induced insulin resistance leading to hyperglycaemia and, subsequently, 
evident diabetes is believed to be part of  the entity known as MetS. The term 
metabolic syndrome means the clustering of  cardiovascular risk factors such 
as central obesity, hypertension, dyslipidemia and glucose intolerance. Insulin 
resistance is considered to be a key factor between these abnormalities. Insulin 
resistance by itself  can directly reduce endothelium-dependent vasodilatation 
(Laakso et al. 1990). It has been reported to be an independent predictor for 
myocardial infarction and death (Hedblad et al. 2002). Insulin resistance has also 
been associated with the risk of  stroke (Kernan et al. 2002) and congestive heart 
failure (Ingelsson et al. 2005).
In insulin resistance there is an excess FFA flux to the liver, and the 
production of  triglycerides in the liver is high. The liver secretes excess amount 
of  VLDL, and a high level of  this triglyceride-rich lipoprotein in the blood 
causes hypertriglyceridemia. Subsequently, cholesteryl ester exchange between 
HDL and VLDL becomes prominent, leading to a decreased concentration of  
HDL-C. MetS and T2DM are typically accompanied with dyslipidemia where 
hypertriglyceridemia and low HDL-C predominate (Eckel et al. 2005, Cornier 
et al. 2008). Although the LDL-C concentration does not markedly differ in 
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subjects with or without MetS, an increased triglyceride concentration results in 
the synthesis of  smaller and denser LDL particles (Kwiterovich 2002). Insulin 
resistance is also typically associated with hypertension (Ferrannini et al. 1987). 
Several mechanisms behind this have been proposed. Insulin is a vasodilator, 
and this effect may be impaired in insulin resistance. An elevated circulating 
glucose concentration increases pancreatic insulin secretion, resulting in 
hyperinsulinaemia. This may cause sodium retention and sympathetic stimulation. 
FFAs themselves may also promote vasoconstriction (Eckel et al. 2005). Adipose-
tissue-derived angiotensinogen, leptin and resistin may also have a hypertensive 
effect in insulin-resistant subjects (Cornier et al. 2008). Endothelial infl ammation 
has been recognized as an important part of  MetS (Sjöholm and Nyström 
2005), and it has been shown that elevation in an infl ammatory marker, (namely) 
high sensitivity C-reactive protein (hsCRP), is associated with increased CVD 
risk in women with MetS (Ridker et al. 2003). An illustration of  the suggested 
pathophysiology of  MetS is depicted in Figure 2.4.
There are various defi nitions for MetS. The fi rst international defi nition 
for MetS was introduced in 1998 by the WHO (Alberti and Zimmet 1998). 
Impaired glucose metabolism, insulin resistance, raised arterial pressure, raised 
triglyceride concentration and/or low HDL-C as well as central obesity and 
microalbuminuria were the components included in this defi nition. Insulin 
resistance and microalbuminuria are somewhat laboured to measure, which has 
restricted the use of  this criterion in practice. The European Group for the Study 
of  Insulin Resistance (EGIR) proposed their defi nition for MetS in 1999 (Balkau 
and Charles 1999). Their goal was to create a more practical criterion than the 
one introduced by the WHO. Microalbuminuria was not included in the EGIR 
defi nition, and fasting insulin measurement, as a marker for insulin resistance, was 
suggested instead of  a clamp study insisted by the WHO. In 2001 the National 
Cholesterol Education Program (NCEP) Adult Treatment Panel III proposed their 
widely used clinical defi nition for MetS (Expert Panel on Detection, Evaluation, 
and Treatment of  High Blood Cholesterol in Adults 2001). The American Heart 
Association (AHA) and the National Heart, Lung, and Blood Institute (NHLBI) 
suggested only minor adjustments to the NCEP defi nition in 2005. They added 
specifi c medications for the components of  the syndrome to be taken into account 
(Grundy et al. 2005). The International Diabetes Federation (IDF) also published 
a worldwide defi nition of  MetS in 2005 (Alberti et al. 2005). Both the NCEP and 
the IDF criteria include increased waist circumference, elevated blood pressure, 
and elevated concentrations of  fasting blood glucose and trigylerides as well as 
low HDL-C as components of  the syndrome. These defi nitions have two basic 
differences. First of  all, the IDF defi nition has a signifi cantly lower cut-off  point 
for waist circumference than the NCEP defi nition. Secondly, the IDF defi nition 
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FIGURE 2.4 The pathophysiology of  metabolic syndrome (insulin resistance). A: Free fatty acids (FFAs) are released in 
abundance from an expanded adipose tissue mass. In the liver, FFAs induce an increased production of  glucose, triglycerides 
and the secretion of  very low-density lipoproteins (VLDL). Associated lipid/lipoprotein abnormalities include a reduction in 
the high-density lipoprotein (HDL) cholesterol level and an increased density of  low-density lipoproteins (LDL). FFAs also 
reduce insulin sensitivity in muscle by inhibiting insulin-mediated glucose uptake. Associated defects include a reduction in 
glucose partitioning to glycogen and increased lipid accumulation in triglyceride (TG). Increases in circulating glucose and, 
to some extent, FFAs increase pancreatic insulin secretion, resulting in hyperinsulinaemia. Hyperinsulinaemia may result in 
enhanced sodium reabsorption and increased sympathetic nervous system (SNS) activity and contribute to the hypertension, 
as might the increased level of  circulating FFAs. B: Superimposed and contributory to the insulin resistance produced by 
excessive FFAs is the paracrine and endocrine effect of  the proinfl ammatory state. Produced by a variety of  cells in adipose 
tissue, including adipocytes and monocyte-derived macrophages, the enhanced secretion of  interleukin-6 (IL-6) and tumour 
necrosis factor alpha (TNF-α), among others, results in more insulin resistance and lipolysis of  adipose tissue triglyceride 
stores to circulating FFAs. IL-6 and other cytokines also are increased in the circulation and may enhance hepatic glucose 
production, the production of  VLDL by the liver and insulin resistance in muscle tissue. Cytokines and FFAs also increase 
the production of  fi brinogen and plasminogen activator inhibitor-1 (PAI-1) by the liver that complements the overproduc-
tion of  PAI-1 by adipose tissue. This results in a pro-thrombotic state. Reductions in the production of  the anti-infl am-
matory and insulin sensitizing cytokine adiponectin are also associated with metabolic syndrome and may contribute to the 
pathophysiology of  the syndrome. Reprinted from The Lancet, 365, Eckel RH, Grundy SM, Zimmet PZ, The metabolic 
syndrome, 1415–1428, Copyright (2005), with permission from Elsevier (Eckel et al. 2005).
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makes the presence of  increased waist circumference mandatory for the diagnosis, 
while the NCEP defi nition considers waist circumference to be equally important 
as the other components. In 2009 the IDF and AHA/NHLBI published new 
unifi ed criteria for MetS attempting to resolve the differences between the 
(various) defi nitions (Alberti et al. 2009). In these new criteria, central obesity is 
not an obligatory component for the syndrome, but rather one of  fi ve equally 
important components. However, no simple cut off  value for waist circumference 
was suggested at this point. Population- and country-specifi c cut-off  values are 
recommended by this new defi nition. 
MetS has been shown to be a predictor of  T2DM (Lorenzo et al. 2003), CHD 
(Bonora et al. 2003) and mortality (Isomaa et al. 2001, Lakka et al. 2002, Malik et 
al. 2004). The presence of  MetS has been related to increased CIMT in several 
studies including diabetic and non-diabetic subjects (Anand et al. 2003, McNeill et 
al. 2004, Scuteri et al. 2004, Ahluwalia et al. 2006, Skilton et al. 2007). It has been 
associated with increased CIMT in subjects free of  diabetes as well (Hulthe et al. 
2000, Leoncini et al. 2005, Tzou et al. 2005, Mohan et al. 2006, Ishizaka et al. 
2009). Arterial stiffness and MetS have also been related with one another (Scuteri 
et al. 2004, Ferreira et al. 2005, Li et al. 2005, Schillaci et al. 2005, Ahluwalia et 
al. 2006). As mentioned earlier, T2DM has been shown to increase CVD events 
in women to a larger extent than in men. It has also been suggested that MetS 
would be a stronger risk factor for early atherosclerosis in women than in men 
(Iglseder et al. 2005, Kawamoto et al. 2007a, Lee et al. 2010). The data regarding 
sex differences is, however, limited and controversial (Ishizaka et al. 2009). The 
various defi nitions and the whole concept of  MetS have received much criticism 
(Kahn et al. 2005). There are doubts as to whether the syndrome is more than the 
sum of  its parts as a CVD risk factor. Some investigators have reported that MetS 
would be a predictor of  atherosclerosis independently of  its components (Scuteri 
et al. 2004, Kawamoto et al. 2005). This issue, however, is highly controversial 
(Bayturan et al. 2010, Mente et al. 2010).
2.3.5  Obesity
Obesity is clearly associated with increased CVD risk (Grundy 2002). In the U.S. 
Diabetes Prevention Program, diabetes incidence was reduced by 58% and an 
average of  5.6 kg weight loss was observed with dietary changes and increased 
physical activity (Knowler et al. 2002). It is not quite clear how much of  the 
association between obesity and CVD risk is mediated by co-existing deterioration in 
other known risk factors, such as insulin resistance, the components of  MetS, physical 
inactivity and proinfl ammatory effects of  obesity. It is possible, however, that obesity 
affects CVD risk via some as yet undiscovered mechanisms (Poirier et al. 2006).
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There is strong evidence suggesting that obesity decreases life expectancy 
(Fontaine et al. 2003). However, some investigators have reported a less convincing 
effect on all cause mortality (Flegal et al. 2005), especially in regard to minor 
overweight (body mass index ≤30). Smoking and pre-existing disease are major 
confounders in the subject matter, since both tend to decrease body weight and, 
on the other hand, increase mortality. Indeed, obesity has been strongly associated 
with mortality after these factors have been eliminated (Adams et al. 2006). Body 
mass index (BMI) seems to have a J-shaped association with mortality, which also 
adds to the complexity of  this topic. 
2.3.6  Markers of inﬂ ammation
As discussed earlier, infl ammation and proinfl ammatory cytokines have a crucial 
role in the pathogenesis of  atherosclerosis (Ross 1999, Libby et al. 2010). The 
measurement of  infl ammatory markers such as hsCRP has raised more and more 
attention in CVD risk evaluation.
2.3.6.1  High-sensitivity C-reactive protein
CRP is the main downstream mediator of  the acute phase and it plays an 
important role in the human innate immunity response (Pradhan et al. 2001). 
There is comprehensive evidence that CRP, measured with high-sensitivity 
assays, is an independent predictor for CVD. It predicts risk independently of  the 
traditional risk factors included in global risk assessment algorithms, such as the 
Framingham Risk Score (FRS), and also independently of  MetS. hsCRP has been 
shown to be an important risk predictor at all levels of  LDL-C (Libby and Ridker 
2006). It also predicts the incidence of  T2DM, supporting the hypothesis that 
diabetes would have an infl ammatory basis (Pradhan et al. 2001). The JUPITER 
trial investigators reported that statin therapy signifi cantly reduced major CVD 
events in subjects without hyperlipidemia, which led the authors to conclude 
that part of  the risk reduction might be caused by the anti-infl ammatory effects 
of  statins (Ridker et al. 2008). The causal role of  CRP in the pathogenesis of  
atherosclerosis has been studied in large genetic trials. Recent reports are arguing 
against such a role (Zacho et al. 2008, Elliott et al. 2009).
The relationship between CRP and CIMT is controversial. There are some 
studies reporting a modest but independent relationship between elevated CRP 
and increased CIMT (Sitzer et al. 2002). Most studies have not, however, found 
signifi cant correlations independently of  other risk factors (Blackburn et al. 
2001, Folsom et al. 2001, Makita et al. 2005, Lorenz et al. 2007). Wang et al. 
found an independent relationship between CRP and CIMT in women but not 
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in men (Wang et al. 2002). Kivimäki et al. used CRP genetics with a Mendelian 
randomization method, concluding that there is no causal association between 
CRP and CIMT (Kivimäki et al. 2007). CRP has also been related to arterial 
stiffness (Mattace-Raso et al. 2004, Yasmin et al. 2004, Kullo et al. 2005). Some 
of  the studies found this relation to be independent of  other CVD risk factors 
(Mattace-Raso et al. 2004, Yasmin et al. 2004), while other investigators concluded 
this to be mediated by confounding risk factors (Kullo et al. 2005).
2.3.6.2  Other markers of inﬂ ammation
Adipose tissue is a major source of  infl ammatory cytokine IL-6 (Allen and Febbraio 
2009), which promotes CRP synthesis in the liver (Pradhan et al. 2001). It has been 
proposed to induce insulin resistance (Lazar 2005). The circulating IL-6 level has 
been reported to be elevated in obesity (Bastard et al. 2000), and IL-6, like CRP, has 
been shown to be a predictor for T2DM (Pradhan et al. 2001). The possible role of  
IL-6 in the pathogenesis of  insulin resistance and diabetes is, however, controversial. 
It is possible that IL-6 level is a marker of  obesity-induced infl ammation rather than 
an active mediator in this process (Pradhan et al. 2001). There are also reports that 
IL-6 might have favourable effects in controlling obesity-associated pathology, such 
as opposing weight gain (Wernstedt et al. 2004, Berg and Scherer 2005). In some 
experimental studies IL-6 has enhanced insulin sensitivity in humans and mice (Carey 
et al. 2006, Sadagurski et al. 2010), raising even more controversy. It is possible that IL-6 
acts as a promoter of  infl ammation in some situations, while depressing infl ammatory 
process in other circumstances (Berg and Scherer 2005, Allen and Febbraio 2009). An 
increased IL-6 level has been suggested to predict increase in CIMT (Lee et al. 2007), 
and it has been related to arterial stiffness (Roman et al. 2005).
Adipose tissue produces various infl ammatory modulators, such as leptin, 
adiponectin and resistin, which have been suggested to associate with 
atherosclerosis (Berg and Scherer 2005).  Leptin enhances insulin sensitivity and 
reduces appetite. However, hyperleptinaemia has been related to insulin resistance 
and obesity that might be caused by leptin resistance in tissues, and it may act 
as a pathophysiological trigger in CVD (Ren 2004). The adiponectin level is 
decreased in obese subjects (Berg and Scherer 2005), and subjects with the highest 
adiponectin levels have a markedly reduced CVD risk (Pischon et al. 2004). It has 
been suggested that adiponectin acts directly on endothelial and vascular smooth 
muscle cells. It also has anti-infl ammatory and insulin-sensitizing effects, which 
makes it an interesting substance regarding the pathogenesis of  insulin resistance 
and MetS (Goldstein and Scalia 2004, Cornier et al. 2008). Resistin is another 
adipocyte-derived substance that has been linked to obesity, MetS and diabetes. It 
has been hypothesized that resistin may play a pathogenic role in insulin resistance-
related abnormalities (Cornier et al. 2008).
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2.3.7  Genetic risk factors
Atherosclerosis has a genetic basis, and its heritability has been estimated to be 
nearly 50% (Zdravkovic et al. 2002). However, there are no genetic screening tests 
in a substantive role in clinical practice yet (Ridger and Libby 2008). Part of  the 
diffi culty in creating such a test is caused by the fact that atherotrombotic disease 
is a complex process with multiple genetic factors contributing to the overall risk 
(Watkins and Farrall 2006). An example of  a genetic risk factor for CHD that has 
been well characterized is a polymorphism in the apoE gene. In a large meta-
analysis carriers of  the epsilon 4 allele had a 42% higher risk for CHD when 
compared to subjects with the epsilon 3/3 genotype (Song et al. 2004).
Common variations in the genetic code are called polymorphisms. This means 
that they are present in more than 1 percent of  the population. A single nucleotide 
polymorphism (SNP) is a common variation in single nucleotide that does not 
necessarily alter protein structure. Lately, it has become possible to use powerful 
genome-wide scan techniques (Kennedy et al. 2003) in genetic studies. Hundreds 
of  thousands of  SNPs and alleles can now be investigated simultaneously. 
There are several methods in regard to genetic studies that can be utilized in 
different situations. So-called linkage analysis can be used to identify genomic 
regions that contain a possible disease gene. This method is usually applied to 
study Mendelian traits, which are controlled by a single gene locus, and it is 
performed in families (Dawn Teare and Barrett 2005). In genetic association 
studies polymorphisms are associated with traits, which can be, for example, some 
quantitative characteristics or diseases (Cordell and Clayton 2005). Association 
studies can be used to investigate common disorders with no clear Mendelian 
inheritance (Lohmueller et al. 2003). The difference between linkage and 
association studies is that in the latter the same allele (or alleles) is associated with 
a trait in a similar manner across the whole population. Linkage, on the other 
hand, allows different alleles to be associated with a trait in different families 
(Cordell and Clayton 2005). Mendelian randomization is a method used in genetic 
epidemiology based on Mendel’s second law according to which inheritance of  
one trait is independent of  the inheritance of  other traits. In CVD epidemiology, 
for example, a common genetic polymorphism known to have an effect on a 
certain risk factor can be used. In this method the association between a genetic 
variant and the investigated outcome is not generally confounded by other risk 
factors. This means that an epidemiologic study of  genetic variants has similar 
properties as the intention to treat analyses in randomized controlled trials (Davey 
Smith and Ebrahim 2005).
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2.3.7.1  Genome-wide association approach: the coronary heart disease risk variant  
 on chromosome 9p21.3 (rs1333049)
Recent genome-wide association studies have identifi ed several novel loci that 
are strongly associated with CHD. Specifi cally, a common variant located in a 
region adjacent to the cyclin-dependent kinase inhibitors CDKN2A (encoding 
p16INK4a) and CDKN2B (p15INK4b) on chromosome 9p21.3 has been 
associated with increased risk in several separate genome-wide association and 
follow-up studies (Burton et al. 2007, Helgadottir et al. 2007, McPherson et 
al. 2007, Samani et al. 2007, Schunkert et al. 2008). Of  the SNPs in this locus, 
rs1333049 is the one with the strongest association. The risk-associated alleles, 
defi ned by the C allele of  rs1333049, or alleles of  other SNPs in strong linkage 
disequilibrium with it, have consistently shown an increased risk of  25% to 40% 
per copy of  allele. The region associated with CHD on chromosome 9p21.3 is 
located adjacent to the genes that play a central role in the regulation of  the cell 
cycle and may be implicated in the pathogenesis of  atherosclerosis through their 
role in transforming growth-factor-β-induced growth inhibition (Hannon and 
Beach 1994, Kalinina et al. 2004). Interestingly, rs1333049 is located on a region 
of  9p21.3 that does not contain a protein-coding gene. Recent studies have shown 
that this region contains a gene for a large noncoding RNA, ANRIL, which is 
expressed in atherosclerotic tissue (Pasmant et al. 2007, Broadbent et al. 2008). 
It has been suggested that ANRIL may regulate the expression of  adjacent genes 
(Pasmant et al. 2007). The association of  locus 9p21.3 with early atherosclerosis 
has not been studied extensively.
2.3.7.2  Candidate gene approach: IL6−174 G>C genotype
A single G>C base exchange polymorphism in the promoter region of  the IL-6 
gene (IL6−174 G>C, rs1800795) on chromosome 7 has been associated with IL-6 
production. In some studies, allele G homozygous and G/C heterozygous subjects 
have shown a higher expression of  the IL-6 protein, higher transcriptional activity 
and higher inducible IL-6 responses than those homozygous for allele C (Fishman 
et al. 1998, Burzotta et al. 2001, Hulkkonen et al. 2001). In some populations 
higher plasma levels of  IL-6 have been associated with allele C (Chiappelli et al. 
2005, Boiardi et al. 2006). The effect of  this polymorphism on circulating IL-6 
level is therefore complex, and a recent joint analysis of  participants in 17 studies 
did not fi nd any signifi cant association between the IL6−174 G>C polymorphism 
and circulating IL-6 level (Huth et al. 2009). The authors of  this joint analysis 
concluded that it is possible that the effect on IL-6 level may be seen only in certain 
risk populations such as diabetics. 
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The relationship of  this IL-6-related polymorphism with cardiovascular 
risk factors and the risk for cardiovascular events has also been controversial. 
Some studies have related allele C to an increased risk of  myocardial infarction 
(Georges et al. 2001), while others have not found this association (Bennet et al. 
2003). A recent meta-analysis did not observe a signifi cant association between 
this polymorphism and the risk for CHD (Sie et al. 2006). Results have been 
controversial also in regard to the association of  this polymorphism and stroke. 
In a systematic review by Tso et al., the authors concluded that there seems to 
be an association between IL6−174 G>C polymorphism and stroke, but the risk 
allele cannot be clearly assigned (Tso et al. 2007). Allele G has been related to 
peripheral arterial disease (Flex et al. 2002, Libra et al. 2006). On the other hand 
some reports suggest that allele C would be associated with increased mortality 
(Hurme et al. 2005).
Allele C has also been linked to obesity in some studies (Klipstein-Grobusch et 
al. 2006), but in the joint analysis by Huth et al. no association between BMI and 
the IL6−174 G>C polymorphism was found (Huth et al. 2009). Higher CRP level 
(Sie et al. 2006) and insulin resistance (Kubaszek et al. 2003) have also been linked 
to allele C. Some studies, however, have suggested that G allele carriers would be 
more insulin resistant and thus at greater risk regarding this matter (Fernandez-
Real et al. 2000). Indeed, allele C was reported to be protective against T2DM 
in a joint analysis of  21 different studies (Huth et al. 2006). Furhtermore, in a 
more recent joint analysis, carriers of  this allele had lower fasting glucose levels 
independently of  BMI (Huth et al. 2009). 
Allele C of  this polymorphism has been previously associated with increased 
CIMT in British subjects (Mayosi et al. 2005). The same report also included a 
meta-analysis of  previous studies with similar results.  A recent study by Hulkkonen 
et al. found an association between allele C and increased arterial stiffness among 
young men in the Cardiovascular Risk in Young Finns Study cohort (Hulkkonen 
et al. 2009).
2.3.8  Other risk factors
There are numerous other proposed risk factors for atherosclerosis. Homocysteine 
is an amino acid produced by methionine metabolism. Hyperhomocysteinaemia, 
usually due to an insuffi cient dietary intake of  folic acid, has been suggested 
to increase the risk of  CHD (Boushey et al. 1995). In a study using Mendelian 
randomization, a causal role of  hyperhomocysteinaemia and stroke was 
suggested (Casas et al. 2005). In a large systematic review of  57 studies, however, 
homocysteine concentration was only weakly related to CHD (Ford et al. 2002). 
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More importantly, clinical trials of  homocysteine reduction have failed to show 
considerable benefi ts (Lonn et al. 2006). The role of  homocysteine as a CVD risk 
factor remains to be clarifi ed.
 Fibrinogen is an acute-phase reactant and major determinant of  blood viscosity 
and platelet aggregation. It has been strongly related to CVD risk (Danesh et 
al. 2005), but studies investigating the effect of  fi brinogen reduction have not 
yielded convincing benefi ts (Meade et al. 2002). Markers of  fi brinolysis, such as 
plasminogen activator inhibitor-1 (PAI-1), have also been investigated as possible 
risk factors. PAI-1 is an endogenous inhibitor of  fi brinolysis. There are reports 
relating PAI-1 to CHD, but it has not been demonstrated to add considerably to 
the risk as defi ned by traditional risk factors (Ridger and Libby 2008).
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3  AIMS OF THE STUDY
Obesity has become a major risk factor for cardiovascular disease. It predisposes 
to insulin resistance, MetS and T2DM. The independent roles of  these metabolic 
abnormalities in the atherosclerotic process, however, have not been clarifi ed. 
On the other hand, atherosclerosis has a strong genetic basis that is not well 
characterized. These questions were investigated in the present study, with 
(particular) focus on the early stages of  atherosclerosis. Two approaches were used 
in the selection of  the contemporary genetic variants of  interest: the polymorphism 
most strongly associating with CHD in genome-wide association studies, and a 
polymorphism strongly associating with cardiovascular risk factors and CHD in 
candidate gene studies were selected to be investigated in detail. Therefore, the 
roles of  two single nucleotide polymorphisms, rs1333049 (on chromosome 9p21.3) 
and IL6–174 G>C, in the early stages of  atherosclerosis were evaluated. A sub-
population of  a large Finnish health examination survey, the Health 2000 Survey, 
and the population of  the Cardiovascular Risk in Young Finns Study, a multi-
centre study of  atherosclerosis risk factors in children and young adults, were used 
in the investigations. The specifi c aims of  the present thesis are as follows:
1. To investigate the independent associations of  different stages of  glucose 
intolerance with early carotid atherosclerosis (original publication V).
2. To evaluate the independent association of  metabolic syndrome with early 
atherosclerosis (original publications I and III).
3. To study possible sex-related differences in the associations of  metabolic 
syndrome, glucose intolerance and early atherosclerosis (original 
publications I and V).
4. To study the relationship of  the CHD-associated variant on chromosome 
9p21.3 and subclinical atherosclerosis (original publication II).
5. To evaluate whether IL6−174 G>C genotype is related to the risk factors 
and markers of  early atherosclerosis (original publication IV).
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4  SUBJECTS AND METHODS
4.1  Subjects
4.1.1  The Health 2000 Survey
A subpopulation of  a large Finnish cross-sectional health examination survey (the 
Health 2000 Survey) carried out in 2000–2001 (Aromaa and Koskinen 2004) was 
studied. The overall study cohort was a two-stage stratifi ed cluster sample (8,028 
persons) representing the entire Finnish population aged 30 years and older. To 
study CVD and diabetes more thoroughly, a supplemental study was carried out 
(sample size 1,867; participation rate 82%). Subjects in the supplemental study, a 
subpopulation of  the Health 2000 Survey, were 45 years and older, and the study 
was executed in the areas located within 150 km from the fi ve Finnish University 
Hospitals, because specialized equipment was required. In addition to detailed 
risk factor assessments, a carotid ultrasound examination and an oral glucose 
tolerance test (OGTT) were included in the supplemental study. There were 1,353 
subjects (607 men and 746 women; mean age, 58 years; range, 46–76 years) with 
available carotid ultrasound data. Subjects with type 1 diabetes were excluded 
from the study investigating the effect of  glucose tolerance on early atherosclerosis. 
After this exclusion there were 1,304 subjects (579 men and 725 women; mean 
age, 58 years; range, 46–76 years) with available carotid ultrasound and glucose 
tolerance status data. For the genetic studies, there were 1,334 and 1,295 subjects 
with available carotid ultrasound and genotyping data for IL6−174 G>C and 
rs133049, respectively.
 In the catchment areas of  Tampere and Turku University Hospitals, 401 
individuals (176 men and 225 women; mean age, 58 years; range, 46–76 years) 
of  the supplemental study underwent the whole-body impedance cardiography 
measurements. The study areas from the original Health 2000 Survey are shown 
in Figure 4.1.
4.1.2  The Cardiovascular Risk in Young Finns Study
The Cardiovascular Risk in Young Finns Study is a multi-centre study of  
atherosclerosis risk factors in children and young adults. The fi rst cross-sectional 
study was conducted in 1980 and included 3,596 healthy children and adolescents 
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FIGURE 4.1 Study areas of  the original Health 2000 Survey.
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aged 3, 6, 9, 12, 15 and 18 years. Thereafter, these subjects have been followed 
with periodic examinations (Figure 4.2.). In 2001, 2,620 individuals, who had then 
reached the age of  24–39 years, were studied (Juonala et al. 2004a). In addition 
to detailed risk factor assessments, ultrasound measurements of  CIMT and FMD 
were carried out (Raitakari et al. 2003, Juonala et al. 2004b) as well as genotyping 
for the coronary artery disease risk variant on chromosome 9p21.3. Genotyping 
was available for 2,277 individuals and CIMT and FMD data for 2,251 and 2,095 
subjects, respectively. 
4.2  Methods
4.2.1  Physical examination and questionnaires
4.2.1.1  The Health 2000 Survey
Waist circumference was not measured in the supplemental study; therefore, the 
Health 2000 Survey parameters were used to defi ne the presence of  MetS. The mean 
FIGURE 4.2 Progression of  the Cardiovascular Risk in Young Finns Study.
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time interval between the Health 2000 Survey and the supplemental study was 1 year 
and 4 months (range 10–23 months). The mean (±SD) change in body weight during 
this time was 0.52 (±3.43) kg. This was not considered clinically signifi cant, and it is 
likely that the change in waist circumference was not clinically signifi cant either. 
Waist circumference was measured with the subjects in the standing position 
by using the standards created for population health studies (Seidell et al. 2001). 
In the Health 2000 Survey, blood pressure was measured from the right arm 
with a mercury sphygmomanometer (Mercuro 300, Speidel & Keller, Juningen, 
Germany). The fi rst measurement was taken after the subjects had rested at least 5 
minutes in sitting position. Korotkoff ’s fi rst phase was used as the sign of  SBP and 
the fi fth phase as the sign of  diastolic blood pressure (DBP). The measurement 
was repeated 2 minutes after the fi rst measurement and the average of  the 2 
measurements was used to defi ne the presence of  MetS. Current smoking was 
evaluated with a questionnaire and this data was also collected from the Health 
2000 Survey. Those who were currently smoking were defi ned as smokers and the 
rest of  the subjects as non-smokers. 
All the other measurements were collected from the data of  the supplemental 
study. In the supplemental study, blood pressure was measured from the right arm 
after at least 10 minutes’ rest. The measurement was taken 3 times with 1- to 
2-minute intervals. The automatic Omron M4 manometer (Omron Matsusaka, 
Japan, and Netherlands) was used in these measurements. The average of  the 
3 measurements was used in the analysis. Pulse pressure was calculated as the 
remainder of  the average systolic and the average diastolic blood pressure. Height 
and weight were measured and BMI was calculated. 
4.2.1.2  The Cardiovascular Risk in Young Finns Study
Blood pressure was measured using a random-zero sphygmomanometer. Values 
for SBP and DBP were defi ned by Korotkoff  phases I and V, respectively. The 
averages of  3 measurements obtained after 5 minutes of  sitting with 1 to 2 minutes 
between readings were used in the analyses. Height and weight were measured 
and BMI was calculated. Smoking habits were ascertained with a questionnaire.
4.2.2   Blood collection and analyses
In both study populations, venous blood samples were drawn from the 
antecubital vein after an overnight fast. HDL-C, total cholesterol and triglyceride 
concentrations were determined enzymatically (Roche Diagnostics, GmbH, 
Mannheim, Germany for HDL-C; Olympus System Reagent, Hamburg, 
Germany for total cholesterol and triglycerides) with a clinical chemistry 
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analyzer (Olympus, AU400, Hamburg, Germany). LDL-C was calculated with 
the Friedewald formula. Concentrations of  hsCRP were determined using 
a chemiluminescent immunometric assay (Immulite, Diagnostic Products 
Corporation, Los Angeles, CA, USA). OGTT (in the Health 2000 Study only) was 
carried out after 10–12 hours of  fasting.  Subjects were given 75 g of  glucose in a 
10% solution. Venous blood samples for glucose determination were taken before 
and 2 h after the glucose load. Plasma glucose was determined by the glucose 
dehydrokinase method (Diagnostica Merck, Darmstadt, Germany) in a clinical 
chemistry analyzer (Konelab, Vantaa, Finland). 
4.2.3  Genotyping
Genomic DNA was extracted from peripheral blood leukocytes using a 
commercially available kit (Qiagen Inc., Hilden, Germany). rs1333049 was 
genotyped by means of  allelic discrimination using a standard TaqMan assay. 
Fluorescence was detected post polymerase chain reaction using the ABI Prism 
7900HT Sequence Detection System, and genotypes were called with ABI Prism 
SDS software version 2.1 (Applied Biosystems, Foster City, CA, USA).  IL6−174 
G>C genotyping was performed by employing the 5’ - nuclease assay and 
fl uorogenic allele-specifi c TaqMan probes and primers (Livak 1999) as well as the 
ABI Prism 7900HT Sequence Detection System.
4.2.4  Metabolic syndrome, glucose tolerance and Framingham  
 risk scoring
Two different criteria were used to defi ne MetS. According to the NCEP defi nition 
(Expert Panel on Detection, Evaluation, and Treatment of  High Blood Cholesterol 
in Adults 2001), MetS is present if  at least three of  the following criteria are met: 
waist circumference > 102 cm in men and > 88 cm in women, triglycerides ≥ 
1.7 mmol/L, HDL cholesterol < 1.03 mmol/L in men and < 1.29 mmol/L in 
women, blood pressure ≥ 130/≥ 85 mmHg, and fasting glucose ≥ 5.6 mmol/L. 
The fasting glucose threshold of  the NCEP criterion was modifi ed in 2004 
(Grundy et al. 2004b). According to the IDF defi nition (Alberti et al. 2005), MetS 
is present if  waist circumference is increased (≥ 94 cm for men and ≥ 80 cm for 
women) and at least two of  the following four factors are present: 1) triglycerides ≥ 
1.7 mmol/L, or specifi c treatment for this lipid abnormality; 2) HDL cholesterol 
< 1.03 mmol/L in men and < 1.29 mmol/L in women, or specifi c treatment; 3) 
systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg, or 
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treatment for previously diagnosed hypertension; and 4) fasting plasma glucose ≥ 
5.6 mmol/L, or previously diagnosed type 2 diabetes. 
Subjects using insulin were considered to have T2DM and did not participate 
in OGTT. Subjects with oral hypoglycaemic medication or a previous T2DM 
diagnosis were considered to have T2DM, regardless of  their OGTT results. The 
ADA criteria for diabetes (Genuth et al. 2003) were used in the classifi cation of  
subjects with no previously diagnosed diabetes as follows: 1) subjects with fasting 
venous plasma glucose of  >7.0 mmol/l or 2-h venous plasma glucose of  >11.1 
mmol/l in an OGTT were considered to have T2DM; 2) subjects with fasting 
venous plasma glucose of  <7.0 mmol/l and 2-h venous plasma glucose of  7.8–11.0 
mmol/l in an OGTT were considered to have IGT; 3) subjects with fasting venous 
plasma glucose of  5.6–6.9 mmol/l and 2-h venous plasma glucose of  <7.8 mmol/l 
in an OGTT were considered to have IFG; and, fi nally, 4) subjects with fasting 
venous plasma glucose of  <5.6 mmol/l and 2-h venous plasma glucose of  <7.8 
mmol/l in an OGTT were considered to have NGT. In this classifi cation, subjects 
with isolated IGT (normal fasting glucose) and those with both IFG and IGT are 
categorized into the same group (IGT group). IFG and IGT are considered as 
distinct entities, and it would have been logical to report the results for isolated 
IFG and isolated IGT separately. However, the number of  subjects with isolated 
IGT was very small (n=15 in a smallest subgroup), and for this reason the results 
are presented with four glucose tolerance categories, as described above.
The Framingham risk score was defi ned using previously published CHD score 
sheets (Wilson et al. 1998). It gives an estimation of  a subject’s risk for CHD over 
a period of  10 years. The risk score is calculated using the information of  the 
subject’s sex, age, diabetes status, LDL-C and HDL-C levels, blood pressure and 
smoking status.   
4.2.5  Ultrasound examinations
4.2.5.1  The Health 2000 Survey
After a 5-minute rest in the supine position, blood pressure was measured from the 
right arm with a digital blood pressure monitor three times at 1.5-minute intervals. 
Pulse pressure was calculated as the remainder of  mean SBP and DBP. High-
resolution B-mode carotid ultrasound examination of  the right carotid artery 
was performed immediately after the blood pressure measurement according to a 
standardized protocol. A 7.5 MHz or 10 MHz linear array transducer was used. 
The jugular vein was used as an acoustic window whenever possible as described 
by Selzer (Selzer et al. 1994). The sonographer fi rst focused on the distal 1 cm 
of  the common carotid artery (CCA) using the beginning of  the carotid artery 
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bulb (the site where the two parallel walls of  the CCA diverge) as an anatomical 
landmark. The transducer was positioned to visualize both the far and near wall 
lumen-intima and media-adventitia interfaces at a single angle. The sonographer 
then focused on the carotid artery bulb whose distal boundary was the fl ow 
divider and proximal boundary the site where the two parallel walls of  the CCA 
diverge. The transducer was positioned to visualize the far wall interfaces at three 
interrogation angles (lateral, anterior and posterior).
One reader was responsible for reading all the ultrasound images. The computer 
software PROSOUND (Prosound, University of  California (Selzer et al. 1994, 
Selzer et al. 2001)) and its Windows version PROWIN 23.1 were used to track the 
far wall lumen-intima and media-adventitia echoes to determine CIMT over the 
distal 1 cm segment of  the CCA and the carotid bulb. Three summary measures 
were calculated: 1) the mean of  the three average intima-media thickness (IMT) 
measurements of  the CCA (mean CCA IMT), 2) the mean of  the three average 
IMT measurements of  the carotid bulb (mean bulb IMT), and 3) the mean of  these 
two means (mean IMT). The latter was used as a summary measure in this study. 
The maximum CCA IMT value was also used in the present study. 
Carotid artery elasticity indices were used to evaluate arterial stiffness. For the 
elasticity calculations, the computer software PROWIN 23.1 was used to determine 
the arterial diameter over the distal 1 cm length of  the CCA in three images at peak 
systole and end diastole. Systolic and diastolic arterial diameters were calculated as 
the mean of  the three systolic and diastolic arterial diameters, respectively.
Elasticity measurements
On the basis of  the ultrasound measurements and supine blood pressure 
measurements taken immediately before the ultrasound examination, the following 
indices of  arterial elasticity were calculated:
Ep (mmHg) = (PP x DAD)/ADC
YEM (mmHg) = [Ep x DAD/(2 x IMT)]
SI = Ln (SBP/DBP)/(ADC/DAD)
CAC (%/10 mmHg) = 100 x 10 x [(ADC/DAD)/PP]
where, Ep = Peterson’s elastic modulus; PP (pulse pressure) = systolic blood 
pressure - diastolic blood pressure; ADC (arterial diameter change) = systolic 
arterial diameter (SAD) - diastolic arterial diameter (DAD); YEM (Young’s elastic 
modulus); IMT = intima-media thickness (of  the far wall of  CCA at end diastole); 
SI = beta stiffness index; SBP = systolic blood pressure; DBP = diastolic blood 
pressure; CAC = carotid artery compliance.
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4.2.5.2  The Cardiovascular Risk in Young Finns Study
In the Cardiovascular Risk in Young Finns Study, carotid ultrasound examinations 
were performed using a high-resolution ultrasound system (Sequoia 512, Acuson) 
with a 13.0 MHz linear array transducer. CIMT was measured at roughly 10 mm 
from the bifurcation on the left CCA, focusing the image on the posterior wall 
and recording images from the angle showing the greatest distance between the 
lumen-intima interface and the media-adventitia interface (Raitakari et al. 2003). 
At least four measurements were taken at each scan of  the CCA incident with 
the R-wave of  the continuously monitored electrocardiogram to derive mean 
and maximum CIMT. One reader blinded to subjects’ details analyzed the scans. 
To assess brachial artery FMD, the left brachial artery diameter was measured 
both at rest and during reactive hyperaemia. Increased fl ow was induced by the 
infl ation of  a pneumatic tourniquet placed around the forearm to a pressure of  
250 mmHg for 4.5 minutes, followed by release. Three measurements of  arterial 
diameter were performed at end-diastole at a fi xed distance from an anatomic 
marker at rest and at 40, 60 and 80 seconds after cuff  release. The vessel diameter 
after reactive hyperaemia was expressed as the percentage relative to the resting 
scan. The average of  the three measurements at each time point was used in the 
calculation of  the maximum FMD (the greatest value between 40 and 80 seconds) 
(Juonala et al. 2004b).
4.2.6  Pulse wave velocity measurements
PWV was measured with ICGWB using a commercially available circulation monitor 
device CircMon B202 (JR Medical Ltd, Tallinn, Estonia) (Figure 4.3.). Subjects 
were fi rst interviewed and then electrodes (Blue Sensor type R-00-S; Medicotest 
A/S, Ölstykke, Denmark) were applied in a supine position for at least 15 minutes 
prior to the 10-minute PWV measurements. A pair of  electrically connected 
current electrodes was placed on the distal part of  the extremities just proximal 
to the wrists and ankles. Voltage sensing electrodes were placed proximally to the 
current electrodes, with a distance of  5 cm between the centres of  the electrodes. 
With this electrode confi guration, the recorded heart-synchronous changes in 
impedance refl ect the weighted sum of  the pulsatile plethysmograms of  the vessels 
between the electrodes, i.e. almost the whole vascular system. The foot of  the 
whole-body impedance cardiogram coincides with pulse transmission in the aortic 
arch, making it possible to estimate the beginning of  pulse wave transmission in 
the arterial system. Identically, with voltage-sensing electrodes applied to any distal 
region between the current electrodes, pulse-related impedance changes can be 
recorded. In this population the distal impedance plethysmogram was recorded 
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FIGURE 4.3 A, Placement of  electrodes in whole-body impedance cardiography with an additional voltage-
sensing channel on the left calf  for PWV measurement. B, Synchronous recording of  ECG, whole-body ICG, 
and IPG. The time difference between the feet of  the ICG (a) and IPG (b) indicates the pulse transit time 
from aortic arch to popliteal artery. PWV = pulse wave velocity, ECG = electrocardiogram, ICG =imped-
ance cardiography, IPG =impedance plethysmogram. Reprinted from Aatola H, Hutri-Kähönen N, Juonala 
M, Viikari JS, Hulkkonen J, Laitinen T, Taittonen L, Lehtimäki T, Raitakari OT, Kähönen M. Lifetime 
risk factors and arterial pulse wave velocity in adulthood: the cardiovascular risk in young Finns study, Hyper-
tension, 55, 3, 807, with permission from Wolters Kluwer Health (Aatola et al. 2010).
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from a popliteal artery at knee joint level. The active electrode was placed on the 
lateral side of  the knee joint and the reference electrode on the calf, the distance 
between the electrodes being approximately 20 cm. The time difference between 
the feet of  these impedance plethysmograms, recorded from the aortic arch and 
popliteal artery, was measured. The time resolution of  the CircMon recordings 
was 5 ms. The evaluation of  the ICGWB method and PWV measurement using 
ICGWB has been described in detail previously (Kööbi et al. 1997, Kööbi et al. 
2003). The reproducibility values of  the PWV measurements by whole-body 
impedance cardiography (2.42 m/s) and Doppler ultrasound (2.17 m/s) are 
similar (Kööbi et al. 2003).
4.2.7  Statistical methods
Statistical analyses were performed using SPSS for Windows (versions 12.0, 13.0, 
14.0, 15.0, 16.0.1; SPSS Inc., Chicago, IL, USA). In the analysis of  the genetic 
studies, the Statistical Analysis System, SAS (version 8.1; SAS Institute Inc., 
Cary, NC, USA), Statistica for Windows 6.0 (StatSoft Inc., Tulsa, OK, USA) and 
Arlequin (Excoffi er et al. 2005) were also employed. The skewed distributions of  
triglycerides and hsCRP were corrected logarithmically before statistical analyses. 
Suffi ciently normal distributions were achieved with these corrections.  
Possible interactions were tested using the SPSS General Linear Model. 
Student’s t-test (in case there were two groups) or analysis of  variance (ANOVA 
- in case there were more than two groups) were applied to compare the means 
of  continuous variables. Tukey’s or Dunnett’s T3- test was used for multiple 
comparisons in ANOVA. The Chi-square test was employed in the assessment of  
the differences in prevalence rates. Pearson’s correlation coeffi cient was used to 
examine univariate associations of  risk factors and markers of  early atherosclerosis. 
The SPSS general linear model (ANCOVA) was used in the calculation of  
adjusted means and in testing the signifi cance in differences between them. In 
case the ANCOVA p value for the variable of  interest was signifi cant, Fisher’s 
least signifi cant difference test was used in pair-wise group comparisons. Linear 
regression analysis was performed to examine independent relationships between 
CVD risk factors and the markers of  early atherosclerosis. 
Univariate data comparisons between rs1333049 genotype groups (and between 
subjects in the two studies) were based on ANOVA for continuous variables and 
Chi-square test for categorical variables. In the analyses regarding the rs1333049 
genotype, linear regression analysis was used to identify clinical and laboratory 
variables that were independently associated with subclinical atherosclerosis and 
to assess the effect of  this genotype on early atherosclerosis taking these variables 
into account. 95% CI for allele frequencies were calculated using the confi dence 
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interval calculation programme CIA (version 2.1.2). 
Kruskall-Wallis ANOVA was used to evaluate the association of  IL6−174 
G>C with the risk factors and early markers of  atherosclerosis. The extent of  the 
genetic effect of  IL6−174 G>C on selected risk factors was studied with linear 
regression analysis. Before the analysis the regression models were assessed for 
multicollinearity. Variance infl ation factors for covariates in the presented models 
were at acceptable levels, ranging from 1.023 to 1.735 (tolerances ranging from 
0.576 to 0.988).
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5  RESULTS
5.1  Characteristics of the study populations
The main study population of  this thesis consisted of  the subjects in the supplemental 
study of  the Health 2000 Survey. There were 1,353 subjects with available carotid 
ultrasound data in this population. The clinical characteristics of  these subjects 
are presented in Table 5.1. The relationship of  the CHD-associated variant on 
chromosome 9p21.3 (rs1333049) and early carotid atherosclerosis was investigated 
in the population of  the Cardiovascular Risk in Young Finns Study (studied in 2001) 
as well. In this population, there were 2,277 individuals with available genotyping 
data for rs1333049. Their clinical characteristics are shown in Table 5.2.
5.2  Association of glucose tolerance and early   
 atherosclerosis (original publication V)
The effect of  glucose tolerance status on CIMT and carotid artery elasticity (YEM, 
SI, and CAC) was studied in the Health 2000 Survey supplemental study population. 
The interaction between sex and glucose tolerance, in determining CIMT and 
the elasticity indices, was tested. A statistically signifi cant interaction (p <0.05) 
was observed regarding CIMT and CAC, and therefore the results are reported 
separately for men and women. The clinical characteristics and the unadjusted 
means for the markers of  carotid atherosclerosis according to glucose tolerance status 
are presented in Tables 5.3 and 5.4 for men and women, respectively. Of  the 125 (66 
men and 59 women) diabetic subjects, 51 (28 men and 23 women) had previously 
diagnosed T2DM. Of  these 51, 11 (6 men and 5 women) subjects used insulin and 
31 (20 men and 11 women) were on oral hypoglycaemic medication. There was an 
overall tendency for both sexes towards a deteriorating trend in various CVD risk 
factors with the worsening of  glucose tolerance. 
Unadjusted means of  CIMT and elasticity indices had a worsening trend in 
both sexes across the glucose tolerance continuum, with the exception that the 
lowest mean CIMT in men was seen in the IFG group. Signifi cant differences 
between the groups were seen in all variables and in both sexes (ANOVA p<0.01 
for all). In pair-wise group comparisons, means for all variables in the T2DM 
group were signifi cantly worse as compared to the NGT group in men and 
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TABLE 5.1 Clinical and laboratory parameters of  the Health 2000 Survey supplemental study population 
with available carotid ultrasound data (n = 1353). 
Male Female
n=572-607# n=717-746# p
Age (years) 58.0±7.8 58.4±8.2 0.431
Current smoking (%)* 27.5 18.9 <0.001
Body mass index (kg/m2) 27.4±3.9 27.0±4.8 0.077
Waist circumference (cm)* 99.2±11.3 88.8±12.7 <0.001
HDL cholesterol (mmol/l) 1.4±0.4 1.7±0.4 <0.001
LDL cholesterol (mmol/l) 3.4±0.9 3.4±0.9 0.269
Total cholesterol (mmol/l) 5.5±1.0 5.7±0.9 0.005
Triglycerides (mmol/l) 1.5±1.2 1.3±0.6 <0.001
Fasting glucose (mmol/l) 6.1±1.3 5.6±1.0 <0.001
2 h glucose (mmol/l) 7.1±3.2 6.9±2.8 0.402
hsCRP (mg/l) 2.8±4.0 3.0±4.5 0.586
SBP (mmHg) 141.4±20.4 136.4±22.5 <0.001
DBP (mmHg) 87.3±10.8 82.0±9.7 <0.001
PP (mmHg) 54.1±13.8 54.4±16.2 0.771
Medication for hypertension 28.3 29.6 0.604
Statin medication 13.0 10.7 0.193
MetS deﬁ ned by NCEP (%)* 39.7 35.8 0.139
MetS deﬁ ned by IDF (%)* 48.6 41.0 0.005
IFG 41.1 24.8 <0.001
IGT 18.2 16.3 0.366
T2DM 10.3 7.4 0.062
Values are means ± SD except for the prevalences of  current smoking, medications, MetS, IFG, IGT 
and DM2, which are expressed as %. HDL= high-density lipoprotein, LDL= low-density lipoprotein, 
2 h glucose = plasma glucose concentration 2 hours after glucose ingestion in the oral glucose tolerance 
test, hsCRP = high sensitivity C-reactive protein, SBP = systolic blood pressure, DBP = diastolic blood 
pressure, PP = pulse pressure, MetS = metabolic syndrome, NCEP = National Cholesterol Education 
Program, IDF = International Diabetes Federation, IFG = impaired fasting glucose, IGT = impaired 
glucose tolerance, T2DM = type 2 diabetes.
* Data from the Health 2000 Survey.  # Some variables have missing data.
women (p<0.05 for all). In women, the IGT group also differed signifi cantly from 
the NGT group in regard to all dependent variables and the IFG group in regard 
to CIMT and CAC (p<0.01 for all). In women there seemed to be a larger change 
in the elasticity indices across the glucose tolerance continuum than in men.
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TABLE 5.2 Clinical and laboratory parameters in the population of  the Cardiovascular Risk in Young 
Finns Study (studied in 2001) with available genotyping data for rs1333049 (n=2277).
Male Female
n=992-1022# n=1220-1255# p
Age (years) 31.7±5.0 31.7±5.0 0.994
Current smoking (%) 30.0 19.6 <0.001
Body mass index (kg/m2) 25.7±4.1 24.5±4.6 <0.001
Waist circumference (cm) 89.8±10.8 79.3±11.4 <0.001
HDL cholesterol (mmol/l) 1.2±0.3 1.4±0.3 <0.001
LDL cholesterol (mmol/l) 3.4±0.9 3.2±0.8 <0.001
Total cholesterol (mmol/l) 5.3±1.0 5.1±0.9 <0.001
Triglycerides (mmol/l) 1.5±1.0 1.2±0.7 <0.001
Fasting glucose (mmol/l) 5.2±0.9 4.9±0.7 <0.001
hsCRP (mg/l) 1.5±3.3 2.3±4.4 <0.001
SBP (mmHg) 121.6±12.3 112.7±12.3 <0.001
DBP (mmHg) 73.2±11.2 68.8±10.0 <0.001
Medication for hypertension 2.7 2.5 0.807
Cholesterol medication 0.1 0.6 0.030
Values are means ± SD except for the prevalences of  current smoking and medications, which are 
expressed as %. HDL= high-density lipoprotein, LDL= low-density lipoprotein, hsCRP = high sensitivity 
C-reactive protein, SBP = systolic blood pressure, DBP = diastolic blood pressure.
# Some variables have missing data.
Age-adjusted means in the markers of  early atherosclerosis according to the 
glucose tolerance status are shown in Table 5.5. In 56 men and 75 women, carotid 
artery elasticity indices could not be determined. The number of  subjects in the 
statistical analysis was therefore smaller in regard to these indices as compared to 
CIMT. Signifi cant differences between the groups were seen in all variables and in 
both sexes (ANCOVA p<0.05 for all). In men, CIMT was signifi cantly increased in 
subjects with T2DM as compared to those without glucose metabolism impairment. 
In women, however, mean CIMT increased with the worsening of  glucose tolerance, 
and all the other groups had a signifi cantly higher CIMT than the NGT group. 
Mean CAC was signifi cantly lower in all glucose intolerance groups and mean YEM 
signifi cantly higher in the IGT and T2DM groups when compared to the NGT 
group in both sexes. In women, the change across the groups appeared to be larger 
in both YEM and CAC than in men. In women, the T2DM and IGT groups had 
a signifi cantly higher mean SI than the NGT group, while in men only the T2DM 
group differed signifi cantly from the NGT group in regard to SI.
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TABLE 5.3 Clinical characteristics of  the male study subjects according to the glucose tolerance status.
Glucose tolerance
NGT IFG IGT T2DM ANOVA
n = 152-174* n = 215-235* n = 97-104* n =58-66* p-value
Age (years) 57.8±8.1 56.7±7.0 59.5±8.2 61.3±7.8# <0.001
Smoking (%) 30.5 29.4 20.2 24.2 0.230
SBP (mmHg) 135.8±19.2 140.4±18.5 146.2±21.9§ 150.8±23.2¶ <0.001
DBP (mmHg) 84.8±10.0 88.3±9.4§ 88.1±12.0 88.6±13.5 0.004
BMI (kg/m2) 26.0±3.0 27.5±3.9¶ 28.4±3.9¶ 30.1±4.5¶ <0.001
Total cholesterol (mmol/l) 5.5±0.9 5.6±0.9 5.7±1.0 5.3±1.1 0.075
LDL cholesterol (mmol/l) 3.5±0.8 3.5±0.9 3.5±0.9 3.0±1.0# 0.001
HDL cholesterol (mmol/l) 1.5±0.4 1.4±0.4 1.4±0.4 1.3±0.4§ 0.001
Triglycerides (mmol/l) 1.2±0.6 1.4±0.6 1.6±0.9§ 2.3±1.8¶ <0.001
Fasting glucose (mmol/l) 5.2±0.2 6.0±0.3¶ 6.0±0.4¶ 8.3±2.2¶ <0.001
2 h glucose (mmol/l) 5.3±1.2 5.7±1.1# 8.9±0.9¶ 14.3±3.8¶ <0.001
hsCRP 2.5±2.9 2.4±2.9 3.4±5.9 4.2±5.9§ 0.001
Antihypertensive med (%) 21.8 20.4 34.6 62.1 <0.001
Statins (%) 12.1 9.4 15.4 25.8 0.005
Previous CVD (%) 11.5 9.8 16.3 27.3 0.002
CIMT (mm) 0.950±0.197 0.934±0.209 0.989±0.261 1.127±0.351§ <0.001
YEM (mmHg) 6591±4146 7008±3951 8575±8681 9402±6207# 0.001
SI 3.59±0.49 3.63±0.43 3.69±0.51 3.84±0.52# 0.005
CAC (%/10 mmHg) 0.98±0.45 0.90±0.40 0.83±0.41 0.71±0.37¶ <0.001
Values are unadjusted means + SD except for the prevalence rates which are expressed as %.
*= Variation of  n is caused by some missing data. NGT= normal glucose tolerance; IFG= impaired 
fasting glucose; IGT= impaired glucose tolerance; T2DM= type 2 diabetes; SBP= systolic blood pressure; 
DBP= diastolic blood pressure; BMI= body mass index; 2 h glucose= plasma glucose 2 h after glucose 
load in oral glucose tolerance test; hsCRP= high sensitivity C-reactive protein; antihypertensive med= % 
of  subjects using antihypertensive medication; statins= % of  subjects using statins; previous CVD=  % of  
subjects with previous knowledge of  coronary heart disease, stroke, or arterial stenosis, or thrombosis in a 
lower limb; YEM = Young’s elastic modulus; SI = beta stiffness index; CAC = carotid artery compliance.
#p <0.05, §p < 0.01, ¶p <0.001, pairwise comparison with the NGT group; Dunnett’s T3 correction for 
multiple comparisons in ANOVA.
The results of  the ANCOVA model with adjustments for age and other CVD risk 
factors are presented in Table 5.6. Among men, none of  the parameters differed 
signifi cantly between the groups (ANCOVA p>0.1 for all) after these further 
adjustments. In women, adjusted means in CIMT did not differ signifi cantly 
between the groups in this model (p=0.341). In the elasticity indices, however, 
signifi cant differences were observed (ANCOVA p<0.05 for all) even after these 
adjustments. In this model, the T2DM group had signifi cantly higher YEM and SI 
when compared to the NGT group. The T2DM and IFG groups had signifi cantly 
lower CAC compared to the NGT group. Along with glucose tolerance (p<0.001), 
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TABLE 5.4 Clinical characteristics of  the female study subjects according to glucose tolerance status.
Glucose tolerance
NGT IFG IGT T2DM ANOVA
n = 336-371* n =160-176* n =105-119* n =49-59* p-value
Age (years) 56.5±7.6 58.7±8.3# 60.4±8.4¶ 63.8±7.6¶ <0.001
Smoking (%) 20.8 19.9 15.1 13.6 0.373
SBP (mmHg) 129.0±20.8 138.1±19.7¶ 146.6±21.5¶ 155.6±22.2¶ <0.001
DBP (mmHg) 79.7±9.8 83.3±8.4¶ 85.7±9.4¶ 85.6±8.2¶ <0.001
BMI (kg/m2) 25.6±4.3 27.4±4.7¶ 28.9±4.9¶ 30.6±4.5¶ <0.001
Total cholesterol (mmol/l) 5.6±0.9 5.8±0.9 5.8±0.9 5.5±1.0 0.053
LDL cholesterol (mmol/l) 3.3±0.8 3.5±0.9 3.5±0.8 3.3±0.9 0.078
HDL cholesterol (mmol/l) 1.8±0.4 1.7±0.4 1.6±0.4¶ 1.4±0.3¶ <0.001
Triglycerides (mmol/l) 1.1±0.5 1.3±0.6¶ 1.5±0.7¶ 1.8±0.7¶ <0.001
Fasting glucose (mmol/l) 5.1±0.3 5.9±0.3¶ 5.7±0.5¶ 7.3±2.2¶ <0.001
2 h glucose (mmol/l) 5.6±1.1 6.1±1.0¶ 9.0±0.8¶ 14.1±4.0¶ <0.001
hsCRP 2.4±4.2 2.3±2.4 5.0±6.8¶ 4.5±4.5¶ <0.001
Antihypertensive med (%) 17.5 29.5 40.3 69.5 <0.001
Statins (%) 6.7 9.7 13.4 23.7 <0.001
Previous CVD (%) 5.4 11.9 12.6 15.3 0.006
CIMT (mm) 0.852±0.175 0.923±0.226§ 0.957±0.227¶ 0.998±0.255¶ <0.001
YEM (mmHg) 5824±3757 6487±3772 7577±4144§ 10424±7142¶ <0.001
SI 3.56±0.46 3.65±0.44 3.75±0.47§ 3.92±0.47¶ <0.001
CAC (%/10 mmHg) 1.10±0.58 0.89±0.39¶ 0.78±0.43¶ 0.61±0.32¶ <0.001
Values are unadjusted means + SD except the prevalence rates which are expressed as %.
*= Variation of  n is caused by some missing data. NGT= normal glucose tolerance; IFG= impaired 
fasting glucose; IGT= impaired glucose tolerance; T2DM= type 2 diabetes; SBP= systolic blood pressure; 
DBP= diastolic blood pressure; BMI= body mass index; 2 h glucose= plasma glucose 2 h after glucose 
load in oral glucose tolerance test; hsCRP= high sensitivity C-reactive protein; antihypertensive med= % 
of  subjects using antihypertensive medication; statins= % of  subjects using statins; previous CVD=  % of  
subjects with previous knowledge of  coronary heart disease, stroke, or arterial stenosis, or thrombosis in a 
lower limb; YEM = Young’s elastic modulus, SI = beta stiffness index, CAC = carotid artery compliance.
#p <0.05, §p < 0.01, ¶p <0.001, pair-wise comparison with the NGT group; Dunnett’s T3 correction for 
multiple comparisons in ANOVA.
SBP (p<0.001) and age (p=0.012) remained as signifi cant predictors in women for 
YEM in this model. In regard to SI the signifi cant predictors were SBP (p<0.001), 
age (p<0.001) and glucose tolerance (p=0.038). In the model investigating CAC, 
the signifi cant predictors were SBP (p<0.001), age (p<0.001), LDL-C (p=0.030) 
and glucose tolerance (p=0.031).
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TABLE 5.5 Carotid artery intima-media thickness (CIMT) and elasticity indices according to glucose 
tolerance status in men and women, adjusted for age.
Glucose tolerance
NGT IFG IGT T2DM ANCOVA
Men n =152-174* n =215-235* n =97-104* n =59-66* p-value
CIMT (mm) 0.953±0.016 0.953±0.014 0.969±0.021 1.083±0.026¶ <0.001
YEM (mmHg) 6589±437 7191±371 8397±549# 9032±709§ 0.007
SI 3.59±0.04 3.65±0.03 3.66±0.05 3.79±0.06§ 0.045
CAC (%/10 mmHg) 0.98±0.03 0.88±0.03# 0.86±0.04# 0.76±0.05¶ 0.002
Women n=336-371* n=160-176* n=105-119* n=49-59*
CIMT (mm) 0.875±0.009 0.918±0.014§ 0.930±0.017§ 0.928±0.024# 0.005
YEM (mmHg) 6043±223 6433±320 7257±398§ 9782±586¶ <0.001
SI 3.59±0.02 3.64±0.03 3.70±0.04# 3.83±0.06¶ 0.001
CAC (%/10 mmHg) 1.06±0.03 0.90±0.04¶ 0.84±0.05¶ 0.73±0.07¶ <0.001
Values are age-adjusted means ± SE. *= variation of  n is caused by missing elasticity data for some 
subjects. NGT= normal glucose tolerance, IFG= impaired fasting glucose, IGT= impaired glucose 
tolerance, T2DM= type 2 diabetes, YEM = Young’s elastic modulus, SI = beta stiffness index, CAC = 
carotid artery compliance.
#p <0.05, §p < 0.01, ¶p <0.001, pair-wise comparison with the NGT group; Fisher’s least signifi cant 
difference test was used if  a signifi cant ANCOVA p value for glucose tolerance was observed.
TABLE 5.6 Carotid artery intima-media thickness (CIMT) and elasticity indices according to glucose 
tolerance status in men and women, adjusted for age, smoking, LDL cholesterol, BMI, SBP, triglycerides 
and HDL cholesterol.
Glucose tolerance
NGT IFG IGT T2DM ANCOVA
Men n =149-171* n =213-233* n =94-100* n =51-57* p-value
CIMT (mm) 0.972±0.017 0.965±0.014 0.978±0.022 1.046±0.031 0.101
YEM (mmHg) 6969±457 7062±381 7969±567 8222±783 0.317
SI 3.59±0.04 3.64±0.03 3.64±0.05 3.72±0.07 0.461
CAC (%/10 mmHg) 0.95±0.03 0.89±0.03 0.90±0.04 0.88±0.06 0.587
Women n=335-369* n=157-173* n=103-117* n=48-58*
CIMT (mm) 0.899±0.011 0.927±0.014 0.923±0.018 0.905±0.026 0.341
YEM (mmHg) 6260±247 6172±321 6448±404 9042±593¶ <0.001
SI 3.59±0.03 3.62±0.04 3.66±0.05 3.80±0.07§ 0.038
CAC (%/10 mmHg) 1.03±0.03 0.93±0.04# 0.94±0.05 0.84±0.07# 0.031
Values are adjusted means ± SE. Adjustments for age, smoking, LDL cholesterol, BMI, SBP, triglycerides 
and HDL cholesterol. *= variation of  n is caused by missing elasticity data in some subjects. There were 
also a few missing covariate values. BMI= body mass index, SBP= systolic blood pressure, NGT= normal 
glucose tolerance, IFG= impaired fasting glucose, IGT= impaired glucose tolerance, T2DM= type 2 
diabetes, YEM = Young’s elastic modulus, SI = beta stiffness index, CAC = carotid artery compliance. 
#p <0.05, §p < 0.01, ¶p <0.001, pair-wise comparison with the NGT group; Fisher’s least signifi cant 
difference test was used if  a signifi cant ANCOVA p value for glucose tolerance was observed.
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When the second ANCOVA model was further adjusted with the subjects’ 
status in regard to antihypertensive and statin medications as well previous CVD 
(previous knowledge of  CHD, stroke, or arterial stenosis or thrombosis in a lower 
limb) the main fi ndings remained essentially similar (data not shown). The only 
exception was that in regard to SI, the ANCOVA p value was borderline (p=0.067 
vs. p=0.038 in the previous model) signifi cant in women.
5.3  Association of metabolic syndrome and early   
 atherosclerosis (original publications I and III)
In these studies MetS was defi ned by the NCEP defi nition unless otherwise stated. 
The prevalence of  MetS in the Health 2000 Survey supplemental study was 40% 
and 49% in men and 36% and 41% in women using the NCEP and IDF defi nitions, 
respectively. Subjects with MetS were more frequently on antihypertensive 
medication and had higher BMI, waist circumference, blood pressure and higher 
concentrations of  triglycerides, fasting plasma glucose and hsCRP as well as lower 
HDL-C concentration (p<0.05 for all) than the subjects without MetS in both 
sexes. Women with metabolic MetS were older, used statins more often and had 
higher LDL-C and total cholesterol concentrations than women without MetS. In 
men, these variables did not differ signifi cantly according to the presence of  MetS. 
Current smoking status did not differ signifi cantly according to the presence of  
MetS (p>0.1) in either of  the sexes.  Clinical characteristics of  the Health 2000 
Survey supplemental study population are presented in Table 5.7 according to the 
presence of  MetS.
5.3.1  Metabolic syndrome, its components and carotid   
 intima-media thickness (original publication III)
The effects of  MetS and its components on CIMT (mean IMT) were studied in 
the Health 2000 Survey supplemental study population. A borderline statistically 
signifi cant interaction was found between sex and the presence of  metabolic 
syndrome in determining CIMT (p=0.058), and the sexes were therefore analyzed 
separately. For both sexes, CIMT was signifi cantly (p<0.001 for both) higher in 
subjects with MetS (1.02 and 0.98 mm in men and women, respectively) than in 
those without MetS (0.94 and 0.85 mm in men and women, respectively). Age, 
SBP, pulse pressure, HDL-C, triglycerides, fasting plasma glucose, hsCRP and 
FRS correlated statistically signifi cantly with CIMT in both sexes (Table 5.8). 
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TABLE 5.7 Clinical characteristics of  the Health 2000 Survey supplemental study population (with 
available carotid ultrasound data) according to the presence of  MetS (n = 1353).
Male Female
MetS MetS
Yes
(n=225-241)*
No
(359-366)* p
Yes
(n=257-267)*
No
(469-479)* p
Age (years) 58.7 ± 7.6 57.6 ± 8.0 0.075 61.3 ± 8.3 56.7 ± 7.7 <0.001
Smoking (%) 24.9 29.2 0.242 18.4 19.2 0.775
Body mass index 
(kg/m2) 29.7 ± 3.9 26.0 ± 3.2 <0.001 30.1 ± 4.9 25.3 ± 3.8 <0.001
Waist circumference 
(cm) 106.8 ± 10.1 94.2 ± 9.1 <0.001 97.5 ± 11.9 83.9 ± 10.4 <0.001
Heart rate 
(beats/min) 67.6 ± 12.9 65.3 ± 11.9 0.023 68.6 ± 11.6 67.9 ± 10.0 0.421
HDL cholesterol 
(mmol/l) 1.2 ± 0.3 1.6 ± 0.4 <0.001 1.4 ± 0.3 1.9 ± 0.4 <0.001
LDL cholesterol 
(mmol/l) 3.4 ± 0.9 3.5 ± 0.9 0.208 3.6 ± 0.9 3.2 ± 0.8 <0.001
Total cholesterol 
(mmol/l) 5.4 ± 1.0 5.6 ± 1.0 0.147 5.8 ± 1.0 5.6 ± 0.8 0.002
Triglycerides 
(mmol/l) 2.0 ± 1.6 1.2 ± 0.6 <0.001 1.6 ± 0.8 1.0 ± 0.4 <0.001
Fasting glucose 
(mmol/l) 6.6 ± 1.6 5.8 ± 1.0 <0.001 6.1 ± 1.4 5.3 ± 0.5 <0.001
hsCRP (mg/l) 3.6 ± 5.2 2.3 ± 2.9 <0.001 4.2 ± 4.7 2.3 ± 4.3 <0.001
SBP (mmHg) 148.9 ± 20.7 136.4 ± 18.6 <0.001 147.3 ± 21.7 130.3 ± 20.7 <0.001
DBP (mmHg) 90.1 ± 11.0 85.4 ± 10.2 <0.001 85.3 ± 9.0 80.2 ± 9.6 <0.001
PP (mmHg) 58.7 ± 15.0 51.1 ± 12.1 <0.001 62.0 ± 17.2 50.1 ± 13.9 <0.001
Medication for 
hypertension 41.5 19.7 <0.001 46.1 20.5 <0.001
Statin medication 15.4 11.5 0.165 14.6 8.6 0.010
Values are means ± SD except for smoking and medications, which are expressed as%.
MetS = metabolic syndrome defi ned by the NCEP defi nition, NCEP = National Cholesterol Education 
Program, HDL= high-density lipoprotein, LDL= low-density lipoprotein, hsCRP = high sensitivity 
C-reactive protein, SBP = systolic blood pressure, DBP = diastolic blood pressure, PP = pulse pressure.
* Variation of  n is due to missing data for some subjects. 
Adapted from Atherosclerosis, 204, Sipilä K, Moilanen L, Nieminen T, Reunanen A, Jula A, Salomaa V, 
Kaaja R, Kukkonen-Harjula K, Lehtimäki T, Kesäniemi YA, Koivistoinen T, Nieminen MS, Tuomilehto 
J, Kähönen M, Metabolic syndrome and carotid intima media thickness in the Health 2000 Survey, 276-
281, Copyright (2009), with Permission from Elsevier.
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BMI, waist circumference, LDL-C, total cholesterol and DBP had signifi cant 
correlations with CIMT in women but not in men.
A stepwise linear regression model was used to investigate the independent effects 
of  MetS components and other CVD risk factors on CIMT (Table 5.9, model A). The 
initial model included variables signifi cantly correlating with CIMT in the univariate 
model. In men, age and triglycerides were independent predictors explaining 24% 
of  the variation in CIMT. In women, age, pulse pressure and triglycerides were 
independent predictors explaining 29% of  the variation in CIMT. The same regression 
analyses were performed with MetS included in the model as an independent variable 
(Table 5.9, model B). In men this did not change the results, and MetS did not appear 
in the fi nal model as an independent predictor. In women, however, MetS remained 
in the fi nal model as an independent predictor (p<0.001) for CIMT together with age 
and pulse pressure. The change in the explained variance of  the model was 1% (29%–
TABLE 5.8 Correlations between cardiovascular risk factors and CIMT in men (n=496-607*) and 
women (n =628-746*). 
Men Women
r p r p
Age (years) 0.464 <0.001 0.515 <0.001
Body mass index (kg/m2) 0.045 0.267 0.171 <0.001
Waist circumference (cm) 0.077 0.057 0.189 <0.001
HDL cholesterol (mmol/l) -0.131 0.001 -0.157 <0.001
LDL cholesterol (mmol/l) -0.069 0.094 0.131 <0.001
Total cholesterol (mmol/l) -0.055 0.174 0.113 0.002
Triglycerides (mmol/l) 0.161 <0.001 0.231 <0.001
Fasting glucose (mmol/l) 0.116 0.004 0.134 <0.001
hsCRP (mg/l) 0.122 0.003 0.111 0.003
SBP (mmHg) 0.137 0.001 0.352 <0.001
DBP (mmHg) -0.008 0.849 0.148 <0.001
PP (mmHg) 0.208 <0.001 0.402 <0.001
FRS 0.370 <0.001 0.428 <0.001
CIMT = carotid artery intima-media thickness, r = Pearson’s correlation coeffi cient, HDL= high-density 
lipoprotein, LDL= low-density lipoprotein, hsCRP = high sensitivity C-reactive protein, SBP = systolic 
blood pressure, DBP = diastolic blood pressure, PP = pulse pressure, FRS = Framingham risk score.
* Variation of  n is due to missing data for some subjects.
Adapted from Atherosclerosis, 204, Sipilä K, Moilanen L, Nieminen T, Reunanen A, Jula A, Salomaa V, 
Kaaja R, Kukkonen-Harjula K, Lehtimäki T, Kesäniemi YA, Koivistoinen T, Nieminen MS, Tuomilehto J, 
Kähönen M, Metabolic syndrome and carotid intima media thickness in the Health 2000 Survey, 276-281, 
Copyright (2009), with Permission from Elsevier.
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30%) in women after the inclusion of  MetS, in addition to its components. Another 
linear regression model was performed using MetS (instead of  its components) and 
other CVD risk factors (signifi cantly correlating with CIMT in univariate model) as 
independent variables (Table 5.10). In this model, age and MetS were independent 
determinants for CIMT in both sexes. All the above-mentioned regression models 
were also performed using the presence of  antihypertensive medication and statin 
TABLE 5.9. Linear regression models of  the relationships between cardiovascular risk factors and CIMT.
MODEL A Men (n =594) Women (n=720)
CIMT CIMT
Risk variable β ± SE p R2 change 
(%)
Risk variable β ± SE p R2 change 
(%)
Age (years) 0.014 ± 0.001 <0.001 21 Age (years) 0.010 ± 0.001 <0.001 26
Triglycerides 
(mmol/l)
0.205 ± 0.041 <0.001 3 PP (mmHg) 0.002 ± <0.001 <0.001 3
Triglycerides 
(mmol/l)
0.107 ± 0.037 0.004 1
R2 24 % R2 29 %
MODEL B Men (n =594 ) Women (n=720)
CIMT CIMT
Risk variable β ± SE p R2 change 
(%)
Risk variable β ± SE p R2 change 
(%)
Age (years) 0.014 ± 0.001 <0.001 21 Age (years) 0.010 ± 0.001 <0.001 26
Triglyserides 
(mmol/l)
0.205 ± 0.041 <0.001 3 PP (mmHg) 0.002 ± <0.001 <0.001 3
Metabolic 
syndrome
0.059 ± 0.015 <0.001 2
R2 24% R2 30%
CIMT = carotid artery intima-media thickness, β = regression coeffi cient, SE = standard error, PP = 
pulse pressure, R² = adjusted R square value of  the whole model, R² change = change in the adjusted 
R square value after the addition of  the respective variable into the model. The initial stepwise 
regression model for men included age, fasting plasma glucose, high-density lipoprotein cholesterol, 
pulse pressure, high-sensitivity CRP, triglycerides (models A and B) and metabolic syndrome (model B 
only) as independent variables.  The initial stepwise regression model for women included age, waist 
circumference, fasting plasma glucose, high-density lipoprotein cholesterol, pulse pressure, high-sensitivity 
CRP, triglycerides, low-density lipoprotein cholesterol (models A and B) and metabolic syndrome (model 
B only) as independent variables.
Adapted from Atherosclerosis, 204, Sipilä K, Moilanen L, Nieminen T, Reunanen A, Jula A, Salomaa V, 
Kaaja R, Kukkonen-Harjula K, Lehtimäki T, Kesäniemi YA, Koivistoinen T, Nieminen MS, Tuomilehto 
J, Kähönen M, Metabolic syndrome and carotid intima media thickness in the Health 2000 Survey, 276-
281, Copyright (2009), with Permission from Elsevier.
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medication as independent variables. The main fi ndings remained similar (data not 
shown). The results remained essentially similar also when the enter method was used 
instead of  a stepwise method in the regression models.
To further evaluate the sex-related differences in the effect of  MetS on CIMT, 
adjusted means (with different adjustments) for CIMT were calculated with 
ANCOVA (unpublished data). As mentioned earlier, CIMT was higher in subjects 
with MetS in comparison to those who did not suffer from it in both sexes. This 
fi nding remained statistically signifi cant in both sexes after the adjustment with 
age and other CVD risk factors (p=0.006 and p<0.001 for men and women 
respectively). When further adjusted with the components of  MetS, women, but 
not men, with MetS still had signifi cantly higher CIMT compared to the ones 
without the syndrome (p=0.186 and p=0.008 for men and women respectively). 
The patterns of  unadjusted and adjusted means for CIMT in men and women 
according to the presence of  MetS are shown in Figure 5.1.
TABLE 5.10 Linear regression models of  the relationships between metabolic syndrome, other cardiovascu-
lar risk factors and CIMT.
Men (n = 597) Women (n = 722)
CIMT CIMT
Risk variable β ± SE p R2 change 
(%)
Risk variable β ± SE p R2 change 
(%)
Age (years) 0.014 ± 0.001 <0.001 21 Age (years) 0.012 ± 0.001 <0.001 26
Metabolic 
syndrome
0.064 ± 0.018 <0.001 2 Metabolic 
syndrome
0.074 ± 0.014 <0.001 3
R2 22 % R2 29 %
CIMT =carotid artery intima-media thickness, β = regression coeffi cient, SE = standard error, R² = 
adjusted R square value of  the whole model, R² change = change in the adjusted R square value after 
the addition of  the respective variable into the model. The initial stepwise regression model for men 
included age, high-sensitivity CRP and metabolic syndrome as independent variables. The initial stepwise 
regression model for women included age, high-sensitivity CRP, low-density lipoprotein cholesterol and 
metabolic syndrome as independent variables.
Adapted from Atherosclerosis, 204, Sipilä K, Moilanen L, Nieminen T, Reunanen A, Jula A, Salomaa V, 
Kaaja R, Kukkonen-Harjula K, Lehtimäki T, Kesäniemi YA, Koivistoinen T, Nieminen MS, Tuomilehto 
J, Kähönen M, Metabolic syndrome and carotid intima media thickness in the Health 2000 Survey, 276-
281, Copyright (2009), with Permission from Elsevier.
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FIGURE 5.1 Unadjusted and adjusted means for CIMT in men and women. MetS = metabolic syndrome; 
NS = non signifi cant; LDL-C = low-density lipoprotein cholesterol; hsCRP = high sensitivity C-reactive 
protein; No Adj = no adjustment; Adj 1= adjusted for age, LDL-C, hsCRP and smoking; Adj 2 = 
adjusted for risk factors in the Adj 1 model and the components of  MetS.
In order to examine the combined effects of  MetS and the Framingham Risk 
Score on CIMT, the population was divided into four risk profi le categories. In 
the fi rst category, subjects had low FRS (indicating a 10-year CHD risk less than 
10%) and no MetS. The second category consisted of  subjects with low FRS and 
MetS. In the third category, subjects had high FRS (indicating a 10-year CHD risk 
greater than 10%) and no MetS. Finally, the fourth category consisted of  subjects 
with MetS and high FRS. In both sexes, there were signifi cant differences in 
CIMT between the risk categories (ANOVA p value <0.001). In men CIMT was 
signifi cantly higher in subjects with high FRS compared to subjects with low FRS, 
regardless of  the presence or absence of  MetS (p<0.01) (Figure 5.2). In women 
who had low FRS and MetS, CIMT was signifi cantly higher compared to women 
with low FRS without MetS (p=0.012). A similar pattern was observed in women 
with high FRS (p=0.007) (Figure 5.2).
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5.3.2  Metabolic syndrome, its components and arterial pulse  
 wave velocity (original publication I)
The relationships of  MetS, its components and PWV were evaluated in a smaller 
subpopulation of  the Health 2000 Survey supplemental study. There were 401 
individuals (176 men and 225 women) included in these analyses. The NCEP and IDF 
defi nitions for MetS were compared as predictors of  PWV. Due to the smaller sample 
size, men and women were analyzed together. Moreover, the interaction between sex 
and MetS status in determining PWV was not signifi cant (p=0.304). Analyses were 
FIGURE 5.2 Carotid artery intima-media thickness (mean and SD) according to the risk profi le category. 
IMT = intima-media thickness, FRS = Framingham risk score, MetS = metabolic syndrome, ns = non 
signifi cant. Reprinted from Atherosclerosis, 204, Sipilä K, Moilanen L, Nieminen T, Reunanen A, Jula 
A, Salomaa V, Kaaja R, Kukkonen-Harjula K, Lehtimäki T, Kesäniemi YA, Koivistoinen T, Nieminen 
MS, Tuomilehto J, Kähönen M, Metabolic syndrome and carotid intima media thickness in the Health 
2000 Survey, 276-281, Copyright (2009), with Permission from Elsevier.
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also made separately for subjects without known CVD or diabetes, and the results for 
men and women separately are presented as well (unpublished data). 
The prevalence of  MetS was 41% and 47% in men and 40% and 44% in 
women by using the NCEP and IDF defi nitions, respectively. Subjects with MetS 
were older and had higher BMI, waist circumference, blood pressure and higher 
TABLE 5.11 Clinical characteristics of  the subjects with available PWV data (n = 400) according to the 
MetS status.
MetS by NCEP deﬁ nition MetS by IDF deﬁ nition
Yes
(n=156-162)*
No
(n=227-238)*
p Yes
(n=175-182)*
No
(n=208-218)*
p
Age (years) 59.5 ± 7.7 57.6 ± 7.9 0.017 59.5 ± 7.6 57.4 ± 8.0 0.009
Sex (men, %) 44 44 0.883 46 43 0.555
Current smoking (%) 24 23 0.748 24 23 0.689
Body mass index 
(kg/m2)
29.3 ± 3.9 25.6 ± 3.7 < 0.001 29.0 ± 3.8 25.5 ± 3.9 < 0.001
Waist circumference 
(cm)
101.5 ± 11.2 89.2 ± 10.8 < 0.001 100.9 ± 10.8 88.5 ± 11.0 < 0.001
Heart rate (beat/min) 64.9 ± 10.1 63.3 ± 10.7 0.133 64.6 ± 9.7 63.4 ± 11.1 0.260
HDL cholesterol 
(mmol/l)
1.4 ± 0.4 1.7 ± 0.5 < 0.001 1.4 ± 0.4 1.7 ± 0.5 < 0.001
LDL cholesterol 
(mmol/l)
3.6 ± 0.9 3.3 ± 0.9 0.008 3.5 ± 0.9 3.3 ± 0.9  0.028
Total cholesterol 
(mmol/l)
5.7 ± 1.0 5.5 ± 0.9 0.213 5.6 ± 1.0 5.6 ± 0.9  0.429
Triglycerides 
(mmol/l)
1.7 ± 0.8 1.2 ± 0.5 < 0.001 1.7 ± 0.8 1.1 ± 0.5 < 0.001
Fasting glucose 
(mmol/l)
6.3 ± 1.7 5.5 ± 0.7 < 0.001 6.2 ± 1.6 5.5 ± 0.7 < 0.001
hsCRP (mg/l) 4.1 ± 5.6 2.2 ± 3.0 < 0.001 4.0 ± 5.4 2.1 ± 2.8 < 0.001
SBP (mmHg) 142.3 ± 19.5 129.1 ± 18.4 < 0.001 140.2 ± 19.3 129.6 ± 19.1 < 0.001
DBP (mmHg) 85.1 ± 9.2 81.0 ± 9.7 < 0.001 85.0 ± 8.7 80.1 ± 10.0 < 0.001
PP (mmHg) 57.2 ± 15.4 48.2 ± 11.8 < 0.001 55.3 ± 15.4 48.9 ± 12.1 < 0.001
Values are means ± SD except for sex and smoking, which are expressed as %.
PWV = pulse wave velocity, MetS = metabolic syndrome, NCEP = National Cholesterol Education 
Program, IDF = International Diabetes Federation, HDL= high-density lipoprotein, LDL= low-density 
lipoprotein, hsCRP = high sensitivity C-reactive protein, SBP = systolic blood pressure, DBP = diastolic 
blood pressure, PP = pulse pressure.
* Variation of  n is caused by some missing data.
Adapted from Metabolism, 56, Sipilä K, Koivistoinen T, Moilanen L, Nieminen T, Reunanen A, Jula A, 
Salomaa V, Kaaja R, Kööbi T, Kukkonen-Harjula K, Majahalme S, Kähönen M, Metabolic syndrome 
and arterial stiffness: the Health 2000 Survey, 320-326, Copyright (2007), with permission from Elsevier.
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concentrations of  LDL-C, triglycerides, fasting plasma glucose and hsCRP as well 
as lower HDL-C concentrations (p<0.05 for all) than the subjects without MetS, 
regardless of  the defi nition used. Resting heart rate, total cholesterol level, or 
current smoking status did not signifi cantly differ (p>0.1 for all) according to the 
MetS status. Twenty-eight percent of  the study population used antihypertensive 
medication, and 11% were on statins. Selected clinical and demographic data 
is shown in Table 5.11. In both sexes, PWV was signifi cantly higher in subjects 
with MetS (for both defi nitions, p<0.01) than in those without it (Figure 5.3). 
Correlations between CVD risk factors and PWV are given in Table 5.12. When 
the sexes were analysed together, all risk factors correlated signifi cantly with 
PWV, with the exceptions of  total cholesterol and LDL-C. In women, there were 
signifi cant correlations for total cholesterol and LDL-C as well.
FIGURE 5.3 Pulse wave velocity (mean and SD) in men and women with or without metabolic syndrome, 
according to the NCEP defi nition. **P<0.01. The pattern was essentially the same using the IDF 
defi nition. NCEP = National Cholesterol Education Program, IDF = International Diabetes Federa-
tion. Reprinted from Metabolism, 56, Sipilä K, Koivistoinen T, Moilanen L, Nieminen T, Reunanen A, 
Jula A, Salomaa V, Kaaja R, Kööbi T, Kukkonen-Harjula K, Majahalme S, Kähönen M, Metabolic 
syndrome and arterial stiffness: the Health 2000 Survey, 320-326, Copyright (2007), with permission 
from Elsevier.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
2
4
6
8
10
12
14
PW
V
 (m
/s
)
nemoWneM
** **
No metabolic syndrome Metabolic syndrome
** **
72
A stepwise linear regression model was used to investigate the independent 
effects of  risk factors in determining PWV. The initial regression model included 
risk factors signifi cantly correlating with PWV in the univariate model. The 
independent predictors for PWV were SBP, age, fasting blood glucose and waist 
circumference in the whole population and SBP, age and waist circumference 
in subjects without CVD and DM, explaining 55% and 61% of  the variation 
in PWV, respectively (Table 5.13). In men SBP, age, fasting glucose and hsCRP, 
and in women SBP, age and fasting glucose prevailed as independent predictors, 
explaining 60% and 51% of  the variation in PWV, respectively (Table 5.14). The 
inclusion of  MetS (in addition to its components) into the regression models did 
not change the results.
TABLE 5.12 Correlations between cardiovascular risk factors and PWV in all subjects (n = 393-401*), 
in subjects free of  CVD and DM (n = 197-200*), in men (n=171-176*), and in women (n =222-
225*).
All subjects
Subjects free 
of CVD and 
diabetes Men Women
r p r p r p r p
Age (years) 0.510 < 0.001 0.518 < 0.001 0.521 <0.001 0.506 <0.001
Body mass index (kg/m2) 0.238 < 0.001 0.274 < 0.001 0.283 <0.001 0.212 0.001
Waist circumference (cm) 0.343 < 0.001 0.353 < 0.001 0.308 <0.001 0.277 <0.001
HDL cholesterol (mmol/l) -0.161 0.001 -0.255 <0.001 -0.083 0.277 -0.111 0.098
LDL cholesterol (mmol/l) 0.062 0.217 0.208 0.003 -0.105 0.169 0.185 0.006
Total cholesterol (mmol/l) 0.028 0.577 0.120 0.090 -0.113 0.135 0.183 0.006
Triglycerides (mmol/l) 0.199 < 0.001 0.174 0.014 0.130 0.086 0.216 0.001
Fasting glucose (mmol/l) 0.341 < 0.001 0.252 < 0.001 0.392 <0.001 0.257 <0.001
CRP (mg/l) 0.226 < 0.001 0.214 0.003 0.346 <0.001 0.149 0.026
SBP (mmHg) 0.627 < 0.001 0.694 < 0.001 0.572 <0.001 0.656 <0.001
DBP (mmHg) 0.392 < 0.001 0.496 < 0.001 0.253 <0.001 0.448 <0.001
PP (mmHg) 0.619 < 0.001 0.642 < 0.001 0.588 <0.001 0.662 <0.001
PWV = pulse wave velocity, CVD = cardiovascular disease, DM = diabetes mellitus, r = Pearson 
correlation coeffi cient, HDL= high-density lipoprotein, LDL= low-density lipoprotein, CRP = C-reactive 
protein, SBP = systolic blood pressure, DBP = diastolic blood pressure, HR = heart rate, PP = pulse 
pressure.
* Variation of  n is caused by some missing data.
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TABLE 5.13 Linear regression models of  the relationships between cardiovascular risk factors and PWV in 
all subjects (n = 390) and in subjects free of  CVD and DM (n = 196).
All subjects Subjects free of CVD and diabetes
Risk variable β ± SE p R2 change Risk variable Β ± SE p R2 change
SBP (mmHg) 0.05±0.00 < 0.001 40% SBP (mmHg) 0.06±0.01 <0.001 48%
Age (years) 0.10±0.01 < 0.001 11% Age (years) 0.10±0.01 <0.001 12%
Fasting glucose 
(mmol/l)
0.27±0.07 < 0.001 3% Waist 
circumference 
(cm)
0.02±0.01 0.042 1%
Waist 
circumference 
(cm)
0.03±0.01 < 0.001 1%
R2 55 % 61%
PWV = pulse wave velocity, CVD = cardiovascular disease, DM = diabetes mellitus, β = regression 
coeffi cient, SE = standard error, R² change = change in the adjusted R² value after the addition of  the 
respective variable into the model, SBP = systolic blood pressure, R² = adjusted R square value of  the 
whole model.  The initial stepwise regression models included age, sex, waist circumference, fasting 
plasma glucose, high-density lipoprotein cholesterol, SBP, high-sensitivity C-reactive protein, triglycerides, 
and low-density lipoprotein cholesterol (only in subjects free of  CVD and diabetes) as independent 
variables.
Adapted from Metabolism, 56, Sipilä K, Koivistoinen T, Moilanen L, Nieminen T, Reunanen A, Jula A, 
Salomaa V, Kaaja R, Kööbi T, Kukkonen-Harjula K, Majahalme S, Kähönen M, Metabolic syndrome 
and arterial stiffness: the Health 2000 Survey, 320-326, Copyright (2007), with permission from Elsevier.
TABLE 5.14 Linear regression models of  the relationships between cardiovascular risk factors and PWV in 
men and women
Men (n =170) Women (n=218)
Risk variable β ± SE p R2 change Risk variable β ± SE p R2 change
SBP (mmHg) 0.056±0.007 <0.001 33% SBP (mmHg) 0.056±0.006 <0.001 43%
Age (years) 0.121±0.014 <0.001 21% Age (years) 0.084±0.015 <0.001 7%
Fasting 
glucose 
(mmol/l)
0.358±0.082 <0.001 5% Fasting 
glucose 
(mmol/l)
0.206±0.101 0.042 1%
hsCRP (mg/
ml)
0.894±0.261 0.001 3%
R2 60% R2 51%
PWV = pulse wave velocity, β = regression coeffi cient, SE = standard error, R² change = change in 
the adjusted R² value after the addition of  the respective variable in to the model, SBP = systolic blood 
pressure, hsCRP = high-sensitivity C-reactive protein, R² = adjusted R square value of  the whole model.  
The initial stepwise regression model for men included SBP, age, fasting plasma glucose, hsCRP and waist 
circumference as independent variables.  The initial stepwise regression model for women included SBP, 
age, fasting plasma glucose, hsCRP, waist circumference, triglycerides, low-density lipoprotein-cholesterol 
and smoking as independent variables.
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Another regression model was calculated, including MetS (instead of  its 
components) and other CVD risk factors in the model. The independent predictors 
for PWV were age, MetS, sex and hsCRP in the whole population and age, MetS 
and sex in subjects without CVD and DM. These models explained 33%–34% of  
the variation in PWV (depending on the defi nition of  MetS used) (Table 5.15). In 
men age, hsCRP and MetS (defi ned by the NCEP defi nition) and in women age 
and MetS (defi ned by the NCEP defi nition) were independent predictors for PWV, 
explaining 35% and 30% of  the variation in PWV, respectively. The regression 
coeffi cient for MetS was higher in women (β= 1.047) than in men (β= 0.703) (Table 
5.16). All the main fi ndings remained essentially similar when the enter method was 
used instead of  the stepwise method in the regression models (data not shown).
TABLE 5.15 Linear regression models for the relationships between MetS (defi ned by NCEP or IDF), other car-
diovascular risk factors and PWV in all subjects (n= 392) and in subjects free of  CVD and DM (n= 197).
All subjects
Subjects free of 
CVD and diabetes
Risk variable β ± SE p R2 change Risk variable β ± SE p R2 change
Age (years) 0.14±0.01 < 0.001 26% Age (years) 0.13±0.02 <0.001 26
MetS using the 0.92±0.20 < 0.001 4% MetS using the 0.84±0.25 <0.001 5
NCEP deﬁ nition NCEP deﬁ nition
Sex -0.82±0.19 < 0.001 3% Sex -0.72±0.23 0.002 2
hsCRP (mg/l) 0.52±0.21 0.016 0.8%
R2 34% 33%
Age (years) 0.14±0.01 <0.001 26% Age (years) 0.13±0.02 <0.001 26%
Sex -0.80±0.19 <0.001 3% MetS using the 
IDF 
0.78±0.24 0.001 4%
deﬁ nition
MetS using the IDF 0.67±0.20 0.001 3% Sex -0.69±0.24 0.004 3%
deﬁ nition
hsCRP (mg/l) 0.60±0.21 0.005 1%
R2 33% 33%
MetS = metabolic syndrome, PWV=pulse wave velocity, CVD = cardiovascular disease, DM = diabetes 
mellitus, β = regression coeffi cient, SE = standard error, R² change = change in the adjusted R² value 
after the addition of  the respective variable in to the model, NCEP = National Cholesterol Education 
Program, IDF = International Diabetes Federation, hsCRP = high-sensitivity C-reactive protein, R² = 
adjusted R square value of  the whole model.
Initial stepwise regression models included age, sex, hsCRP, MetS (defi ned by NCEP or IDF) and low-
density lipoprotein cholesterol (only in subjects free of  CVD and diabetes) as independent variables.
Adapted from Metabolism, 56, Sipilä K, Koivistoinen T, Moilanen L, Nieminen T, Reunanen A, Jula A, 
Salomaa V, Kaaja R, Kööbi T, Kukkonen-Harjula K, Majahalme S, Kähönen M, Metabolic syndrome 
and arterial stiffness: the Health 2000 Survey, 320-326, Copyright (2007), with permission from Elsevier.
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5.4  Coronary heart disease-associated locus on   
 chromosome 9p21.3 and subclinical atherosclerosis  
 (original publication II)
The association between the CHD-associated locus on chromosome 9p21.3 
(rs1333049) and subclinical atherosclerosis was studied in the Health 2000 Survey 
supplemental study and the Cardiovascular Risk in the Young Finns Study 
(studied in 2001) populations. The age range of  the subjects was 24 to 39 years 
(55% female) in the Young Finns Study and 46 to 76 years (55% female) in the 
Health 2000 cohort. The frequency of  the C allele for rs1333049 was 0.41 (95% 
CI: 0.40 to 0.43) in the Young Finns Study and 0.42 (95% CI: 0.40 to 0.44) among 
the Health 2000 subjects, and the genotypes were in Hardy Weinberg equilibrium 
in both cohorts. The characteristics of  the subjects in each study as partitioned 
by genotype for rs1333049 are shown in Table 5.17. Overall, the older subjects 
from the Health 2000 survey had higher BMI, LDL-C and HDL-C levels as well 
as higher average systolic and diastolic blood pressures when compared with the 
subjects in the Young Finns Study (p<0.001). However, there was no signifi cant 
difference in any of  these traits according to rs1333049 genotype in either age 
group (Table 5.17). Both mean and maximum CIMT were higher in the Health 
2000 cohort when compared to the Young Finns subjects (Table 5.17). However, 
the rs1333049 genotype yielded no effect on either phenotype in either the Young 
Finns Study (p=0.959 and p=0.977, respectively) or in the Health 2000 cohort 
(p=0.714 and p=0.729). Specifi cally, a higher CIMT was not observed in subjects 
TABLE 5.16 Linear regression models for the relationships between MetS (defi ned by NCEP), other cardio-
vascular risk factors and PWV in men and women.
Men (n =171 ) Women (n =219 )
Risk variable β ± SE p R2 change Risk variable β ± SE p R2 change
Age (years) 0.136±0.018 <0.001 26% Age (years) 0.136±0.17 <0.001 26%
hsCRP (mg/ml) 1.189±0.348 0.001 8% MetS 1.047±0.272 <0.001 5%
MetS 0.703±0.297 0.019 2%
R2 35% R2 30%
MetS = metabolic syndrome, PWV = pulse wave velocity, NCEP = National Cholesterol Education 
Program, β = regression coeffi cient, SE = standard error, R² = adjusted R square value of  the whole 
model, R² change = change in the adjusted R square value after the addition of  the respective variable 
in to the model, hsCRP= high-sensitivity C-reactive protein. Initial stepwise regression model for men 
included age, hsCRP and MetS syndrome as independent variables. Initial stepwise regression model 
for women included age, hsCRP, low-density lipoprotein-cholesterol, smoking and MetS syndrome as 
independent variables.
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carrying the CHD-risk-associated allele (C) in either cohort. Likewise, brachial 
FMD responses (available in the Young Finns Study) were similar across the 
genotypes (Table 5.17, p=0.521). 
The results of  the multivariable linear regression analysis of  mean CIMT in 
the two studies are shown in Table 5.18. In the Young Finns Study, there were 
highly signifi cant independent associations of  age, sex, BMI and SBP with CIMT 
and a borderline signifi cant association of  smoking. In the Health 2000 cohort, 
there were similarly signifi cant independent associations of  age, sex and SBP with 
CIMT. HDL-C and smoking, but not BMI, were also independently associated 
with CIMT in this cohort. Taking these factors into account, the rs1333049 
genotype had no independent association with mean CIMT (Table 5.18). The 
results for maximum CIMT were similar (data not shown).
TABLE 5.18 Determinants of  mean CIMT in the Cardiovascular Risk in Young Finns Study and the 
Health 2000 Cohort: Results from multivariable regression analysis
Young Finns Study Health 2000 Cohort
β  (SE) p β (SE) p
Sex 0.0101 (0.0043) 0.017 0.0247 (0.0094) 0.009
Age 0.0050 (0.0004) <0.001 0.0097 (0.0006 <0.001
BMI 0.0024 (0.0005) <0.001 0.0015 (0.0011) 0.190
SBP 0.0054 (0.0020) 0.010 0.0096 (0.0024) <0.001
DBP 0.0060 (0.0025) 0.015 0.0036 (0.0050) 0.472
LDL-C 0.0036 (0.0023) 0.121 0.0009 (0.0051) 0.863
HDL-C 0.0004 (0.0066) 0.947 -0.0264 (0.0131) 0.045
Triglycerides -0.0062 (0.0045) 0.161 0.0337 (0.0296) 0.255
Smoking 0.0086 (0.0048) 0.050 0.0242 (0.0107 0.024
rs1333049 GG/GC vs. CC -0.0009 (0.0048) 0.845 0.0107 (0.0112) 0.337
CIMT = carotid artery intima media thickness, β = regression coeffi cient (beta), SE = standard error, BMI 
= body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, LDL-C= low-density 
lipoprotein cholesterol, HDL-C= high-density lipoprotein cholesterol. The beta values are based on the 
following: age, per year increase; BMI, per 1 kg/m2 increase; for SBP and DBP, per 10 mmHg increase; 
for LDL-C, HDL-C and triglycerides, per 1 mmol/l increase. The beta for triglycerides is for log-
transformed values. The beta coeffi cients for the comparison of  GG/GC vs. CC genotypes are shown. 
The results were similar when modelling GG vs. GC vs. CC or GG vs. CC. The CHD-risk-associated 
allele is the C allele.
Adapted from Samani NJ, Raitakari OT, Sipilä K, Tobin MD, Schunkert H, Juonala M, Braund PS, 
Erdmann J, Viikari J, Moilanen L, Taittonen L, Jula A, Jokinen E, Laitinen T, Hutri-Kähönen N, 
Nieminen MS, Kesäniemi YA, Hall AS, Hulkkonen J, Kähönen M, Lehtimäki T. Coronary artery 
disease-associated locus on chromosome 9p21 and early markers of  atherosclerosis, Arterioscler. Thromb. 
Vasc. Biol. 2008;28(9):1679-1683.
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5.5  Association of IL6-174 G>C genotype with the risk  
 factors and markers of early atherosclerosis   
 (original publication IV)
The association of  IL6-174 G>C genotype (rs1800795) with the risk factors and 
markers of  early atherosclerosis (CIMT and CAC) was studied in the Health 2000 
Survey supplemental study population. The characteristics of  this population 
according to the IL6-174 G>C genotype are shown in Table 5.19. This genotype 
was determined in 1,334 subjects (n = 727 women, n = 607 men). The distribution 
(prevalence given in parenthesis) of  IL6−174 G>C genotypes in our population 
was as follows: GG, n = 258 (19.3%); GC, n = 685 (51.3%); and CC, n = 391 
(29.3%). The allele frequency for allele G was 0.450 and for allele C 0.550. These 
fi gures are similar with previously published fi gures in the Finnish population 
(Hulkkonen et al. 2001, Hulkkonen et al. 2009) and other European populations 
(Huth et al. 2009). As expected, the distributions of  individual IL-6 alleles followed 
the Hardy–Weinberg equation (p=0.21). 
In men, several signifi cant associations between IL6−174 G>C genotype and 
cardiovascular risk factors were found. Serum total cholesterol levels and LDL-C 
levels increased according to IL6−174 G>C genotype in the order GG>GC>CC 
(Table 5.19). Opposite associations (GG<GC<CC) were observed with serum 
triglyceride, fasting insulin and fasting glucose concentrations as well as BMI 
(Table 5.19). IL6−174 allele G homozygocity seemed to be associated with a 
benefi cial effect on HDL-C, SBP and DBP, but these fi ndings were only borderline 
signifi cant (Table 5.19). No signifi cant associations between IL6−174 G>C 
genotype and CAC, CIMT or hsCRP were found in this cohort. 
In order to evaluate the independent associations of  IL6−174 G>C genotype 
and CVD risk factors, linear regression analyses were carried out. In the 
multivariable models IL6−174 G>C  genotype remained an independent predictor 
for serum total cholesterol and LDL-C concentrations when adjusted for age, BMI, 
current smoking, use of  statins and concentrations of  fasting glucose and fasting 
insulin (Table 5.20). Moreover, the trend in the association of  IL6−174 G>C 
genotype and SBP increased in signifi cance (p=0.028) in the multivariable model 
when adjusted by age, BMI, current smoking, antihypertensive treatment and 
concentrations of  fasting glucose, fasting insulin and total cholesterol (Table 5.20). 
IL6−174 G>C genotype was also associated with fasting glucose concentration 
when adjusted for age, BMI and current smoking (Table 5.20), and with BMI 
when adjusted for age, current smoking and concentrations of  fasting glucose and 
total cholesterol (p=0.043, β=0.470, SE=0.232, whole model R2=7%). The trends 
in the associations between IL6–174 G>C genotype and HDL-C concentration, 
triglyceride level and DBP could not be reassured (p=0.139–0.652). When linear 
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regression model R2 values were calculated with and without the IL-6 genotype, the 
IL-6 genotype explained 0.7%–1.3% of  the variation observed in total cholesterol, 
LDL-C, fasting glucose, BMI and SBP levels. Among women there were no 
signifi cant associations between IL6−174 G>C genotype and cardiovascular risk 
factors or the above-mentioned early markers of  atherosclerosis (Table 5.20).
TABLE 5.20 Multivariable linear regression model of  the relationships between IL-6 genotype and total 
cholesterol, LDL-C, SBP as well as fasting glucose levels adjusted with common cardiovascular risk fac-
tors in men (n = 727).
Parameter
Total cholesterol,
β±SE
LDL-C,
β ±SE
SBP, 
β ±SE
Fasting glucose level,
β ±SE
IL-6 genotype −0.123±0.056* −0.133±0.051** 2.567±1.167* 0.176±0.077*
Age −0.011±0.005* −0.007±0.005 0.407±0.110*** 0.014±0.007*
BMI 0.012±0.011 0.017±0.011 0.945±0.238*** 0.074±0.014***
Smoking 0.021±0.087 0.016±0.080 −3.344±1.814 0.069±0.121
Fasting glucose level −0.010±0.034 −0.067±0.033* 2.404±0.699***
Fasting insulin level −0.014±0.006* −0.011±0.006 0.054±0.133
Total cholesterol 3.529±0.861***
Statin medication −0.594±0.116*** −0.643±0.107***
Antihypertensive 
medication −0.652±1.986
R2 9.1% 11.8% 13.7% 6.7%
β= regression coeffi cient, SE = standard error, R² = adjusted R square value of  the whole model, 
LDL-C= low-density lipoprotein cholesterol, SBP = systolic blood pressure, BMI = body mass index.
For IL-6 genotype, the regression coeffi cient is for a 1-unit change in allele G content (null or 1 or 2 copies 
of  allele G). For smoking, the regression coeffi cient is for categorical change from non-smoker to smoker, 
and for statin and antihypertensive treatments the regression coeffi cient is for categorical change of  being 
with or without medication. 
* p < 0.05.
** p < 0.01.
*** p < 0.001.
Adapted from Atherosclerosis, 207, Riikola A, Sipilä K, Kähönen M, Jula A, Nieminen MS, Moilanen L, 
Kesäniemi YA, Lehtimäki T, Hulkkonen J, Interleukin-6 promoter polymorphism and cardiovascular risk 
factors: the Health 2000 Survey, 466-470, Copyright (2009), with permission from Elsevier.
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6  DISCUSSION
6.1  Study populations
6.1.1  The Health 2000 Survey
The overall study cohort of  the Health 2000 Survey (8,028 subjects) represents 
the entire Finnish population aged 30 years and older. This survey was designed 
to evaluate the risk factor levels, morbidity and functional capacity of  the Finnish 
population. The results presented in this thesis are based mainly on the data from 
the supplemental study (sample size 1,867), which was carried out to perform 
a detailed evaluation in regard to CVD and diabetes. The sample size in the 
additional study is based on power calculations to ensure that the relationships of  
interest could be effi ciently studied. The subjects in the supplemental study were, 
due to logistical reasons, living in the area located within 150 km from one of  
the fi ve Finnish University Hospitals. The sample is thus not representative of  the 
whole Finnish population. Nevertheless, it is a comprehensive cross-section of  the 
middle-aged and elderly Finnish population living in urban areas. 
There are some study limitations concerning this population. The results are 
based on cross-sectional data and the causality between the observed relationships 
cannot be assessed. Furthermore, the subjects are Caucasians and the results may 
not apply to other ethnicities. Although a comprehensive evaluation of  the risk 
factors for atherosclerosis was made in the supplemental study, waist circumference 
was not measured. For this reason, the presence or absence of  MetS was defi ned 
using the data of  the main study. The mean time interval between the Health 2000 
Survey and the supplemental study was 1 year and 4 months (range 10–23 months), 
and the mean (SD) change in body weight during this time was 0.52 (3.43) kg. This 
time interval was considered not to have a signifi cant effect on the results. 
6.1.2  The Cardiovascular Risk in Young Finns Study
The Cardiovascular Risk in Young Finns Study population (3,596 subjects in 1980) 
was randomly chosen from the national population register from the areas of  all 
fi ve Finnish University Hospitals (Juonala et al. 2004a). Therefore, the original 
population was quite representative of  the young Finnish population living in 
urban areas. This population, studied in 2001 (2,620 subjects), formed the second 
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cohort in the study evaluating the relationships between the CHD-risk-associated 
variant on chromosome 9p21.3 and early carotid atherosclerosis. In 2001, 63.5% 
of  the original population participated in the follow-up study. Although the 
amount of  dropouts is substantial, the risk profi le among the remaining subjects is 
well representative of  the original population (Juonala et al. 2004a). 
There are some study limitations concerning this population. The present results 
are based on cross-sectional data and causality between the observed relationships 
cannot be assessed. Moreover, the subjects are Caucasians and the results may not 
apply to other ethnicities.
6.2  Methodological considerations
6.2.1  Ultrasound measurements
6.2.1.1  Carotid artery intima-media thickness
Atherosclerotic changes measured by ultrasound can be considered as indirect 
subclinical markers for systemic atherosclerosis. Previous studies have shown that 
CIMT is increased in subjects with CHD (Craven et al. 1990, Salonen et al. 1994, 
Khoury et al. 1997) and it also associates with the extent of  atherosclerosis in 
coronary arteries (Khoury et al. 1997, Lekakis et al. 2000, Kablak-Ziembicka et 
al. 2004). Several prospective studies have also demonstrated that increased CIMT 
is related to an elevated risk of  myocardial infarction and stroke (Belcaro et al. 
1996, Bots et al. 1997, Chambless et al. 1997, O’Leary et al. 1999, Chambless et 
al. 2000). Subjects with increased CIMT had a 1.3–5.1-fold risk of  myocardial 
infarction and a 1.3–8.5-fold risk of  stroke in these studies (Bots et al. 1997, 
Chambless et al. 1997, O’Leary et al. 1999, Chambless et al. 2000). Increased 
CIMT has also been associated with increased mortality (Staub et al. 2006). 
CIMT has been mostly measured from CCA because this is relatively 
easy. Atherosclerotic plaques, however, are usually seen fi rst in the carotid 
bulb, suggesting that measuring this segment of  the arterial wall might be the 
most sensitive marker for early atherosclerosis. Measuring several segments 
simultaneously may decrease errors in the measurements and capture the systemic 
nature of  atherosclerosis better (Howard et al. 1994a, Espeland et al. 1999). 
Although CIMT has been validated well, it is only an estimation of  systemic 
atherosclerosis, and this must be noted when interpreting the results.
In the Health 2000 Survey a high-resolution B-mode carotid ultrasound 
examination of  the right carotid artery was performed. One reader was responsible 
for reading all ultrasound images. CIMT was measured from three digitized end 
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diastole images of  the CCA and the carotid bulb. The means of  the CCA and 
carotid bulb IMT measurements, as well as the maximum CCA IMT value, were 
used in the present study. The intra-reader reproducibility of  the measurements 
was assessed. The reader made the measurement twice from 571 randomly 
selected images from 108 study subjects several weeks apart. The mean difference 
of  these two measurements was 0.001 mm (SD 0.123). The intraclass correlation 
and the coeffi cient of  variation were 0.934 (p<0.001) and 9.2%, respectively.
In the Cardiovascular Risk in Young Finns Study, carotid ultrasound 
examinations were performed using a high-resolution ultrasound system, and 
CIMT was measured from the left CCA. One reader blinded to the subjects’ 
details analyzed the scans. The between-visit (2 visits 3 months apart) coeffi cient of  
variation in mean CIMT values for a subset of  the subjects was 6.4% (Raitakari et 
al. 2003). This method was thus reproducible and valid in both study populations.
6.2.1.2  Carotid artery elasticity
Arterial stiffness has been shown to be a predictor for coronary events and 
cardiovascular mortality (Blacher et al. 1999, Laurent et al. 2001, Boutouyrie et 
al. 2002, Cruickshank et al. 2002). Stiffness of  the carotid arteries, specifi cally, has 
been related to CHD (Hirai et al. 1989), stroke (Tsivgoulis et al. 2006) and all-
cause as well as cardiovascular mortality (Blacher et al. 1998). In the present study, 
it was evaluated using indices that measure different aspects of  carotid artery 
elasticity. CAC measures the ability of  an artery to expand in response to pulse 
pressure caused by cardiac contraction and relaxation (Juonala et al. 2005). On 
the other hand, YEM is an estimate of  arterial stiffness controlling for intima-
media thickness, and SI has been considered to be relatively independent of  blood 
pressure (Salomaa et al. 1995). 
For the elasticity calculations the arterial diameter of  the CCA was measured. 
The indices of  arterial elasticity were calculated on the bases of  ultrasound 
measurements and supine blood pressure. A possible limitation of  this method is 
the fact that blood pressure was not measured from the same artery as the arterial 
diameters. However, the validity of  this method in estimating central arterial 
stiffness has been demonstrated (Imura et al. 1986, Stefanadis et al. 1990). The 
intra-reader reproducibility of  the arterial diameter measurements was assessed. 
The reader measured the arterial diameter twice from 594 randomly selected 
images from 99 study subjects several weeks apart. The mean difference of  the 
two measurements was 0.014 mm (SD 0.145). The intraclass correlation and 
coeffi cient of  variation were 0.990 (p<0.001) and 1.3%, respectively. This method 
was therefore reproducible and valid.
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6.2.1.3  Brachial ﬂ ow-mediated dilatation
FMD of  the brachial artery has been shown to correlate with coronary endothelial 
function (Anderson et al. 1995). It has also been reported to predict cardiovascular 
events (Bonetti et al. 2003). Brachial FMD was measured in the Cardiovascular 
Risk in Young Finns Study. To assess this parameter, the left brachial artery 
diameter was measured both at rest and during reactive hyperaemia (Juonala et 
al. 2004b). The vessel diameter after reactive hyperaemia was expressed as the 
percentage relative to the resting scan. This method has been originally described 
by Celermajer et al. (Celermajer et al. 1992). The greatest weakness of  this method 
is the variability of  the measurements. FMD responses are affected by numerous 
physical and environmental factors (Corretti et al. 2002). The 3-month between-
visit coeffi cient of  variation was 3.2% for brachial artery diameter measurements 
and 26.0% for FMD measurements (Juonala et al. 2004b). The fl uctuation in FMD 
measurements was substantial while the reproducibility of  the brachial artery 
diameter measurements was very good. This suggests that much of  the variation 
in FMD was caused by physiological factors and not by measurement error.
6.2.2  Pulse wave velocity measurement
Arterial stiffness can be evaluated by measuring the velocity of  the pulse wave 
along the arterial tree. Previously, PWV measurements have been taken mostly 
by methods using Doppler ultrasound or mechanoelectrical pulse transducers 
(Lehmann et al. 1992, Wilkinson et al. 1998). It can also be measured with the 
ICGWB method that was used in the present study. The evaluation of  the PWV 
measurement using this method has been described in detail previously (Kööbi 
et al. 1997, Kööbi et al. 2003). ICGWB has not been utilized in scientifi c studies as 
much as other techniques, but the reproducibility values of  PWV measurements 
by ICGWB (2.42 m/s) and Doppler ultrasound (2.17 m/s) are similar (Kööbi et 
al. 2003), suggesting that ICGWB can be used in epidemiological studies as well. 
Indeed, this method has recently been successfully applied in an epidemiological 
setting in the Cardiovascular Risk in Young Finns Study (Aatola et al. 2010).
6.3  Glucose tolerance and early atherosclerosis
The results of  the present thesis show that there are sex-related differences in the 
extent of  early carotid atherosclerosis according to the glucose tolerance status. 
These fi ndings suggest that glucose intolerance might have a stronger association 
with early atherosclerosis in women than in men. 
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It is known that subjects with T2DM have signifi cantly increased early carotid 
atherosclerosis when compared to those without glucose tolerance impairment 
(Kawamori et al. 1992, Folsom et al. 1994, Pujia et al. 1994, Niskanen et al. 1996, 
Bonora et al. 1997, Emoto et al. 1998, Tropeano et al. 2004, Sharrett et al. 2006, 
Martens et al. 2008). Some (Hanefeld et al. 1999a, Mohan et al. 2006, Zhang et 
al. 2006, Faeh et al. 2007), but not all (Niskanen et al. 1996, Tuomilehto et al. 
1998, Wagenknecht et al. 1998) of  the previous studies have found similar results 
in regard to IGT. In a recent meta-analysis, Brohall et al. concluded that CIMT 
in subjects with IGT is slightly increased in comparison to those with normal 
glucose metabolism (Brohall et al. 2009). Non-diabetic glucose intolerance has 
also been associated with increased stiffness of  the carotid arteries (Salomaa et 
al. 1995, van Popele et al. 2000). The present results, after the adjustment for 
age, are in concert with previous reports in regard to diabetic subjects. With 
reference to IGT, however, some sex-related differences were observed. In the 
current population, women with IGT had a signifi cantly worse profi le in terms of  
carotid atherosclerosis than women with normal glucose metabolism after age had 
been taken into account. Among men the IGT group differed signifi cantly from 
the control group only in regard to YEM and CAC. In the age-adjusted model 
even IFG was related to decreased CAC in both sexes and to increased CIMT 
in women. Some authors have reported similar fi ndings (van Popele et al. 2006, 
Zhang et al. 2006), but most of  the previous studies have not observed signifi cant 
changes in early carotid atherosclerosis in subjects with IFG (Bonora et al. 1999, 
Hanefeld et al. 1999b, Tropeano et al. 2004, Faeh et al. 2007). The present fi nding 
of  the deteriorating trend in the atherosclerosis of  the carotid arteries across the 
glucose tolerance continuum is in concert with earlier literature (Henry et al. 
2003). In the current population, subjects with IGT tended to have increased 
CIMT and decreased carotid artery elasticity when compared to those with IFG. 
This observation is in line with previous data (Hanefeld et al. 2000).
The fact that the observed associations weakened substantially after the 
adjustments for age and other cardiovascular risk factors leads to the conclusion 
that these associations are partly mediated by the overall risk factor profi le of  the 
subjects with glucose metabolism disorders. Nonetheless, there were sex-related 
differences even after these adjustments. No signifi cant differences between the 
groups were seen in men, but a trend of  worsening carotid artery elasticity across 
the glucose tolerance categories was observed in women even after the further 
adjustments. In pair-wise comparison the diabetes group had signifi cantly less 
elastic carotid arteries than the group of  subjects with normal glucose metabolism. 
Furthermore, even the IFG group had signifi cantly lower carotid artery compliance 
than the control group. All in all, there were different patterns between the sexes 
in the relationships between glucose tolerance and early atherosclerosis.
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The number of  studies with sex-specifi c results has been limited concerning 
the association of  glucose tolerance and early carotid atherosclerosis. In a study 
by Kawamoto et al., T2DM had a stronger association with elevated CIMT in 
women than in men (Kawamoto et al. 2007b). On the other hand, other studies 
have not confi rmed this fi nding (Folsom et al. 1994, Wei et al. 1996, Temelkova-
Kurktschiev et al. 1999). In these studies, only subjects with normal glucose 
metabolism or diabetes were involved. Two studies investigated the associations 
between glucose tolerance and CIMT in subjects with normal glucose tolerance, 
IGT or T2DM and did not fi nd signifi cant sex-related differences (Niskanen et al. 
1996, Bonora et al. 2000). Salomaa et al. observed a stronger association between 
blood glucose and carotid artery elasticity in women than in men (Salomaa et 
al. 1995) – in this study, however, glucose tolerance was categorized according to 
the fasting glucose values only. In a study by van Popele et al., the stiffness of  
the carotid arteries was evaluated in subjects with normal glucose tolerance, IFG 
or T2DM, and no sex-related differences were seen (van Popele et al. 2006). 
Henry et al. did not fi nd a signifi cant interaction between glucose tolerance and 
sex regarding arterial stiffness (Henry et al. 2003). Their study included subjects 
with normal glucose tolerance, T2DM or impaired glucose metabolism – i.e., 
subjects with IFG or IGT. None of  the above-mentioned studies have included 
both IFG and IGT groups. All in all, previous results regarding sex-related 
differences are limited and controversial. The variation in the fi ndings might be 
partly explained by population differences between the studies and by variation 
in the classifi cation for glucose intolerance. Moreover, most of  the studies have 
not specifi cally investigated sex-related differences. An overview of  the studies 
evaluating sex-related differences regarding glucose tolerance as a risk factor for 
early atherosclerosis is provided in Table 6.1.
To conclude, the present results suggest that women with glucose intolerance 
may be at a greater risk for early atherosclerotic changes than men. In both sexes, 
carotid atherosclerosis tends to increase with the worsening of  glucose tolerance, 
but the changes are at least partly mediated by the overall deterioration in the 
cardiovascular risk factor profi le of  the subjects with impaired glucose metabolism.
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6.4  Metabolic syndrome and early atherosclerosis
The fi ndings of  the present thesis show that MetS is associated in both sexes with 
increased early atherosclerosis. The results suggest, however, that the association 
may be stronger in women than in men. 
6.4.1  Metabolic syndrome as an independent risk factor
MetS has been shown to be a risk factor for T2DM (Lorenzo et al. 2003), CHD 
(Bonora et al. 2003) and mortality (Isomaa et al. 2001, Lakka et al. 2002, Malik 
et al. 2004). It has also been associated with increased CIMT (Hulthe et al. 2000, 
Anand et al. 2003, McNeill et al. 2004, Scuteri et al. 2004, Ahluwalia et al. 2006, 
Skilton et al. 2007) as well as increased arterial stiffness (PWV as a surrogate) in 
several studies (Czernichow et al. 2005, Ferreira et al. 2005, Li et al. 2005, Schillaci 
et al. 2005, Ahluwalia et al. 2006).  The results of  the current study are well in line 
with previous data, and the associations were seen in both sexes (regarding PWV 
and CIMT) and with two different MetS defi nitions (regarding PWV).
There were no signifi cant differences between the NCEP and IDF defi nitions in 
their ability to determine PWV in the present study. The main difference between 
the two defi nitions is that the latter makes central obesity mandatory for diagnosis. 
The IDF defi nition also has a lower waist circumference threshold. Because of  the 
latter, the IDF defi nition produces a higher prevalence for MetS than the NCEP 
defi nition. In the current population, the prevalence fi gures were remarkably 
high, 45.4% and 40.4%, for the IDF and NCEP defi nitions, respectively. This is 
probably related to the age structure of  the study population (45 years and above). 
Nevertheless, this increases our understanding of  the magnitude of  MetS as an 
important cardiovascular risk factor among the Finnish middle-aged population.
 Type 2 diabetes is a stronger risk factor for cardiovascular events in women 
than in men (Beckman et al. 2002). Because T2DM and MetS are closely related, 
it is reasonable to hypothesize that there might be similar sex-specifi c differences 
in the relationship between MetS and early atherosclerosis. Indeed, some reports 
have suggested that the association between MetS and CIMT is more pronounced 
in women than in men (Iglseder et al. 2005). Furthermore, in four different studies, 
MetS has been independently associated with CIMT only in women (Kawamoto 
et al. 2007a, Chen et al. 2008, Lee et al. 2010, Lin et al. 2010). Nishida et al. 
suggested that the increase in the number of  MetS components is associated more 
strongly with CIMT in women than in men (Nishida et al. 2007). Skilton et al. 
studied the effect of  this syndrome, defi ned by three different defi nitions (NCEP, 
IDF or AHA), on CIMT. They concluded that the IDF, but not the other defi nitions, 
89
was independently associated with CIMT in women (Skilton et al. 2007). In 
men, none of  the defi nitions were found to associate with CIMT independently. 
Several studies have reported that MetS is an independent predictor of  PWV only 
in women (Choi et al. 2004, Ferreira et al. 2007, Protogerou et al. 2007). In a 
recent investigation with Chinese subjects, Lin et al. found a stronger association 
between arterial stiffness (PWV and carotid artery elasticity) and MetS in women 
than in men (Lin et al. 2010). On the other hand, Scuteri et al. suggested that 
MetS is associated with a similar deterioration in CIMT, aortic PWV and stiffness 
of  the carotid arteries in both sexes (Scuteri et al. 2010). Empana et al. did not 
fi nd sex-related differences in the effect of  MetS on CIMT either (Empana et al. 
2007). Interestingly, Ishizaka et al. found a signifi cant association between MetS 
and increased CIMT in men but not in women when studying subjects without 
diabetes (Ishizaka et al. 2009). In summary, some of  the previous evidence suggests 
that MetS would have a more pronounced infl uence on early atherosclerosis in 
women than in men. The matter is, however, somewhat controversial. An overview 
of  the studies evaluating sex-related differences regarding MetS as a risk factor for 
early atherosclerosis is shown in Table 6.2.
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In the present study, MetS was found to be an independent determinant of  
CIMT together with age in both sexes, when it was included in the regression 
model instead of  its components. However, the explained variance of  the model 
was smaller in men (22%) than in women (29%). Moreover, when MetS was 
added into the regression model together with its components, it remained an 
independent determinant for CIMT in women but not in men. It should be kept 
in mind that the change in the explained variance of  this model was rather small 
(1%) also in women. MetS was also independently associated with PWV in both 
sexes, the regression coeffi cient (β) being larger for women (1,047) than for men 
(0,703). In other words, a similar sex-related pattern was observed as with CIMT. 
When MetS was added into the regression model together with its components, it 
did not remain a signifi cant predictor for PWW for either sex. Some authors have 
reported earlier that MetS is associated with early atherosclerosis independently 
of  its components (Scuteri et al. 2004, Kawamoto et al. 2005). However, the 
hypothesis that MetS would increase cardiovascular risk more than the sum of  its 
parts has been critically questioned. There is no convincing evidence supporting 
the hypothesis (Kahn et al. 2005, Bayturan et al. 2010).
The clinical signifi cance of  the fi ndings in epidemiological studies is not 
straightforward. The clinical importance of  the observed differences in CIMT 
can be estimated by comparing them to previous data. Prospective studies have 
shown that a 0.1mm increase in CIMT is associated with a 20% to 30% higher 
risk of  subsequent CHD (Bots et al. 1997, Hodis et al. 1998, O’Leary et al. 1999). 
In a study by Burke et al. subjects with a previous myocardial infarction had a 
0.07 mm greater CIMT compared to healthy controls (Burke et al. 1995). In 
another study subjects with a previous stroke had a 0.1 and 0.07 mm higher CCA 
IMT compared to subjects without stroke among women and men, respectively 
(Chambless et al. 2000). In the present study, the adjusted means for CIMT 
(adjustments for age, LDL-C, hsCRP and smoking) were 0.051 mm (men) and 
0.074 mm (women) higher in subjects with MetS than in those without it (Figure 
5.1, unpublished data). In other words, the increase in CIMT as mediated by 
MetS was 0.023 mm higher in women than in men. This is an indirect estimate 
of  the clinical signifi cance, but it supports the conclusion that the observed sex-
specifi c difference is meaningful.
6.4.2  Metabolic syndrome as a risk factor beyond the Framingham  
 Risk Score
Few studies have elaborated the association of  MetS and CIMT after taking the 
Framingham Risk Score into account. Hassinen et al. found in a prospective 
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study with elderly women that MetS is associated with accelerated progression in 
CIMT independently of  this risk score (Hassinen et al. 2006). Teramura et al. also 
suggested that MetS, as defi ned by Japanese criteria, would have additive predictive 
value on CIMT beyond the Framingham score values (Teramura et al. 2007). 
On the other hand, Ahluwalia et al. suggested that MetS would not have such 
an additive effect (Ahluwalia et al. 2006). To the best of  the author’s knowledge, 
sex-related differences in the associations between MetS, the Framingham Risk 
Score and CIMT have not been studied previously. In the present study, these 
associations were modifi ed by sex. The study population was divided into four 
risk profi le categories according to the Framingham score value and MetS status. 
In men, CIMT was signifi cantly higher if  the score value was high, regardless of  
the MetS status. In women, however, CIMT was signifi cantly higher if  MetS was 
present, regardless of  the Framinghan Risk Score category. These fi ndings suggest 
that MetS has a different, and in some circumstances stronger, association with 
early atherosclerosis in women than in men.
In conclusion, the present results suggest that MetS is, in both sexes, associated 
with early atherosclerosis independently of  the risk factors that are not included 
in its defi nition. These associations are, however, modifi ed by sex, and MetS may 
increase the risk of  early atherosclerotic changes more in women than in men. In 
men, traditional risk factors, as defi ned by the Framingham Risk Score, are strong 
determinants of  CIMT, and MetS appears to offer no additional information. In 
women, however, MetS may add to the risk of  subclinical atherosclerosis beyond 
the score values. This additive relationship was observed particularly in women 
with a low risk score, indicating that MetS is an important risk factor for women 
with a low cardiovascular risk according to the traditional risk factors. The NCEP 
and IDF defi nitions were both similarly associated with PWV, which suggests that 
both defi nitions are able to identify subjects with increased arterial stiffness. 
6.5  Coronary heart disease-associated locus on   
 chromosome 9p21.3 and early atherosclerosis
The chromosome 9p21.3 locus has a robust association with CHD, which has been 
demonstrated with a wide range of  populations (Burton et al. 2007, Helgadottir 
et al. 2007, McPherson et al. 2007, Samani et al. 2007, Broadbent et al. 2008, 
Schunkert et al. 2008). The SNP (rs1333049) included in the present study has had 
the strongest association with CHD in these genome-wide association studies. The 
region associated with CHD is located adjacent to genes that play a central role 
in the regulation of  the cell cycle and may be related to atherosclerosis through 
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their role in transforming growth-factor-β-induced growth inhibition (Hannon 
and Beach 1994, Kalinina et al. 2004). In this context, it is relevant to examine 
the association of  this locus with different stages of  atherosclerosis. Interestingly, 
one study has also shown an association of  the locus with abdominal aortic 
aneurysms as well as with intracranial aneurysms, suggesting that the mechanism 
of  its effect on the vascular wall might be more complex than simple promotion 
of  the development of  atherosclerosis (Helgadottir et al. 2007). Furthermore, 
the SNP of  interest has not been identifi ed in genome-wide association studies 
investigating stroke (Matarin et al. 2007, Ikram et al. 2009) or peripheral arterial 
disease (Koriyama et al. 2010). On the other hand, in some candidate gene studies 
this particular SNP has been signifi cantly associated with stroke (Smith et al. 2009) 
and peripheral arterial disease (Cluett et al. 2009).
The association of  the 9p21.3 locus with early atherosclerosis has not been 
examined extensively. Studying the relationships between the risk factors and 
arterial wall thickness in a young predisease cohort provides a useful means of  
investigating the early impact of  such determinants on atherosclerosis. Because 
genetic determinants could be active from a young age, the association of  this 
polymorphism with CIMT was studied in a cohort of  young adult subjects. It 
was also studied in a second cohort with a similar age range as in those in which 
the association of  the locus with CHD was originally demonstrated. Somewhat 
surprisingly, no evidence was observed in support of  an association between this 
polymorphism and any of  the CIMT parameters in either age group. Similarly, 
there was no signifi cant association between the polymorphism and brachial FMD 
in the Young Finns Study. After the publication of  this study, others have reported 
similar results (Cunnington et al. 2009).
Some possible explanations for the lack of  association between the studied SNP 
and early atherosclerosis must be discussed: 1) Both cohorts were population-
based, ethnically homogeneous, and of  Caucasoid origin where the association 
of  CHD with this polymorphism has been well demonstrated (Burton et al. 2007, 
Helgadottir et al. 2007, McPherson et al. 2007, Samani et al. 2007, Schunkert et 
al. 2008). Therefore, the population structure does not offer a plausible explanation 
for the fi ndings. 2) The measurements of  CIMT and FMD were performed 
using standardised protocols by trained personnel. Therefore, it is not likely that 
the observations would be explained by imprecise measurements. 3) The power 
calculations in the present data have shown that there was 80% power at an alpha 
of  0.05 to detect 0.02 mm and 0.06 mm differences in CIMT between CC and 
GG subjects in the Young Finns Study and the Health 2000 cohort, respectively. 
This means that there was 99% power at an alpha of  0.01 to detect a 0.2 mm 
difference in both cohorts. Previous literature has demonstrated that an increase in 
CIMT by 0.1 mm would elevate the risk for future CHD by 20% to 30% (Bots et al. 
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1997, Hodis et al. 1998, O’Leary et al. 1999). According to a recent meta-analysis 
each copy of  the risk allele (allele C) of  this polymorphism is associated with a 
24% increase in the risk of  CHD (95% CI: 20% to 29%) (Schunkert et al. 2008). 
Therefore, the expected effect of  this SNP on CIMT would be approximately 0.1 
mm per allele, assuming that the association with CHD was mediated through 
a similar mechanism. Moreover, several previously reported associations between 
other cardiovascular risk factors and CIMT were easily detected in both cohorts. 
Based on this knowledge, it does not seem likely that inadequate power to detect an 
effect would explain the lack of  association between the 9p21.3 locus and CIMT. 
One plausible explanation for the lack of  association between this CHD-
associated locus and CIMT would be that it is related to the risk of  CHD through 
mechanisms that are not refl ected by changes in arterial wall thickness. Similarly, 
the fi ndings suggest that this polymorphism does not enhance the risk of  CHD 
primarily causing endothelial dysfunction at a young age. If  the mechanism of  
the effect of  the 9p21.3 locus on CHD is related to cell growth and turnover, it 
is possible that it affects coronary plaque stability or vulnerability rather than its 
development per se.
6.6  Association of IL6-174 G>C genotype with the risk  
 factors and markers of early atherosclerosis
The effect of  the IL6−174 G>C genotype (rs1800795) on circulating IL-6 levels 
is complex. Although individual studies have associated either the C or the G 
allele with increased circulating IL-6 levels, a recent joint analysis of  participants 
from 17 studies found no such association (Huth et al. 2009). The authors of  this 
analysis concluded that the genotype might yield an effect on IL-6 levels only in 
certain populations, such as diabetics. Indeed, the CC genotype has been related 
to elevated IL-6 levels in a large study of  elderly subjects with a high prevalence of  
diabetes (Walston et al. 2007).
Several previous studies have found associations between this polymorphism, 
CVD events and cardiovascular risk factors. Allele C has been related to increased 
risk for myocardial infarction (Georges et al. 2001, Humphries et al. 2001, 
Chiappelli et al. 2005) in men as well as obesity (Berthier et al. 2003, Klipstein-
Grobusch et al. 2006), insulin resistance (Kubaszek et al. 2003), elevated CRP level 
(Humphries et al. 2001, Sie et al. 2006), and increased all-cause mortality among 
the elderly (Bruunsgaard et al. 2004, Hurme et al. 2005). In some populations, on 
the other hand, allele C has been related to a decreased risk (Basso et al. 2002) 
or severity (Mysliwska et al. 2006) of  CHD, a lower risk for stroke (Balding et al. 
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2004) and also better insulin sensitivity (Fernandez-Real et al. 2000) in comparison 
to allele G. Moreover, allele G has been suggested to contribute to the development 
of  peripheral arterial disease (Flex et al. 2002, Libra et al. 2006).
All in all, the previous results seem quite controversial. In a recent meta-analysis, 
no signifi cant association between the investigated polymorphism and the risk for 
CHD was found (Sie et al. 2006). Furthermore, the authors of  a systematic review 
regarding its association with stroke stated that the literature is confl icting, which 
might refl ect the complexity of  IL-6 physiology (Tso et al. 2007). They could not 
show either of  the alleles to universally contribute to the stroke risk. In a joint analysis 
of  21 different studies, allele C had a protective effect against T2DM (Huth et al. 
2006), and in a more recent joint analysis carriers of  this allele had lower fasting 
glucose levels independently of  BMI (Huth et al. 2009). No signifi cant association 
between IL6−174 G>C polymorphism and BMI was observed in the joint analysis 
by Huth et al. or in a meta-analysis by Qi et al. (Qi et al. 2007, Huth et al. 2009).
6.6.1  IL6-174 G>C genotype and the risk factors for    
 atherosclerosis
The results of  the present study suggest that the IL6−174 G>C polymorphism 
associates independently with total cholesterol, LDL-C, fasting plasma glucose, 
SBP and BMI in men. In women, however, no signifi cant associations were 
observed between this genotype and cardiovascular risk factors.
 In men, allele C was associated with decreased total cholesterol and 
LDL-C concentrations. The previous results in regard to the association of  
this polymorphism and lipid metabolism are limited and inconsistent. Some 
similarities with the present fi ndings were reported by Barbieri et al. (Barbieri et 
al. 2005). In their population, including men and women, allele C was associated 
with lower total cholesterol levels than allele G. On the other hand, Cardellini et 
al. reported quite the opposite results in a population sample of  obese subjects 
(Cardellini et al. 2005). They did not observe this association in normal-weight 
subjects. Henningsson et al. found an association between the CC genotype and 
low total cholesterol and LDL-C levels in women (Henningsson et al. 2006). There 
was no association in men between this polymorphism and the lipid pattern, and 
the authors suggested that there are sex-specifi c differences in these associations. 
Some studies have not found associations between this genotype and the lipid 
pattern (Lieb et al. 2004, Wernstedt et al. 2004, Moleres et al. 2009). However, 
possible sex-related differences have not been investigated in these studies. 
There were no signifi cant associations between the IL6−174 G>C polymorphism 
and HDL-C or triglyceride concentrations in the present study, which is in line with 
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some previous reports (Moleres et al. 2009). In a very small population Fernandez-
Real et al. found an association between allele G and high triglyceride as well as low 
HDL-C concentrations (Fernandez-Real et al. 2000b). On the other hand, allele C 
has been associated with a lower HDL-C concentration in men (Hulkkonen et al. 
2009) and a higher triglyceride concentration in women (Henningsson et al. 2006). 
In the present study, an adverse association of  allele C was observed with 
SBP, BMI and fasting plasma glucose level. The observed trend for increasing 
blood pressure with the increasing number of  allele C copies is in line with 
previous studies by Humphries et al. (Humphries et al. 2001) and Hulkkonen 
et al. (Hulkkonen et al. 2009) with middle-aged British men and young Finnish 
men, respectively. There are also reports showing no association between this 
polymorphism and blood pressure (Lieb et al. 2004), and it has not been identifi ed 
in large genome-wide association studies on blood pressure (Levy et al. 2009). The 
current results regarding BMI are in concert with some of  the studies relating allele 
C with obesity (Berthier et al. 2003, Wernstedt et al. 2004, Klipstein-Grobusch et 
al. 2006). The observed associations between the polymorphism, fasting glucose 
and BMI differ, however, from the results of  the recent joint analysis by Huth et 
al. (Huth et al. 2009). In fact, the present results are opposite to this analysis as 
regards fasting glucose levels. Possible differences in the populations might explain 
some of  this discrepancy. The overall pattern in the present results is rather 
similar in comparison to the results reported by Hulkkonen et al. (Hulkkonen et 
al. 2009), who also performed their study on the Finnish population. The level 
of  the effect size was also similar in these studies. In both studies allele C was 
associated with deterioration in multiple metabolic risk factors in men. If  there 
truly are sex-specifi c differences in these associations, this might also explain some 
of  the variation in the previous literature.
6.6.2  IL6-174 G>C genotype and the markers of early   
 atherosclerosis
The IL6−174 G>C polymorphism was not associated with the markers of  early 
atherosclerosis in the present cohort in either sex, or when men and women were 
analyzed together. This polymorphism has been previously associated with CIMT 
in British adults with a wide age range (Mayosi et al. 2005) and with arterial 
stiffness among young men in the Cardiovascular Risk in Young Finns study 
cohort (Hulkkonen et al. 2009). The article by Mayosi et al. also included a meta-
analysis of  the previous studies and the results were similar. There are several 
possible reasons for the lack of  association between the mentioned polymorphism 
and early atherosclerosis among the middle-aged and elderly subjects included 
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in the present study. Among the most evident reasons are differences in age, 
baseline blood pressure, body mass or composition, and metabolic as well as 
pharmacological factors between the study cohorts. Furthermore, it is possible 
that the subtle allelic effects, which can be observed in young populations, are 
overrun by stronger lifestyle-related covariates in older cohorts. Post-hoc power 
calculations in the present data have shown that there was 80% power at an alpha 
of  0.05 to detect 0.08 mm and 0.07 mm differences in CIMT between CC and 
GG subjects in men and women, respectively. Therefore, smaller differences may 
not have been detected. On the other hand, the respective detectable difference in 
CIMT was 0.05 mm when the sexes were pooled together.
6.6.3  Clinical characteristics and the eff ects of the IL6-174   
 G>C genotype
The IL-6 gene is under complex regulation, and it is known that many factors, such 
as glucocorticoids, IL-1 and oestrogen (17-beta estradiol), affect its transcription 
activity (Pottratz et al. 1994, Fried et al. 1998). It has been reported that adipose 
tissue accounts for up to 30% of  the total circulating concentrations of  IL-6 in 
healthy subjects (Mohamed-Ali et al. 1997, Yudkin et al. 1999). One of  the reasons 
that no associations between the IL6−174 G>C genotype and cardiovascular 
risk factors were observed in women in the current study may be related to the 
inhibitory effect of  oestrogens on IL-6 transcription activity. 
Allele C may be associated with a lower transcription peak after stimulation but 
a slower decline to baseline in comparison to allele G. As a result, there would be 
higher chronic levels of  IL-6 in allele C carriers than in GG carriers and, on the 
contrary, higher levels in GG subjects in response to acute infl ammation (Terry 
et al. 2000). It has been recently shown that this kind of  genetic effect of  this 
polymorphism on circulating IL-6 levels is clearly seen in normal-weight (BMI<25 
kg/m2) but not in overweight (BMI>25) subjects (Sanderson et al. 2009). Authors 
of  this particular study also noted that the baseline IL-6 level was higher in 
overweight subjects than in those with a normal (body) weight, suggesting that 
there are mutual interactions between IL-6, body composition and infl ammation 
(Sanderson et al. 2009). Moreover, these interactions were emphasized in another 
study with adolescent subjects, where allele C carriers were shown to have higher 
values of  lipoprotein (a) and CRP concentrations as their percentage of  body fat 
mass increased (Moleres et al. 2009). The authors concluded that subjects carrying 
the C allele might be at a greater risk of  developing obesity-related disorders. IL-6 
is a key infl ammatory factor stimulating the expression of  acute-phase proteins 
such as CRP in the liver (Heinrich et al. 1990, Keller et al. 1996). In a recent 
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study consisting of  5,924 participants, Sie et al. found signifi cantly higher CRP 
levels in allele C carriers when compared to the non-carriers of  this allele (Sie 
et al. 2006). The difference in the mean CRP levels between the CC and GG 
genotypes was approximately 0.25 mg/l. In the present study, however, no such 
association was observed. On the basis of  the current and previous results, it is 
tempting to speculate whether the associations of  the IL6-174 G>C genotype with 
plasma lipids, fasting glucose and BMI refl ect direct effects of  IL-6 in the liver 
intermediate metabolism (gluconeogenesis), cholesterol synthesis, and acute phase 
protein induction. These possible metabolic effects of  IL-6 should be studied 
further.
In conclusion, there are signifi cant associations between the IL6−174 G>C 
genotype and the levels of  total cholesterol, LDL-C, fasting plasma glucose and 
BMI in middle-aged and elderly men. There also appears to be an increasing 
trend in blood pressure with the increasing number of  allele C copies of  this 
polymorphism in men. It must be stated that although the absolute effect size 
of  this genotype for risk factor levels is relatively low, the genetic determinants 
presently studied are very common. Therefore, at the population level, this 
polymorphism might be an important genetic risk factor in men. However, the 
effect of  the genotype on different risk factors seems to vary between positive and 
negative depending on the risk factor in question. Hence, the signifi cance of  the 
investigated polymorphism remains uncertain. There are possible sex-specifi c 
differences in the associations of  the IL6−174 G>C genotype and cardiovascular 
risk factors. The effect of  this genotype may also depend on such factors as the 
subject’s body fat mass and metabolic as well as infl ammatory state. The vast 
heterogeneity in the literature regarding the effect of  this polymorphism on 
atherosclerosis could be explained by these factors.
6.7  Clinical implications and future research needs
The growing epidemic of  a sedentary lifestyle and obesity has introduced new 
challenges in the work for the prevention of  cardiovascular disease. Metabolic 
risk factors such as T2DM and MetS have gained vast amounts of  attention in 
the fi eld of  cardiovascular research recently. Their role in the development of  
atherosclerosis has not, however, been fully clarifi ed, and the whole concept of  
MetS has received much criticism (Kahn et al. 2005). There is little doubt that 
overweight and obesity-related disorders are risk factors for atherosclerosis. 
Their role independent of  traditional risk factors has, however, been subject 
to much debate. The evidence is not convincing that MetS would be a greater 
cardiovascular risk factor than the sum of  its parts (Bayturan et al. 2010). It has, 
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nevertheless, been suggested that it acts as an early warning sign especially in 
younger subjects with a relatively low risk according to the individual risk factors 
(Cameron et al. 2009). 
The present results show that MetS and impaired glucose metabolism are 
risk factors for early atherosclerosis in both sexes. These fi ndings are in line with 
earlier reports. However, the associations between metabolic risk factors and early 
atherosclerosis seem to be modifi ed by sex. The present results suggest that these 
associations might be more pronounced in women. There have been some earlier 
indications of  this (Salomaa et al. 1995, Iglseder et al. 2005), but the issue has 
not been substantially covered. According to the present results MetS is not an 
additional risk factor beyond its components in men, nor is the possible additional 
value very prominent in women either. The fi ndings that the effects of  risk factors 
differ between men and women are not surprising, given the fact that the sexes 
differ in genetic and hormonal background. One may speculate some possible 
explanations for these sex-related differences. Menopause and oestrogenic status 
are possible and commonly suggested mediators for sex-related differences in 
cardiovascular risk. Women in the present study were mostly postmenopausal, and 
it is reasonable to speculate that this might have increased their vulnerability to 
such risk factors as glucose intolerance and MetS. It has also been shown that 
the deteriorating tendency in other metabolic risk factors, such as central obesity, 
lipid profi le and hypertension, is stronger in diabetic women than their male 
counterparts (Howard et al. 1998). Insulin resistance has been suggested to be the 
key element in this process of  reversing the usually favourable female risk profi le in 
diabetic women (Howard et al. 1998). 
If  women with metabolic risk factors truly are at greater risk of  CVD, this 
warrants physicians and researchers to pay more and more attention to women’s 
cardiovascular health as the prevalence of  obesity increases. Further studies are 
needed to confi rm the sex-specifi c differences and also to clarify the molecular 
mechanisms behind them. 
Another rapidly growing fi eld in cardiovascular research is genetics. Genetic 
risk factors for CVD have been studied vigorously in recent years. However, 
few clinical tools have been derived from this work, the main reason being the 
complexity of  atherosclerosis as a disease. It is a multifactorial process whose 
molecular biology has not been fully discovered. Another important reason is that 
the effects of  genetic risk factors may vary between populations. Other factors 
– such as obesity, smoking and hypertension – may also modify the effects. The 
interactions are not easy to control in scientifi c studies, because many of  them are 
yet unidentifi ed. 
Previous literature regarding the effects of  the IL6−174 G>C genotype on the 
risk factors and markers of  early atherosclerosis emphasize the above-mentioned 
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problems. The results of  the current study suggest that allele C of  this genotype 
is associated with higher blood pressure, and with blood glucose level as well as 
obesity in men. Comparable results have been reported (Humphries et al. 2001, 
Berthier et al. 2003, Klipstein-Grobusch et al. 2006, Hulkkonen et al. 2009), but 
large joint and meta-analyses have yielded contradictory results (Qi et al. 2007, 
Huth et al. 2009). These confusing results may arise from population differences, 
as the effect of  this polymorphism may also depend on the subject’s metabolic 
and infl ammatory state. The present results also suggest that there are sex-specifi c 
differences in the studied associations. The true role of  the studied genotype in the 
pathogenesis of  atherosclerosis needs to be elaborated further.
The chromosome 9p21.3 locus has been shown to have a robust association 
with CHD in a wide range of  populations (Burton et al. 2007, Helgadottir 
et al. 2007, McPherson et al. 2007, Samani et al. 2007, Broadbent et al. 2008, 
Schunkert et al. 2008). Interestingly, no such association with early atherosclerosis 
was found in the present study. The reason for this might be that the effect of  the 
locus may be related to advanced stages of  the atherosclerosis process and not so 
much to its initiation. This fi nding emphasizes the fact that atherosclerosis and its 
complications are results of  a long process. Risk factors may thus be associated 
with different parts of  the process.
In the future, cardiovascular research needs to concentrate on more 
personalized approaches. Risk factors that need to be taken into account may 
depend considerably on sex, age, ethnicity and other factors. Even some of  the 
traditional risk factors may have to be re-evaluated in specifi c populations.
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7  SUMMARY AND      
 CONCLUSIONS
Obesity is becoming a major cardiovascular risk factor. It is related to insulin 
resistance, metabolic syndrome and type 2 diabetes. The independent associations 
of  metabolic syndrome and different stages of  glucose intolerance with early 
atherosclerosis were studied in the population of  the Health 2000 Survey. 
Possible sex-related differences in these relationships were one of  the main 
areas of  interest. Atherosclerosis also has a strong genetic basis that has not 
been thoroughly established. In the present thesis, two contemporary genetic 
variants were studied in detail. These particular genetic variants were identifi ed 
utilizing different genetic approaches. The relationship between the coronary 
heart disease-associated locus on chromosome 9p21.3 (rs1333049) and early 
atherosclerosis was investigated among the populations of  the Health 2000 Survey 
and the Cardiovascular Risk in Young Finns Study, because this polymorphism 
has emerged as having the strongest association with coronary heart disease in 
genome-wide association studies. The associations between the IL6−174 G>C 
genotype, early atherosclerosis and cardiovascular risk factors were evaluated in 
the Health 2000 Survey population, because this polymorphism has been strongly 
associated with cardiovascular risk factors and coronary heart disease in candidate 
gene studies. Moreover, IL-6 is closely connected to the infl ammatory cascade, as 
are MetS and glucose intolerance, which were also included in the main focus of  
this thesis. The principal conclusions of  the present study are as follows:
I There is a trend of  increasing carotid atherosclerosis according to the 
worsening of  glucose tolerance in both sexes. This trend is already seen in 
the non-diabetic stages of  glucose intolerance. Impaired glucose tolerance 
generally associates with a worse profi le in early carotid atherosclerosis when 
compared to impaired fasting glucose. A deterioration in the overall CVD risk 
factor profi le in subjects with glucose intolerance plays an important part in 
mediating the observed associations. These results also suggest that women 
with glucose intolerance may have a greater risk for early atherosclerotic 
changes than men.
II Metabolic syndrome is, in both sexes, associated with early atherosclerosis 
independently of  the risk factors that are not included in its defi nition among 
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middle-aged and elderly Finns. This association is modifi ed by sex and may be 
more pronounced in women than in men. Metabolic syndrome is associated 
with increased carotid artery intima-media thickness especially in women with 
low cardiovascular risk as defi ned by traditional risk factors. 
III No association between the chromosome 9p21.3 locus (rs1333049) and early 
carotid atherosclerosis was found in either young Finnish adults or middle-
aged and elderly Finns. These results suggest that this locus is related to the 
risk of  coronary heart disease through mechanisms that are not refl ected by 
changes in arterial intima-media thickness. Similarly, the fi ndings propose 
that this genetic locus does not enhance the risk of  coronary heart disease, 
primarily causing endothelial dysfunction at a young age. 
IV There were signifi cant associations between the IL6−174 G>C genotype 
and the levels of  total cholesterol, LDL-C, fasting plasma glucose and BMI 
among middle-aged and elderly men. This polymorphism also appears to 
be associated with systolic blood pressure in men. The results were, however, 
contradictory for the different risk factors in regard to which allele had a 
favourable association. No such associations were observed in women. Possible 
sex-specifi c differences in the associations of  the IL6−174 G>C genotype and 
cardiovascular risk factors may partly explain the heterogeneity in the previous 
results regarding the effect of  this genotype on atherosclerosis. The impact 
may also depend on factors such as body fat mass, and the metabolic as well as 
infl ammatory state.
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Abstract
Metabolic syndrome and its components have been associated with arterial stiffness and cardiovascular disease. The objective of this
study was to examine the independent influences of metabolic syndrome, its components, and other cardiovascular risk factors on arterial
stiffness as well as to compare 2 definitions for metabolic syndrome (National Cholesterol Education Program [NCEP] and International
Diabetes Federation [IDF]) in their ability to identify subjects with arterial stiffness. The study population consisted of 401 Finnish men and
women aged 45 years and older who participated in a substudy of the Finnish population–based Health 2000 Survey. Pulse wave velocity
(PWV) measured by whole-body impedance cardiography was used as a marker of elevated arterial stiffness. In multivariate models, systolic
blood pressure, age, waist circumference, and fasting blood glucose (P V .001 for all) were independent determinants for PWV. In the
models including metabolic syndrome instead of its components, the NCEP and IDF definitions were similarly associated with PWV (P V
.01 for both), the other independent determinants being age, sex (P b .001 for both) and plasma C-reactive protein concentration (P = .016
and P = .005 in models containing the NCEP and IDF definitions, respectively). Systolic blood pressure, age, waist circumference, and
fasting blood glucose level were independently associated with increased arterial stiffness. Metabolic syndrome determined increased arterial
stiffness independently of other known cardiovascular risk factors. The NCEP and IDF definitions did not differ in their ability to identify
subjects with increased arterial stiffness.
D 2007 Elsevier Inc. All rights reserved.
1. Introduction
Metabolic syndrome is a cluster of cardiovascular risk
factors such as central obesity, hypertension, dyslipidemias,
and glucose intolerance. It has been shown to be a predictor
of type 2 diabetes mellitus [1], coronary heart disease [2],
and mortality [3-5]. Metabolic syndrome has various
definitions. The National Cholesterol Education Program
(NCEP) Adult Treatment Panel III proposed their widely
used clinical definition for metabolic syndrome in 2001 [6].
Recently, the International Diabetes Federation (IDF) also
published a worldwide definition of metabolic syndrome
[7]. These definitions have 2 basic differences. First, the
IDF definition has a significantly lower cutoff point for
waist circumference than the NCEP definition. Second, the
IDF definition makes the presence of increased waist
circumference mandatory for diagnosis, whereas the NCEP
definition considers waist circumference as important as the
other components.
Arterial stiffness has been a strong independent predictor
of coronary events and cardiovascular mortality in several
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patient groups [8-11]. It can be evaluated by measuring
pulse wave velocity (PWV) along the arterial tree. The
individual components of metabolic syndrome have been
previously associated with increased arterial stiffness and
higher PWV values [12,13]. Hypertension in particular has
been linked to increased arterial stiffness [14]. Metabolic
syndrome as a whole, mostly according to the NCEP
criteria, has also been associated with arterial stiffness
[13,15-18]. The NCEP and the IDF criteria have been
compared in few studies so far. Both definitions have been
similarly associated with coronary heart disease [19] and
mortality [20]. To our knowledge, these criteria have not
been compared regarding their ability to identify subjects
with increased arterial stiffness.
The aim of this study was to evaluate the relationships
among metabolic syndrome, its individual components, and
arterial stiffness. Furthermore, we set out to discover
whether the NCEP and the IDF definition can identify
subjects with increased arterial stiffness similarly. We also
intended to test the applicability of the whole-body
impedance cardiography (ICGWB) method for measuring
PWV in a large epidemiological study.
2. Methods
2.1. Study population
We studied a subpopulation of a large Finnish cross-
sectional health examination survey (the Health 2000
Survey) carried out in 2000-2001 [21]. The overall study
cohort was a two-stage stratified cluster sample (8028 per-
sons) representing the entire Finnish population aged
30 years and older. To study cardiovascular disease (CVD)
and diabetes more thoroughly, a supplemental study was
carried out (sample size, 1867; participation rate, 82%). The
subjects, a subpopulation of the Health 2000 Survey, in the
supplemental study were 45 years and older, and the study
was executed in the catchment areas of the 5 Finnish
university hospitals because specialized equipment was
required. In the catchment areas of Tampere and Turku
university hospitals, 401 individuals (176 men and 225 wom-
en; mean age, 58 years; range, 46-76 years) participated in the
supplemental study and underwent the ICGWB measure-
ments. These individuals were selected to be our study group.
Waist circumference was not measured in the supple-
mental study; therefore, the Health 2000 Survey parameters
were used to define the presence of metabolic syndrome. All
the other measurements and laboratory tests used in the
present study were collected from the data of the supple-
mental study. The mean time interval between the Health
2000 Survey and the supplemental study was 1 year and
4 months (range, 10-23 months). The mean (FSD) change
in body weight during this time was 0.52 (F3.43) kg.
Because this change was not clinically significant, it is
likely that change in waist circumference was not clinically
significant either. Because most of the women in our study
population had reached menopause, we did not analyze
premenopausal and postmenopausal women separately. To
evaluate a possible conflicting influence of concomitant
diseases on the associations between the risk factors and
PWV, we also created a smaller sample excluding subjects
with CVD and diabetes. Subjects with previous myocardial
infarction or stroke, or with diagnosed diabetes, coronary
heart disease, cardiac insufficiency, cardiac arrhythmia,
hypertension, arterial stenosis, or thrombosis in a lower
limb or other CVD were excluded. The subjects who had
fasting plasma glucose concentration of 7 mmol/L or higher
or who had 2-hour glucose value of 11.1 mmol/L or higher
in the oral glucose tolerance test were excluded. From this
smaller sample, we also excluded subjects who were on
antihypertensive medication or statins. After these addition-
al exclusions, 200 individuals free of CVD and diabetes
remained with available PWV data.
2.2. Metabolic syndrome
We used 2 different criteria to define metabolic syn-
drome. According to the NCEP definition [6], a person has
metabolic syndrome if at least 3 of the following criteria are
met: waist circumference greater than 102 cm for men and
greater than 88 cm for women; triglycerides, 1.7 mmol/L or
greater; high-density lipoprotein (HDL) cholesterol, less
than 1.03 mmol/L for men and less than 1.29 mmol/L for
women; systolic blood pressure, 130 mm Hg or higher, and
diastolic blood pressure, 85 mm Hg or higher; and fasting
glucose, 5.6 mmol/L or higher. The fasting glucose
threshold of the NCEP criterion was modified in 2004 [22].
According to the IDF definition [7], a person has
metabolic syndrome if waist circumference is increased
(z94 cm for men and z80 cm for women) and at least 2 of
the following factors are present: triglycerides, 1.7 mmol/L
or greater, or specific treatment of this lipid abnormality;
HDL cholesterol, less than 1.03 mmol/L in men and less
than 1.29 mmol/L in women, or specific treatment; systolic
blood pressure 130 mm Hg or higher or diastolic blood
pressure 85 mm Hg or higher, or treatment of pre-
viously diagnosed hypertension; fasting plasma glucose,
5.6 mmol/L or higher, or previously diagnosed type 2
diabetes mellitus. The IDF definition has ethnicity-specific
cutoff points for waist circumference.
2.3. Pulse wave velocity
Pulse wave velocity was measured by ICGWB using a
commercially available circulation monitor device (Circ-
Mon B202, JR Medical, Tallinn, Estonia). Subjects were
first interviewed and then electrodes (Blue Sensor type
R-00-S; Medicotest, O¨lstykke, Denmark) were applied
while subjects were in the supine position for at least
15 minutes before the 10-minute PWV measurements. A
pair of electrically connected current electrodes was placed
on the distal part of the extremities just proximal to the
wrists and ankles. Voltage-sensing electrodes were placed
proximally to the current electrodes, with a distance of 5 cm
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between the centers of the electrodes. With this electrode
configuration, the recorded heart-synchronous changes in
impedance reflect the weighted sum of the pulsatile
plethysmograms of the vessels between the electrodes, ie,
almost the whole vascular system. The foot of the whole-
body impedance cardiogram coincides with pulse transmis-
sion in the aortic arch, making it possible to estimate the
beginning of pulse wave transmission in the arterial system.
Similarly, with voltage sensing electrodes applied to any
distal region between the current electrodes, pulse-related
impedance changes can be recorded. In this study, the distal
impedance plethysmogram was recorded from a popliteal
artery at knee joint level. The active electrode was placed on
the lateral side of the knee joint and the reference electrode
on the calf, the distance between the electrodes being about
20 cm. The time difference between the feet of these
impedance plethysmograms, recorded from the aortic arch
and popliteal artery, was measured. The time resolution of
the CircMon recordings was 5 milliseconds. The evaluation
of the ICGWB method and PWV measurement using ICGWB
has been described in detail previously [23,24]. Reproduc-
ibility values of the PWVmeasurements by ICGWB (2.42m/s)
and Doppler ultrasound (2.17 m/s) are similar [24].
2.4. Waist circumference, body mass index, blood pressure,
and smoking
Waist circumference was measured with subjects in the
standing position by using the standards created for
population health studies [25]. Height and weight were
measured and body mass index (BMI) was calculated. In the
Health 2000 Survey, blood pressure was measured from the
right arm with a mercury sphygmomanometer (Mercuro
300, Speidel & Keller, Juningen, Germany). The first
measurement was taken after subjects had rested at least
5 minutes in the sitting position. Korotkoff’s first phase was
used as the sign of systolic blood pressure and the fifth
phase as the sign of diastolic pressure. The measurement
was repeated 2 minutes after the first measurement. The
average of the 2 measurements was used in the analysis. In
the supplemental study, blood pressure was measured from
the right arm after at least 10 minutes’ rest. The measure-
ment was taken 3 times with 1- to 2-minute intervals. The
automatic Omron M4 manometer (Omron Matsusaka,
Japan, and Omron Healthcare Europe, Hoofddorp, the
Netherlands) was used in these measurements. The average
of the 3 measurements was used in the analysis. Pulse
pressure was calculated as the difference between the
average systolic and the average diastolic blood pressure.
Current smoking was evaluated with a questionnaire. Those
who were currently smoking were defined as smokers and
the rest of the subjects as nonsmokers. The smoking data
used in the present study were collected from the Health
2000 Survey data.
Table 1
Clinical and laboratory parameters of the study cohort (n = 400) with and without metabolic syndrome (MetS) according to 2 definitions (NCEP, IDF)
MetS by NCEP definition MetS by IDF definition
Yes (n = 156-162)a No (n = 227-238)a P Yes (n = 175-182)a No (n = 208-218)a P
Age (y) 59.5 F 7.7 57.6 F 7.9 .017 59.5 F 7.6 57.4 F 8.0 .009
Sex (men, %) 44 44 .883 46 43 .555
Current smoking (%) 24 23 .748 24 23 .689
BMI (kg/m2) 29.3 F 3.9 25.6 F 3.7 b .001 29.0 F 3.8 25.5 F 3.9 b .001
Waist circumference (cm) 101.5 F 11.2 89.2 F 10.8 b .001 100.9 F 10.8 88.5 F 11.0 b .001
Heart rate (beats/min) 64.9 F 10.1 63.3 F 10.7 .133 64.6 F 9.7 63.4 F 11.1 .260
HDL cholesterol (mmol/L) 1.4 F 0.4 1.7 F 0.5 b .001 1.4 F 0.4 1.7 F 0.5 b .001
LDL cholesterol (mmol/L) 3.6 F 0.9 3.3 F 0.9 .008 3.5 F 0.9 3.3 F 0.9 .028
Total cholesterol (mmol/L) 5.7 F 1.0 5.5 F 0.9 .213 5.6 F 1.0 5.6 F 0.9 .429
Triglycerides (mmol/L) 1.7 F 0.8 1.2 F 0.5 b .001 1.7 F 0.8 1.1 F 0.5 b .001
Fasting glucose (mmol/L) 6.3 F 1.7 5.5 F 0.7 b .001 6.2 F 1.6 5.5 F 0.7 b .001
CRP (mg/L) 4.1 F 5.6 2.2 F 3.0 b .001 4.0 F 5.4 2.1 F 2.8 b .001
SBP (mm Hg) 142.3 F 19.5 129.1 F 18.4 b .001 140.2 F 19.3 129.6 F 19.1 b .001
DBP (mm Hg) 85.1 F 9.2 81.0 F 9.7 b .001 85.0 F 8.7 80.1 F 10.0 b .001
PP (mm Hg) 57.2 F 15.4 48.2 F 11.8 b .001 55.3 F 15.4 48.9 F 12.1 b .001
Values are means F SD except values for sex and smoking, which are percentages. SBP indicates systolic blood pressure; DBP, diastolic blood pressure;
PP, pulse pressure.
a Variation of n is caused by the fact that some values are missing for some subjects.
Fig. 1. PWV (mean and SD) in men and women with or without metabolic
syndrome, according to the NCEP definition. **P b .01. The pattern is
essentially the same using the IDF definition.
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2.5. Laboratory tests
Venous blood samples were drawn from the antecubital
vein after an overnight fast. HDL cholesterol, total
cholesterol, triglyceride, and glucose concentrations were
determined enzymatically (Roche Diagnostics, Mannheim,
Germany, for HDL; Olympus System Reagent, Hamburg,
Germany, for total cholesterol, triglyceride, and glucose)
with a clinical chemistry analyzer (Olympus, AU400,
Hamburg, Germany). C-reactive protein (CRP) concentra-
tions were determined by a chemiluminescent immunomet-
ric assay (Immulite, Diagnostic Products, Los Angeles, CA).
Low-density lipoprotein (LDL) cholesterol was calculated
with the Friedewald formula.
2.6. Statistical analyses
Statistical analyses were performed using SPSS for
Windows (version 13.0; SPSS, Chicago, IL). The skewed
distributions of triglycerides and CRP were corrected
logarithmically before statistical analyses. Chi-square and
t-test analyses were calculated to compare categorical and
continuous variables between the metabolic syndrome
groups, respectively. Pearson correlation coefficients were
used to examine the association between cardiovascular risk
factors and PWV. Stepwise linear regression analysis was
performed for continuous and dichotomous variables to
examine independent relationships among metabolic syn-
drome, its components, other cardiovascular risk factors,
and PWV.
3. Results
The prevalence of metabolic syndrome obtained by using
the NCEP and IDF definitions was, respectively, 41% and
47% in men and 40% and 44% in women. For one
participant, the waist circumference measurement was
missing and the presence of metabolic syndrome could
not be assessed. By both definitions, the subjects with
metabolic syndrome were older, had higher BMI, waist
circumference, LDL cholesterol, triglycerides, fasting plas-
ma glucose, CRP and blood pressure and lower HDL
cholesterol (P b .05 for all) than the subjects who did not
have the syndrome. Subjects with and without metabolic
syndrome did not differ in sex, resting heart rate, total
cholesterol levels, or smoking habits (P N .1 for all).
Twenty-eight percent of the study population was on
antihypertensive medication, and 11% used statins. Selected
clinical and demographic values of the study population are
given in Table 1.
Men had significantly higher mean PWV than women
( P b .001). For both sexes, the mean PWV was
significantly higher in subjects with metabolic syndrome
(using both definitions; P b .01) than those without the
syndrome (Fig. 1 illustrates the data obtained with the
NCEP definition). There was no statistically significant
difference in the mean PWV (P N .1) of current smokers
and nonsmokers. Age, systolic blood pressure, diastolic
blood pressure, pulse pressure, product of heart rate and
pulse pressure, waist circumference, BMI, and levels of
HDL cholesterol, triglycerides, CRP, and fasting plasma
glucose correlated statistically significantly with PWV
(Table 2). Correlations between risk factors and PWV
remained essentially similar in the smaller group excluding
subjects with CVD and diabetes with the exception that the
plasma LDL cholesterol level correlated statistically signif-
icantly with PWV (Table 2).
A stepwise linear regression model was performed to
examine the relationships between cardiovascular risk
Table 2
Univariate correlations between cardiovascular risk factors and PWV in the
whole cohort (n = 393-401) and in the healthy subsample (n = 197-200)
Whole cohort Subsample
r P r P
Age (y) 0.510 b .001 0.518 b .001
BMI (kg/m2) 0.238 b .001 0.274 b .001
Waist circumference (cm) 0.343 b .001 0.353 b .001
HDL cholesterol (mmol/L) 0.161 .001 0.255 b .001
LDL cholesterol (mmol/L) 0.062 .217 0.208 .003
Total cholesterol (mmol/L) 0.028 .577 0.120 .090
Triglycerides (mmol/L) 0.199 b .001 0.174 .014
Fasting glucose (mmol/L) 0.341 b .001 0.252 b .001
CRP (mg/L) 0.226 b .001 0.214 .003
SBP (mm Hg) 0.627 b .001 0.694 b .001
DBP (mm Hg) 0.392 b .001 0.496 b .001
PP (mm Hg) 0.619 b .001 0.642 b .001
HR  PP 0.627 b .001 0.664 b .001
SBP indicates systolic blood pressure; DBP, diastolic blood pressure; HR,
heart rate; PP, pulse pressure.
Table 3
A linear regression model for the relationships between cardiovascular risk factors and PWV in the whole cohort (n = 390) and in the healthy subsample
(n = 196)
Risk variable Whole cohort Risk variable Subsample
b F SE P R2 change (%) b F SE P R2 change (%)
SBP (mm Hg) .05 F .00 b .001 40 SBP (mm Hg) .06 F .01 b .001 48
Age (y) .10 F .01 b .001 11 Age (y) .10 F .01 b .001 12
Fasting glucose (mmol/L) .27 F .07 b .001 3 Waist circumference (cm) .02 F .01 .042 1
Waist circumference (cm) .03 F .01 b .001 1
R2 (%) 55% 61
Initial stepwise regression models included age, sex, waist circumference, fasting plasma glucose, HDL cholesterol, systolic blood pressure, CRP, triglycerides,
smoking and LDL cholesterol (only in the sub sample) as independent variables. b indicates regression coefficient; R2 change, change in adjusted R2 value
after addition of the respective variable in to the model; R2, adjusted R2 value of the whole model.
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factors as independent variables and PWV (Table 3). The
initial stepwise regression model included age, sex, waist
circumference, fasting plasma glucose, HDL cholesterol,
triglycerides, systolic blood pressure, CRP, and smoking as
independent variables. In that model, systolic blood
pressure, age, fasting blood glucose, and waist circumfer-
ence explained 55% (adjusted R2, 55%) of the variation in
PWV. When the same model was adjusted by replacing
systolic blood pressure with pulse pressure or with the
product of heart rate and pulse pressure (data not shown),
the results remained essentially the same (adjusted R2, 53%
and 55%, respectively) with the exception that sex was also
an independent determinant of PWV. We used the same
linear regression model (LDL cholesterol included) for the
smaller sample excluding subjects with CVD and diabetes
(Table 3). Systolic blood pressure, age, and waist circum-
ference explained 61% of the variation in PWV. Therefore,
in this smaller healthier population, fasting plasma glucose
was not an independent factor determining PWV.
Another stepwise linear regression model was performed
by using metabolic syndrome (both definitions separately)
and other known cardiovascular risk factors (age, sex, CRP,
and smoking) as independent variables (Table 4). Age,
metabolic syndrome (using the NCEP or the IDF definition),
sex, and CRP were independent determinants for PWV
(adjusted R2, 34% and 33% in the models containing the
NCEP and the IDF definition, respectively). When CRP was
excluded from the models, the results remained essentially
the same. The same linear regression model (including LDL
as independent variable) was used for the smaller sample
that excluded subjects with CVD and diabetes (Table 4).
Age, metabolic syndrome, and sex explained 33% (using
the NCEP or the IDF definition) of the variation in PWV.
4. Discussion
Metabolic syndrome and its individual components are
risk factors for atherosclerosis and CVD [1-5]. Arterial
stiffness is also related to CVD and atherosclerosis [26] and
has been a strong independent predictor of coronary events
and cardiovascular mortality in several patient groups
[8-11]. In this study, we examined the relationships between
arterial stiffness measured by PWV and single cardiovascu-
lar risk factors as well as metabolic syndrome as a whole.
Our aim was also to compare 2 different definitions for
metabolic syndrome (NCEP and IDF) in their relations with
arterial stiffness.
Age, systolic blood pressure, diastolic blood pressure,
pulse pressure, product of heart rate and pulse pressure,
BMI, waist circumference, and triglyceride, HDL choles-
terol, fasting plasma glucose, and CRP levels correlated
statistically significantly with PWV. The univariate associ-
ations were thus significant between PWV and all the
components of metabolic syndrome. The strongest correla-
tion was observed between systolic blood pressure and
PWV, which is not surprising considering that both are
connected to arterial stiffness. As expected, age was
strongly correlated with PWV. In all, these findings are
well in line with previously published data [14,27]. LDL
cholesterol has also been linked with arterial stiffness
[28,29]. In a smaller sample excluding subjects with CVD
and diabetes, we also found a significant correlation
between LDL cholesterol and PWV.
The mean PWV was significantly higher in the subjects
with metabolic syndrome than in those without the
syndrome, regardless of the definition used. This is in
line with previous studies using the NCEP definition
[13,14,16-18]. To our knowledge, this is the first study to
examine the relationships between metabolic syndrome
and arterial stiffness by using the IDF definition. In our
study, men had significantly higher mean PWV than
women. The results of the Framingham heart study were
in agreement with the present study, the difference in PWV
being small but statistically significant [30]. On the other
hand, several other studies have not reported significant
differences between the sexes [31,32].
Although we did find that many individual risk factors
were associated with arterial stiffness, only some of them
Table 4
Linear regression model for the relationships between metabolic syndrome (MetS), using 2 different definitions, other cardiovascular risk factors and PWV in
the whole cohort (n = 392) and in the healthy sub sample (n = 197)
Risk variable Whole cohort Risk variable Subsample
b F SE P R2 change (%) b F SE P R2 change (%)
Age (y) .14 F .01 b .001 26 Age (y) .13 F .02 b .001 26
MetS using the NCEP definition .92 F .20 b .001 4 MetS using the NCEP definition .84 F .25 b .001 5
Sex .82 F .19 b .001 3 Sex .72 F .23 .002 2
CRP (mg/L) .52 F .21 .016 0.8
R2 (%) 34 33
Age (y) .14 F .01 b .001 26 Age (y) .13 F .02 b .001 26
Sex .80 F .19 b .001 3 MetS using the IDF definition .78 F .24 .001 4
MetS using the IDF definition .67 F .20 .001 3 Sex .69 F .24 .004 3
CRP (mg/L) .60 F .21 .005 1
R2 (%) 33 33
Initial stepwise regression models included age, sex, CRP, smoking, metabolic syndrome, according to the NCEP or the IDF definition and LDL cholesterol
(only in the subsample) as independent variables. b indicates regression coefficient; R2 change, change in adjusted R2 value after addition of the respective
variable in to the model; R2, adjusted R2 value of the whole model.
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appeared in the final regression models as independent
determinants of PWV. As expected, systolic blood pressure
and age were the strongest factors determining arterial
stiffness—a finding that is in agreement with previous data
[33]. In our study population, waist circumference and
fasting plasma glucose were also independent determinants
of arterial stiffness, results consistent with those of previous
studies [13-15,34]. When metabolic syndrome was included
in the regression model instead of its components, it was
found to be an independent determinant of arterial stiffness
(using both definitions) together with age, sex, and CRP
concentration. In the smaller sample that excluded CVD and
diabetes, fasting plasma glucose was not an independent
factor determining PWV. This can be partly explained by the
smaller sample size. On the other hand, metabolic syndrome
remained as an independent factor even in this population
free of CVD and diabetes. Similar results have been
reported previously [18].
We did not find a significant difference between the
NCEP and the IDF definitions in their ability to determine
arterial stiffness. To our knowledge, this has not been
studied previously. The main difference between these
2 definitions is that the latter makes central obesity
mandatory for diagnosis. The IDF definition also has a
lower waist circumference threshold. Because of this, the
IDF definition produces a higher prevalence for metabolic
syndrome than the NCEP definition. In our study popula-
tion, the prevalence figures were 45.4% and 40.4%,
respectively, which are relatively high when compared with
most of the earlier studies. This is probably related to the
age structure of our study population (older than 45 years).
Nevertheless, this increases our understanding of the
magnitude of metabolic syndrome as an important CVD
risk factor.
C-reactive protein correlated significantly with PWV in
the present study. The association of CRP and arterial
stiffness has been reported previously [35-37]. Some
[36,37] of the previous studies have suggested that CRP is
associated with arterial stiffness independently of other
CVD risk factors. In our population, however, CRP was not
independently associated with arterial stiffness when all the
other risk factors were taken into account. In the regression
models with metabolic syndrome included instead of its
components, CRP was an independent determinant. This is
probably due to significant associations between CRP and
all the components of metabolic syndrome.
Previously, PWVmeasurements have been done mostly by
methods using Doppler ultrasound or mechanoelectrical pulse
transducers [38,39]. PWV can also be measured by ICGWB,
which provides a handy and reliable tool for evaluating
arterial stiffness on the basis of PWV simultaneously with
cardiac output and related hemodynamic parameters. The
ICGWBmethod turned out to be applicable especially for large
epidemiologic studies because it is not user dependent and
does not require large personnel resources. The method is
highly repeatable and reproducible [24].
In conclusion, our findings indicate that blood pres-
sure, age, waist circumference, and fasting plasma glucose
concentration are important independent factors for
determining arterial stiffness in a middle-aged and elderly
population. The NCEP and IDF definitions were both
similarly associated with PWV, independently of other
known cardiovascular risk factors. This suggests that both
the NCEP and IDF definitions are able to identify
subjects with increased arterial stiffness in a Finnish
population. However, although metabolic syndrome is an
important factor affecting cardiovascular health and its
prevalence remarkably high in developed countries, its
components have to be carefully evaluated as independent
risk factors.
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Coronary Artery Disease–Associated Locus on Chromosome
9p21 and Early Markers of Atherosclerosis
Nilesh J. Samani, Olli T. Raitakari, Kalle Sipila¨, Martin D. Tobin, Heribert Schunkert, Markus Juonala,
Peter S. Braund, Jeanette Erdmann, Jorma Viikari, Leena Moilanen, Leena Taittonen, Antti Jula,
Eero Jokinen, Tomi Laitinen, Nina Hutri-Ka¨ho¨nen, Markku S. Nieminen, Y. Antero Kesa¨niemi,
Alistair S. Hall, Janne Hulkkonen, Mika Ka¨ho¨nen, Terho Lehtima¨ki
Background—Genome-wide association studies have recently identified a locus on chromosome 9p21 that influences risk
of coronary artery disease (CAD). The effect of the locus on early markers of atherosclerosis is unknown. We examined
its association with carotid intima-media thickness (CIMT) and brachial flow-mediated dilatation (FMD).
Methods and Results—We genotyped 2277 individuals, age 24 to 39 years, from the Cardiovascular Risk in Young Finns
Study with CIMT and FMD measurements and 1295 individuals, age 46 to 76 years, from the Health 2000 Survey with
CIMT for rs1333049, the chromosome 9p21 variant showing the strongest association with CAD. Both mean and
maximum CIMT were significantly higher (P0.001) in the older subjects of the Health 2000 Survey compared with
the Young Finns Study. However, there was no association of the rs1333049 genotype with either mean or maximum
CIMT at either age (P0.959 and 0.977 for the 2 phenotypes in the Young Finns Study and P0.714 and 0.725 in the
Health 2000 Survey). Similarly, there was no association of the locus with variation in FMD in the Young Finns cohort
(P0.521).
Conclusions—The chromosome 9p21 locus does not influence CAD risk through a mechanism that also affects CIMT or
induces early changes in FMD. (Arterioscler Thromb Vasc Biol. 2008;28:1679-1683)
Key Words: genetics  coronary artery diseases  atherosclerosis  carotid-intima media thickness
 endothelial dysfunction
Coronary artery disease (CAD) has a significant geneticdetermination that has hitherto been poorly character-
ized. However, recent genome-wide association studies have
identified several novel loci that are strongly associated with
CAD. Specifically, a common variant located in a region
adjacent to the cyclin dependent kinase inhibitors, CDKN2A
(encoding p16INK4a) and CDKN2B (p15INK4b) on chromo-
some 9p21.3 has been associated with increased risk in 4
separate genome-wide association and follow-up studies.1–5
Clinical manifestations of CAD represent the end stage of
a chronic process. As genetic variants are present from birth,
their effects on markers of atherosclerosis may be discernible
at an earlier stage. Carotid intima-media thickness (CIMT) is
an accurately quantifiable and reproducible marker of athero-
sclerotic risk and predicts future cardiovascular events.6,7
Similarly, impaired brachial artery flow-mediated dilatation
(FMD) is another marker of atherosclerotic risk and predicts
cardiovascular events.8 In this study, we investigated the
association of the CAD associated variant on chromosome
9p21.3 on CIMT in 2 population based cohorts of different
ages, in combination spanning the age range from 24 to 76
years. We also examined its association with variation in
FMD in young healthy subjects.
Materials and Methods
Subjects
We studied subjects from 2 population based cohorts—the Cardio-
vascular Risk in Young Finns Study and the Health 2000 Survey.9,10
The Cardiovascular Risk in Young Finns Study is a multi-center
study of atherosclerotic risk factors of children and young adults
(http://vanha.med.utu.fi/cardio/youngfinnsstudy/). The first cross-
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sectional study was conducted in 1980 and included 3596 healthy
children and adolescents, age 3, 6, 9, 12, 15, and 18 years. Details of
the study design have been presented elsewhere.11 Thereafter, these
subjects have been followed with periodic examinations. In 2001,
2620 individuals, who had then reached the age of between 24 to 39
years, were studied.9 In addition to detailed risk factor assessments,
ultrasound examination of CIMT and brachial endothelial function
were carried out.12,13
The Health 2000 Survey was a large Finnish cross-sectional health
examination survey carried out in 2000 to 2001. The overall study
cohort was a 2-stage stratified cluster sample (8028 persons) repre-
senting the entire Finnish population age 30 years and above.10 To
study cardiovascular disease risk factors and diabetes more thor-
oughly, a supplemental study was carried out (sample size 1867 and
participation rate 82%). The subjects in the supplemental study were
45 years and older, and the study was executed in the catchments
areas of the 5 Finnish University Hospitals because specialized
equipment was required. Carotid ultrasound examination was part of
this supplemental study.14 There were 1295 subjects (595 men and
700 women; mean age, 58 years; range, 46 to 76 years) with
available carotid ultrasound data. These individuals were selected to
be our study group for the present analysis.
Clinical Characteristics
Body mass index (BMI) was calculated as weight in kilograms
divided by the square of height in meters. Blood pressure (BP) was
measured using a random zero sphygmomanometer in the Young
Finns Study and the automatic Omron M4 sphygmomanometer
(Omron Healthcare Europe B.V.) in the supplemental Health 2000
Study. Values for systolic and diastolic blood pressure were defined
by Korotkoff phases I and V, respectively. The averages of 3
measurements obtained after 5 minutes of sitting with 1 to 2 minutes
between readings were used in analyses. Smoking habits were
inquired with a questionnaire.
Laboratory Tests
In both studies, venous blood samples were taken after an overnight
fast. Total cholesterol, HDL cholesterol, triglyceride, and glucose
concentrations were determined enzymatically (Roche Diagnostics,
GmbH for HDL; Olympus System Reagent for total cholesterol,
triglyceride, and glucose) with a clinical chemistry analyser (Olym-
pus, AU400). LDL cholesterol was calculated with the Friedewald
formula.
Ultrasound Imaging
In the Young Finns Study, carotid ultrasound studies were performed
using a high-resolution ultrasound system (Sequoia 512, Acuson)
with 13.0 MHz linear array transducer. CIMT was measured about
10 mm from the bifurcation on the left common carotid artery
focusing the image on the posterior wall and recording images from
the angle showing the greatest distance between the lumen-intima
interface and the media-adventitia interface.12 At least 4 measure-
ments were taken at each scan of the common carotid artery incident
with the R-wave of the continuously monitored ECG to derive mean
and maximum CIMT. The scans were analyzed by 1 reader blinded
to subjects’ details. The between visit (2 visits 3 months apart)
coefficient of variation of mean CIMT measurements for a subset of
the subjects was 6.4%.12
To assess brachial artery FMD, the left brachial artery diameter
was measured both at rest and during the reactive hyperemia.13
Increased flow was induced by inflation of a pneumatic tourniquet
placed around the forearm to a pressure of 250 mm Hg for 4.5
minutes, followed by release. Three measurements of arterial diam-
eter were performed at end-diastole at a fixed distance from an
anatomic marker at rest and at 40, 60, and 80 seconds after cuff
release. The vessel diameter after reactive hyperemia was expressed
as the percentage relative to the resting scan. The between-visit CV
for brachial diameter was 3.2% and for FMD 26.0%.13
In the Health 2000 supplemental study carotid ultrasound exam-
ination of the right carotid artery was performed according to a
standardized protocol using a 7.5 MHz linear array transducer. The
examinations were performed by centrally trained and certified
sonographers at 5 study locations around Finland.14 CIMT measure-
ments were performed off-line with the use of automated imaging
processing software. One reader was responsible for reading all
ultrasound images. Mean and maximum CIMT were again calcu-
lated. The intrareader reproducibility of the CIMT measurements
was assessed by calculation of the CIMT twice from 571 randomly
selected images of 108 study subjects several weeks apart. The mean
difference of the 2 measurements was 0.001 mm (SD 0.123), and the
intraclass correlation was 0.934 (P0.001).14
Genotyping
Genomic DNA was extracted from peripheral blood leukocytes using
a commercially available kit (Qiagen Inc). rs1333049 was genotyped
by allelic discrimination using a standard TaqMan assay (further
details available on request). Fluorescence was detected post poly-
merase chain reaction (PCR) using the ABI Prism 7900HT Sequence
Detector System and genotypes called using ABI Prism SDS
software version 2.1 (ABI). For reference, in the genome-wide
association studies,1,2 the CAD associated (risk) allele for rs133309
was C.
Statistical Analysis
Univariate data comparisons between genotype groups (and between
subjects in the 2 studies) were based on analysis of variance for
continuous variables and Chi-square test for categorical variables.
Because of skewed distributions, the values for triglycerides were
log transformed. Multiple logistic regression analysis was used to
identify clinical and laboratory variables that were independently
associated with mean and maximum CIMT and to assess the effect
of genotype on CIIMT taking these variables into account. The
statistical tests were performed with SPSS (version 14.00) for the
Young Finns Study and SAS (version 8.1) for the Health 2000
cohort. 95% CI for allele frequencies were calculated using confi-
dence interval calculation program, CIA (version 2.1.2). Power
calculations were undertaken using the P/S (Power and Sample size
calculator) program.
Results
The age range of the subjects was 24 to 39 years (55%
female) in the Young Finns Study and 46 to 76 years (55%
female) in the Health 2000 cohort. The frequency of the C
allele for rs1333049 was 0.41 (95% CI: 0.40 to 0.43) in the
Young Finns Study and 0.42 (95% CI: 0.40 to 0.44) in the
Health 2000 subjects and the genotypes were in Hardy
Weinberg equilibrium in both cohorts. The characteristics of
the subjects in each study partitioned by genotype for
rs1333049 are shown in Table 1. Overall, the older subjects
from the Health 2000 survey had higher BMI, LDL, and HDL
cholesterol levels and higher average systolic and diastolic
blood pressures compared with the subjects in the Young
Finns Study (P0.001). However, there was no significant
difference in any of these traits according to rs1333049
genotype in either age group (Table 1).
Both mean and maximum CIMT were higher in the Health
2000 cohort compared with the Young Finns subjects (Table
1). However, there was no effect of the rs1333049 genotype
on either phenotype in either the Young Finns study
(P0.959 and P0.977, respectively) or in the Health 2000
cohort (P0.714 and P0.729). Specifically we did not see
a higher CIMT in subjects carrying the CAD-risk associated
allele (C) in either cohort. Brachial FMD responses (available
in Young Finns) were likewise similar across the genotypes
(Table 1, P0.521).
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The results of multivariate logistic regression analysis of
mean CIMT in the 2 studies are shown in Table 2. In the
Young Finns Study, there were highly significant indepen-
dent effects of age, gender, BMI, and BP on CIMT and
borderline significant effect of smoking. In the Health 2000
cohort, there were similarly significant independent effects of
age, gender, and SBP on CIMT. HDL-cholesterol, and
smoking but not BMI were also independently associated
with CIMT in this cohort. Taking these factors into account
there was no independent effect of the rs1333049 genotype
on mean CIMT (Table 2). The results for maximum CIMT
were similar (not shown).
Discussion
Within a short period of its identification, the chromosome
9p21 locus has been shown to have a robust association with
CAD in a wide range of populations.1–5,15 The risk-associated
allele, defined by the C allele of rs1333049, or alleles of other
SNPs in strong linkage disequilibrium with it examined in
some studies, have consistently shown an increased risk of
25% to 40% per copy of allele. The region of association with
CAD on chromosome 9p21 spans 50 to 60 kb1–4 and is
located adjacent to genes coding for the cyclin-dependent
kinases p16/CDKN2A and p15/CDKN2B as well as p14/
ARF. These genes play a central role in the regulation of the
cell cycle and may be implicated in the pathogenesis of
atherosclerosis through their role in transforming growth
factor (TGF)-–induced growth inhibition.16,17 Interestingly,
although the 9p21 locus itself does not contain a protein
coding gene, recent studies have shown that it codes a large
noncoding RNA, ANRIL, which is expressed in atheroscle-
rotic tissue.15,18 Furthermore, expression of ANRIL is coor-
dinated with that of p14/ARF and possibly also p16/
CDKN2A and p15/CDKN2B, in both physiological and
pathological conditions,18 suggesting that it may regulate the
expression of these genes. Further studies are required, but
this could provide a potential mechanism by which the locus
affects CAD risk.
In this context, it is relevant to examine the association of
the 9p21 locus with other forms of atherosclerotic and
vascular disease as well as markers of atherosclerosis. Indeed,
a recent study has also shown an association of the locus with
abdominal aortic aneurysms as well as with intracranial
aneurysms.19 Among atherosclerosis-related phenotypes,
CIMT has gained particular prominence, both because of
the ease, accuracy, and reproducibility of its measurement
Table 1. Demographic and Phenotypic Characteristics of Subjects in the Cardiovascular Risk in Young Finns Study and in the Health
2000 Cohort Partitioned by Genotype for the Coronary Artery Disease Risk Variant on Chromosomes 9p21.3
Phenotype
Cardiovascular Risk in Young Finns
P Value
Health 2000 Cohort
P ValueGG GC CC GG GC CC
Age, y 31.6 (5.0) 31.8 (5.0) 31.8 (5.0) 0.522 58.0 (8.1) 58.6 (8.2) 57.8 (7.5) 0.292
790 1093 394 454 599 242
Males, % 44 45 46 0.506 48 44 43 0.394
790 1093 394 454 599 242
BMI, kg/m2 25.1 (4.3) 25.0 (4.4) 25.2 (4.5) 0.742 27.2 (4.6) 27.1 (4.3) 27.4 (4.5) 0.618
784 1084 391 450 597 241
LDL chol, mmol/l 3.27 (0.83) 3.30 (0.86) 3.24 (0.82) 0.470 3.39 (0.87) 3.40 (0.86) 3.43 (0.91) 0.839
782 1074 389 450 586 237
HDL chol, mmol/l 1.30 (0.32) 1.30 (0.32) 1.26 (0.30) 0.084 1.59 (0.43) 1.57 (0.42) 1.57 (0.45) 0.798
790 1091 394 453 598 242
Triglycerides, mmol/l 1.31 (0.73) 1.34 (0.92) 1.38 (0.89) 0.643 1.32 (0.66) 1.43 (1.14) 1.42 (0.82) 0.382
790 1093 394 453 598 242
Systolic BP, mm Hg 116.7 (12.8) 116.8 (13.4) 116.0 (12.7) 0.788 138.0 (22.2) 139.0 (21.3) 137.6 (21.3) 0.599
785 1075 393 454 598 241
Diastolic BP, mm Hg 70.7 (10.3) 70.8 (11.1) 70.9 (10.8) 0.980 84.5 (11.2) 84.3 (10.0) 84.3 (10.2) 0.932
785 1075 393 454 598 241
Smoking, % 25 23 22 0.506 24 22 22 0.485
785 1093 394 454 599 242
Mean CIMT, mm 0.58 (0.09) 0.58 (0.09) 0.58 (0.10) 0.959 0.93 (0.23) 0.93 (0.23) 0.94 (0.22) 0.714
779 1082 390 454 599 242
Max CIMT, mm 0.62 (0.10) 0.62 (0.10) 0.62 (0.10) 0.977 0.99 (0.21) 1.00 (0.22) 1.00 (0.21) 0.729
779 1082 390 454 599 242
FMD, % 7.84 (4.34) 8.04 (4.47) 8.12 (4.39) 0.521 NA NA NA
718 1015 362
Values are mean (SD) or prevalence in %. The numbers below each value is the No. of subjects for which the data were available. CIMT indicates carotid intima
media thickness; FMD, Brachial artery flow-mediated dilatation; NA, not available. P values are unadjusted values based on analysis of variance for continuous
variables and Chi-square test for smoking and gender. The CAD-risk associated allele is the C allele.
Samani et al 9p21 CAD Locus and Early Atherosclerosis 1681
 at UNIV HOSPITAL OF TAMPERE on December 22, 2010 atvb.ahajournals.orgDownloaded from 
as well as the evidence for its correlation with atheroscle-
rotic burden and future cardiovascular events.6,7,20,21 Fur-
thermore, because genetic determinants could presumably
be active from a young age, assessment of any association
with CIMT in a young predisease cohort provides a useful
means of investigating the early impact of such determi-
nants on atherosclerosis. Therefore, we examined the
association of the chromosome 9p21 locus in CIMT in 2
cohorts, including a cohort of young adult subjects as well
as a cohort with an age-range similar to cohorts which
demonstrated the association of the locus with CAD.
Somewhat surprisingly, we found no evidence of an associ-
ation of the locus with either mean or maximum CIMT in
either age group.
A number of possible explanations for the lack of associ-
ation of the 9p21 locus with CIMT need to be considered. It
is unlikely that selection bias is a factor. Both cohorts were
population based, ethnically homogeneous, and of Caucasoid
origin where the association with 9p21 has been robustly
demonstrated.1–5 Similarly, it is unlikely that the lack of
association reflects either imprecision of measurement of
CIMT or adequate power to detect an effect. Prospective
studies have shown that every 0.1-mm increase in CIMT is
associated with a 20% to 30% higher risk of subsequent
CAD.7,22,23 In a recent meta-analysis of the association
between rs1333049 and coronary artery disease, each copy of
the risk allele (C) was associated with a 24% (95% CI: 20%
to 29%) increased risk of coronary artery disease.5 These
estimates suggest that the expected effect of the rs1333049 on
CIMT would be approximately 0.1 mm per allele if the
association with CAD was mediated through a similar mech-
anism. Posthoc power calculations in our data showed that we
had 80% power at an alpha of 0.05 to detect a 0.02-mm
difference in mean CIMT between CC and GG subjects in the
Young Finns Study and 0.06 mm in the Health 2000 cohort.
Hence we had 99% power at an alpha of 0.01 to detect a
0.2 mm difference in CIMT between CC and GG subjects in
both cohorts. Furthermore, we easily detected several previ-
ously reported effects of other cardiovascular risk factors on
CIMT in both cohorts. Therefore, a plausible, and perhaps
mechanistically more interesting, explanation is that the
chromosome 9p21 locus affects risk of CAD through mech-
anisms that are not manifested in the carotid wall and
reflected by changes in CIMT.
Endothelial dysfunction is believed to be an early event in
atherosclerosis and may predate the development of clinical
disease by several decades.8,24,25 Reduction in FMD is a
validated marker of endothelial dysfunction and predicts
future cardiovascular events, at least in older adults.8 Several
traditional risk factors for atherosclerosis such as hypercho-
lesterolaemia, diabetes, and hypertension correlate with re-
ductions in FMD.25 Although the lack of a significant
association between the 9p21 locus and FMD in the Young
Finns study does not exclude the possibility that such an
effect will be observed in older subjects, our finding again
suggests that this genetic locus does not enhance risk of
CAD by itself primarily causing endothelial dysfunction at a
young age.
The recent finding that the 9p21 locus is also associated
with the development of intracranial aneurysms19 suggests
that the mechanism of its effect on the vascular wall is
perhaps more complex than simply promoting the develop-
ment of atherosclerosis. If the mechanism relates to cell
growth and turnover as discussed earlier, it is possible that
this affects coronary plaque stability or vulnerability rather
than its development per se. Further studies are necessary to
understand the mechanism(s) by which the chromosome 9p21
locus affects risk of CAD. In this regard, our finding of a lack
of association of the locus with CIMT and with FMD at a
young age provides valuable information in directing this
search.
Sources of Funding
The Young Finns Study has been financially supported by the
Academy of Finland (grants no. 77841, 210283, 34316, 117941), the
Table 2. Determinants of Mean CIMT in the Young Finns Study and the Health 2000 Cohort:
Results From Multivariable Regression Analysis
Young Finns Study Health 2000 Cohort
Beta (error) P Beta (error) P
Gender 0.0101 (0.0043) 0.017 0.0247 (0.0094) 0.009
Age 0.0050 (0.0004) 0.001 0.0097 (0.0006) 0.001
BMI 0.0024 (0.0005) 0.001 0.0015 (0.0011) 0.190
SBP 0.0054 (0.0020) 0.010 0.0096 (0.0024) 0.001
DBP 0.0060 (0.0025) 0.015 0.0036 (0.0050) 0.472
LDL cholesterol 0.0036 (0.0023) 0.121 0.0009 (0.0051) 0.863
HDL cholesterol 0.0004 (0.0066) 0.947 0.0264 (0.0131) 0.045
Triglycerides 0.0062 (0.0045) 0.161 0.0337 (0.0296) 0.255
Smoking 0.0086 (0.0048) 0.050 0.0242 (0.0107) 0.024
rs1333049 GG/GC vs CC 0.0009 (0.0048) 0.845 0.0107 (0.0112) 0.337
BMI indicates body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure. The beta values are
based on the following: age, per year increase; BMI, per 1 kg/m2 increase; for SBP and DBP, per 10 mm Hg increase;
for LDL, HDL, and triglycerides, per 1 mmol/l increase. The beta for triglycerides is for log-transformed values. The
beta coefficients for the comparison of GG/GC vs CC genotypes is shown. The results were similar when modelling
GG vs GC vs CC or GG vs CC. The CAD risk associated allele is the C allele.
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Background and purpose: Metabolic syndrome has been associated with increased carotid intima-media
thickness (CIMT) and cardiovascular disease (CVD). The objective of this study was to examine metabolic
syndrome as a determinant of CIMT in men and women and to compare the Framingham risk score (FRS)
and metabolic syndrome as risk factors for increased carotid atherosclerosis.
Methods: The study population consisted of 1353 Finnish men and women aged 45 years and above who
participated in Finnish population-based Health 2000 Survey. CIMT was used as a marker of subclinical
atherosclerosis. The National Cholesterol Education Program Adult Treatment Panel III criterion was used
to deﬁne the presence of metabolic syndrome.
Results: In multivariable models, metabolic syndrome was an independent determinant of CIMT in both
sexes (p ≤ 0.001 for both). When metabolic syndrome was included in the regression models along with its
components, it was an independent determinant of CIMT in women but not in men. After dividing the pop-
ulation into risk categories according to FRS and the presence of metabolic syndrome, FRS predominantly
determined CIMT regardless of the presence of metabolic syndrome in men. In women, however, CIMT
was signiﬁcantly higher in subjects with metabolic syndrome than in those without it, independently of
the FRS.
Conclusions: Metabolic syndrome is an independent determinant of CIMT in both sexes. In women but not
in men, metabolic syndrome is associated with CIMT independently of its components. Metabolic syn-
drome provides additional information on a person’s risk for early atherosclerosis beyond FRS in women
but not in men.
© 2008 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Metabolic syndrome is a cluster of cardiovascular risk factors
such as central obesity, hypertension, dyslipidemias and glucose
∗ Corresponding author. Tel.: +358 3 311 65302; fax: +358 3 311 65511.
E-mail address: kalle.sipila@uta.ﬁ (K. Sipilä).
intolerance. It has been shown to be a predictor of type 2 diabetes
[1], coronary heart disease (CHD) [2] and mortality [3–5]. Various
deﬁnitions of metabolic syndrome have been proposed for clini-
cal use. The National Cholesterol Education Program (NCEP) Adult
Treatment Panel III proposed their widely used clinical deﬁnition
for metabolic syndrome in 2001 [6].
Carotid artery intima-media thickness (CIMT) is a well-
established marker of subclinical atherosclerosis that can be
0021-9150/$ – see front matter © 2008 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.atherosclerosis.2008.08.029
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measured non-invasively. Increased CIMT has been shown to
predict CHD, cerebrovascular disease [7–9] and cardiovascular mor-
tality [10]. The presence of metabolic syndrome has been linked to
increased CIMT in several studies [11–16]. It has been suggested
that metabolic syndrome is a stronger risk factor for subclinical
atherosclerosis in women than in men [17]. The data regarding sex
differences are, however, limited.
There is an ongoing debate whether metabolic syndrome pro-
vides useful information of the patient’s cardiovascular risk in
addition to the traditional risk factors. The Framingham risk score
(FRS) is a clinical tool for quantifying an individual’s CHD risk [18]
based on traditional risk factors. There are few data comparing
metabolic syndrome and FRS in their ability to identify subjects
with increased CIMT [15,19,20]. To the best of our knowledge,
possible sex differences regarding this issue have not been stud-
ied.
The objective of this study was to ﬁnd out whether metabolic
syndrome associates differently with CIMT in men and women.
Furthermore, we set out to discover whether or not metabolic syn-
drome is a risk factor of CIMT beyond FRS.
2. Methods
2.1. Study population
We studied a subpopulation of a large Finnish cross-sectional
health examination survey (the Health 2000 Survey) carried out in
2000–2001 [21]. The overall study cohort was a two-stage strati-
ﬁed cluster sample (8028 persons) representing the entire Finnish
population aged 30 years and above. In order to study cardiovascu-
lar diseases (CVD) and diabetes more thoroughly, a supplemental
study was carried out (sample size 1867 and participation rate 82%).
The subjects in the supplemental study, a subpopulation of the
Health 2000 Survey, were 45 years and older and the study was
executed in the areas located within 150 km from the ﬁve Finnish
University Hospitals, because specialized equipment was required.
A carotid ultrasound examination was included in this supplemen-
tal study. There were 1353 subjects (607 men and 746 women;
mean age, 58 years; range 46–76 years) with available carotid ultra-
sound data. These individuals formed our study group.
Waist circumference was not measured in the supplemental
study; therefore, the Health 2000 Survey parameters were used to
deﬁne the presence of metabolic syndrome. All the other measure-
ments and laboratory tests used in the present study were collected
from the (data of the) supplemental study. The mean time inter-
val between the Health 2000 Survey and the supplemental study
was 16 months (range 10–23 months). The mean (±S.D.) change in
body weight during this time was 0.52 (±3.43) kg. Since this change
was not clinically signiﬁcant, it is likely that the change in waist
circumference was not clinically signiﬁcant either.
2.2. Metabolic syndrome and the Framingham risk scoring
We used the NCEP deﬁnition [6] to deﬁne the presence of
metabolic syndrome. According to this deﬁnition, a person has
metabolic syndrome if at least three of the following criteria are
met: waist circumference at least 102 cm (men) or 88 cm (women),
triglycerides ≥1.7 mmol/l, HDL cholesterol less than 1.03 mmol/l
(men) or 1.29 mmol/l (women), blood pressure ≥130/≥85 mmHg
and fasting plasma glucose ≥5.6 mmol/l. The fasting glucose thresh-
old of the NCEP criterion was modiﬁed in 2004 [22]. To deﬁne FRS,
we used CHD score sheets that have been previously reported [18].
FRS deﬁned by these sheets gives an estimation of a subject’s risk
for CHD over a period of 10 years.
2.3. Carotid artery studies
High-resolution B-mode carotid ultrasound examination of the
right carotid artery was performed according to a standardized pro-
tocol using a 7.5 MHz linear array transducer. The examinations
were performed by centrally trained and certiﬁed sonographers
at 6 study locations around Finland. CIMT measurements were
performed off-line with the use of automated imaging process-
ing software. One reader was responsible for reading all ultrasound
images. Three summary measures of the CIMT were calculated: (1)
the mean of the three average IMTs of the common carotid artery
(mean CCA IMT), (2) the mean of the three average IMTs of the
carotid bulb (mean bulb IMT), and (3) the mean of these two means
(mean IMT). Mean IMT was used in the present study. This method
has been described in detail previously [23]. The intra-reader repro-
ducibility of the CIMT measurements was assessed. The reader
measured the CIMT twice from 571 randomly selected images of
108 study subjects several weeks apart. The mean difference of
the two measurements was 0.001 mm (S.D. 0.123), the intra-class
correlation 0.934 (p < 0.001) and the coefﬁcient of variance 9.2%.
2.4. Waist circumference, body mass index, blood pressure and
smoking
Waist circumference was measured in the standing position
using the standards created for population health studies [24].
Height and weight were measured and body mass index (BMI)
calculated. In the Health 2000 Survey, blood pressure was mea-
sured with a mercury sphygmomanometer (Mercuro 300, Speidel
& Keller, Juningen, Germany) from the right arm. The ﬁrst mea-
surement was carried out after at least ﬁve minutes of rest in
the sitting position. Korotkoff’s ﬁrst phase was used as the sign
of systolic blood pressure and the ﬁfth phase as the sign of dias-
tolic pressure. The measurement was repeated two minutes after
the ﬁrst measurement. The average of the two measurements was
used in the analysis. In the supplemental study, blood pressure was
measured after at least ten minutes rest from the right arm. The
measurement was taken three times with 1–2-min intervals. The
automatic Omron M4 manometer (Omron Matsusaka Co., Japan,
Omron Healthcare Europe B.V., Hoofddorp, the Netherlands) was
used. The average of the three measurements was used in the anal-
ysis. Pulse pressure was calculated as the difference between the
average systolic and the average diastolic blood pressure. Current
smoking was evaluated with a questionnaire. Those who were cur-
rently smoking were deﬁned as smokers and the rest of the subjects
as non-smokers. The smoking data used in the present study were
collected from the Health 2000 Survey data.
2.5. Laboratory tests
Venous blood samples were drawn from the antecubital
vein after an overnight fast. HDL cholesterol, total cholesterol,
triglyceride and plasma glucose concentrations were determined
enzymatically (Roche Diagnostics, GmbH, Mannheim, Germany
for HDL; Olympus System Reagent, Hamburg, Germany for total
cholesterol, triglycerides and glucose) with a clinical chemistry
analyser (Olympus, AU400, Hamburg, Germany). High sensitivity
C-reactive protein (hs-CRP) concentrations were determined using
a chemiluminescent immunometric assay (Immulite, Diagnostic
Products Corporation, Los Angeles, CA, USA). LDL cholesterol was
calculated with the Friedewald formula.
2.6. Statistical analyses
The skewed distributions of triglycerides and hs-CRP were cor-
rected logarithmically before statistical analyses. Chi-square and
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Table 1
Clinical and laboratory parameters of the study cohort (n = 1353) with and without metabolic syndrome (MetS), according to NCEP deﬁnition
MetS
Male Female
Yes (n = 225–241)a No (n = 359–366)a p Yes (n = 257–267)a No (n = 469–479)a p
Age (years) 58.7 ± 7.6 57.6 ± 8.0 0.075 61.3 ± 8.3 56.7 ± 7.7 <0.001
Smoking 0.242 0.775
Yes (%) 24.9 29.2 18.4 19.2
No (%) 75.1 70.8 81.6 80.8
Body mass index (kg/m2) 29.7 ± 3.9 26.0 ± 3.2 <0.001 30.1 ± 4.9 25.3 ± 3.8 <0.001
Waist circumference (cm) 106.8 ± 10.1 94.2 ± 9.1 <0.001 97.5 ± 11.9 83.9 ± 10.4 <0.001
Heart rate (beats/min) 67.6 ± 12.9 65.3 ± 11.9 0.023 68.6 ± 11.6 67.9 ± 10.0 0.421
HDL cholesterol (mmol/l) 1.2 ± 0.3 1.6 ± 0.4 <0.001 1.4 ± 0.3 1.9 ± 0.4 <0.001
LDL cholesterol (mmol/l) 3.4 ± 0.9 3.5 ± 0.9 0.208 3.6 ± 0.9 3.2 ± 0.8 <0.001
Total cholesterol (mmol/l) 5.4 ± 1.0 5.6 ± 1.0 0.147 5.8 ± 1.0 5.6 ± 0.8 0.002
Triglycerides (mmol/l) 2.0 ± 1.6 1.2 ± 0.6 <0.001 1.6 ± 0.8 1.0 ± 0.4 <0.001
Fasting glucose (mmol/l) 6.6 ± 1.6 5.8 ± 1.0 <0.001 6.1 ± 1.4 5.3 ± 0.5 <0.001
Hs-CRP (mg/l) 3.6 ± 5.2 2.3 ± 2.9 <0.001 4.2 ± 4.7 2.3 ± 4.3 <0.001
SBP (mmHg) 148.9 ± 20.7 136.4 ± 18.6 <0.001 147.3 ± 21.7 130.3 ± 20.7 <0.001
DBP (mmHg) 90.1 ± 11.0 85.4 ± 10.2 <0.001 85.3 ± 9.0 80.2 ± 9.6 <0.001
PP (mmHg) 58.7 ± 15.0 51.1 ± 12.1 <0.001 62.0 ± 17.2 50.1 ± 13.9 <0.001
Medication for hypertension 41.5 19.7 <0.001 46.1 20.5 <0.001
Statin medication 15.4 11.5 0.165 14.6 8.6 0.010
Values are means ± S.D. except smoking and medication which are expressed as %. NCEP: National Cholesterol Education Program, Hs-CRP: high sensitivity C-reactive protein,
SBP: systolic blood pressure, DBP: diastolic blood pressure, PP: pulse pressure.
a Variation of n is due to missing data for some subjects.
t-test analyses were performed to compare categorical and contin-
uous variables between the subjects with and without metabolic
syndrome, respectively. Pearson’s correlation coefﬁcients were
used to examine the association between cardiovascular risk fac-
tors and CIMT. Interaction between sex and the prevalence of
metabolic syndrome on CIMT was analyzed using analysis of covari-
ance (ANCOVA). Stepwise linear regression analysis was performed
for continuous and dichotomous variables to examine independent
relationships between metabolic syndrome, its components, other
cardiovascular risk factors and CIMT. Analysis of variance (ANOVA)
was used to examine CIMT in subjects in different risk proﬁle cat-
egories. We used Tukey’s correction as a post-hoc test in ANOVA
to examine the differences between the risk proﬁle categories. Sta-
tistical analyses were performed using SPSS for Windows (version
15.0; SPSS Inc., Chicago, IL, USA).
3. Results
The prevalence of metabolic syndrome using the NCEP def-
inition was 40% in men and 36% in women. The subjects with
metabolic syndrome were more frequently on antihypertensive
medication, in addition to having higher BMI, waist circumference,
triglycerides, fasting plasma glucose, hs-CRP and blood pressure
as well as lower HDL cholesterol (p < 0.05 for all) than the sub-
jects without the syndrome in both sexes (Table 1). Women with
metabolic syndrome were older, used statins more often and had
higher LDL and total cholesterol than women not suffering from
the syndrome. In men these variables did not differ signiﬁcantly
according to the presence of metabolic syndrome. Subjects with
and without metabolic syndrome did not differ in smoking habits
(p > 0.1).
A borderline signiﬁcant interaction was found between sex
and the prevalence of metabolic syndrome in determining CIMT
(p = 0.058). Because of this and our original hypothesis that the
effect of metabolic syndrome on CIMT might be different between
the sexes, we analyzed men and women separately. For both sexes,
the mean CIMT was signiﬁcantly (p < 0.001 for both) higher in sub-
jects with metabolic syndrome (1.02 and 0.98 mm in men and
women, respectively) than in those without the syndrome (0.94 and
0.85 mm in men and women, respectively). There was no statisti-
cally signiﬁcant difference in the mean CIMT (p > 0.1 for both sexes)
of current smokers and non-smokers. The correlation of age, sys-
tolic blood pressure, pulse pressure, HDL cholesterol, triglycerides,
fasting plasma glucose, hs-CRP and FRS with CIMT was statistically
signiﬁcant in both sexes (Table 2). The correlation of BMI, waist cir-
cumference, LDL cholesterol, total cholesterol and diastolic blood
pressure with CIMT was statistically signiﬁcant in women but not
in men.
Stepwise linear regression models were constructed for men
and women separately to examine the inﬂuence of known
cardiovascular risk factors on CIMT as independent variables
(Table 3, model A). The initial stepwise regression models included
variables that had signiﬁcant univariate correlation with CIMT. In
men, age and triglycerides were independent predictors explain-
ing 24% of the variation in CIMT. In women, age, pulse pressure
and triglycerides were independent predictors explaining 29% of
the variation in CIMT. We performed the same regression analyses
Table 2
Correlations between cardiovascular risk factors and CIMT in males (n = 496–607a)
and females (n = 628–746a)
Men Women
r p r p
Age (years) 0.464 <0.001 0.515 <0.001
Body mass index (kg/m2) 0.045 0.267 0.171 <0.001
Waist circumference (cm) 0.077 0.057 0.189 <0.001
HDL cholesterol (mmol/l) −0.131 0.001 −0.157 <0.001
LDL cholesterol (mmol/l) −0.069 0.094 0.131 <0.001
Total cholesterol (mmol/l) −0.055 0.174 0.113 0.002
Triglycerides (mmol/l) 0.161 <0.001 0.231 <0.001
Fasting glucose (mmol/l) 0.116 0.004 0.134 <0.001
Hs-CRP (mg/l) 0.122 0.003 0.111 0.003
SBP (mmHg) 0.137 0.001 0.352 <0.001
DBP (mmHg) −0.008 0.849 0.148 <0.001
PP (mmHg) 0.208 <0.001 0.402 <0.001
FRS 0.370 <0.001 0.428 <0.001
CIMT: carotid intima-media thickness, r: Pearson’s correlation coefﬁcient, Hs-CRP:
high sensitivity C-reactive protein, SBP: systolic blood pressure, DBP: diastolic blood
pressure, PP: pulse pressure, FRS: Framingham risk score value.
a Variation of n is due to missing data for some subjects.
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Table 3
Linear regression models for the relationships between cardiovascular risk factors
and CIMT in males and females
Risk variable CIMT
ˇ ± S.E. p R2 change (%)
Model A
Male (n = 594)
Age (years) 0.014 ± 0.001 <0.001 21
Triglycerides (mmol/l) 0.205 ± 0.041 <0.001 3
R2 (%) 24
Female (n = 720)
Age (years) 0.010 ± 0.001 <0.001 26
PP (mmHg) 0.002 ± <0.001 <0.001 3
Triglycerides (mmol/l) 0.107 ± 0.037 0.004 1
R2 (%) 29
Model B
Male (n = 594)
Age (years) 0.014 ± 0.001 <0.001 21
Triglycerides (mmol/l) 0.205 ± 0.041 <0.001 3
R2 (%) 24
Female (n = 720)
Age (years) 0.010 ± 0.001 <0.001 26
PP (mmHg) 0.002 ± <0.001 <0.001 3
Metabolic syndrome 0.059 ± 0.015 <0.001 2
R2 (%) 30
CIMT: carotid intima-media thickness, ˇ: regression coefﬁcient, S.E.: standard error,
PP: pulse pressure, R2: adjusted R square value of the whole model, R2 change:
change in adjusted R square value after addition of the respective variable in to the
model. Initial stepwise regression model for men included age, fasting plasma glu-
cose, HDL cholesterol, pulse pressure, high sensitivity-CRP, triglycerides (models A
and B) and metabolic syndrome (model B only) as independent variables. Initial
stepwise regression model for women included age, waist circumference, fasting
plasma glucose, HDL cholesterol, pulse pressure, high sensitivity-CRP, triglycerides,
LDL cholesterol (models A and B) and metabolic syndrome (model B only) as inde-
pendent variables.
with metabolic syndrome included in the models as an inde-
pendent variable (Table 3, model B). In men this did not change
the results, and metabolic syndrome was not an independent
predictor of CIMT in this model. In women, however, metabolic syn-
drome was an independent predictor (p < 0.001) of CIMT together
with age and pulse pressure (R2 = 0.30). Another stepwise linear
regression model was performed for both sexes using metabolic
syndrome (instead of its components) and other known cardio-
vascular risk factors (that signiﬁcantly correlated with CIMT in
univariate models) as independent variables (Table 4). Age and
metabolic syndrome were independent determinants for CIMT in
both sexes (adjusted R2 0.22 and 0.29 in men and women, respec-
tively). We also performed all the above mentioned regression
models using the presence of antihypertensive medication and
statin medication as independent variables. The main ﬁndings
remained similar (data not shown).
In order to examine the associations of metabolic syndrome and
FRS with CIMT, we divided the population into four risk proﬁle
groups. In the ﬁrst group, subjects had low FRS (indicating a 10-year
Fig. 1. Carotid IMT (mean and S.D.) according to the risk proﬁle group in both sexes.
FRS = Framingham risk score and MetS = metabolic syndrome.
CHD risk less than 10%) and no metabolic syndrome. The second
group consisted of subjects with low FRS and metabolic syndrome.
In the third group, subjects had high FRS (indicating a 10-year CHD
risk greater than 10%) and no metabolic syndrome. The fourth group
consisted of subjects with metabolic syndrome and high FRS. In
both sexes, there were signiﬁcant differences in CIMT between the
risk groups (p < 0.001). In men CIMT was signiﬁcantly higher in both
of the high-FRS groups than in any of the low-FRS groups, regard-
less of metabolic syndrome (p < 0.01) (Fig. 1). In women who had
low FRS and metabolic syndrome, CIMT was signiﬁcantly higher
than in women with low FRS without the syndrome (p = 0.012). A
similar pattern was observed in women with high FRS (p = 0.007).
4. Discussion
Metabolic syndrome and its individual components are risk
factors for atherosclerosis and CVD [1–5]. CIMT is a well-known
marker of subclinical atherosclerosis and predicts future CHD and
myocardial infarction [7–9]. The association between metabolic
syndrome and CIMT has been reported in several populations
[11–16]. It has been suggested that this association is stronger in
women than in men [17]. In the present study, our primary target
was to investigate these possible sex differences in the associations
of metabolic syndrome and CIMT. We were especially interested in
the inﬂuence of metabolic syndrome on CIMT beyond traditional
Table 4
Linear regression model for the relationships between metabolic syndrome, cardiovascular risk factors and CIMT
Risk variable CIMT
Male (n = 597) Female (n = 722)
ˇ ± S.E. p R2 change (%) ˇ ± S.E. p R2 change (%)
Age (years) 0.014 ± 0.001 <0.001 21 0.012 ± 0.001 <0.001 26
Metabolic syndrome 0.064 ± 0.018 <0.001 2 0.074 ± 0.014 <0.001 3
R2 22% 29%
CIMT: carotid intima-media thickness, ˇ: regression coefﬁcient, S.E.: standard error, R2: adjusted R square value of the whole model, R2 change: change in adjusted R square
value after addition of the respective variable in to the model. Initial stepwise regression model for men included age, high sensitivity-CRP and metabolic syndrome as
independent variables. Initial stepwise regression model for women included age, high sensitivity-CRP, LDL cholesterol and metabolic syndrome as independent variables.
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risk factors deﬁned by such risk stratiﬁcation tools as FRS. Indeed,
our data suggest that the associations between metabolic syn-
drome, FRS and early atherosclerosis are modiﬁed by sex.
Age, HDL cholesterol, triglycerides, fasting plasma glucose, hs-
CRP, systolic blood pressure, pulse pressure and FRS had statistically
signiﬁcant correlations with CIMT in univariable models for both
sexes. BMI, waist circumference, LDL cholesterol, total cholesterol
and diastolic blood pressure had statistically signiﬁcant univari-
ate correlations with CIMT in women but not in men. Comparable
associations between CIMT and cardiovascular risk factors have
been reported previously [25–29]. The mean CIMT was signiﬁcantly
higher in subjects with metabolic syndrome than those without the
syndrome in both sexes. This is in line with previously reported data
[16,30,31]. In women the univariate correlations between cardio-
vascular risk factors and CIMT were stronger than in men. Nishida
et al. have reported comparable results [28].
Although we did ﬁnd that many individual risk factors were
associated with CIMT, only some of them appeared in the ﬁnal
regression models as independent determinants of CIMT. As
expected, age was clearly the strongest factor determining CIMT
in both sexes—a ﬁnding which is in agreement with previous data
[13,15]. In our study population, triglyceride concentration was also
independently associated with CIMT in men. In women, pulse pres-
sure and triglycerides appeared in the ﬁnal model as independent
predictors of CIMT. The ﬁnal model for women was somewhat
stronger, explaining 29% of the variance in CIMT, whereas the
adjusted R2 in men was 24%.
It has been reported earlier that metabolic syndrome is inde-
pendently associated with CIMT [13]. In the present study, when
metabolic syndrome was included in the regression models instead
of its components, it was found to be an independent determinant
of CIMT together with age in both sexes. However, the adjusted
R2 dropped to 0.22 in men while remaining at 0.29 in women.
When metabolic syndrome was included in the regression models
together with its components, it was found to be an independent
determinant for CIMT in women but not in men. Similar ﬁndings
have been reported previously [13,27], but in these studies sexes
have not been analyzed separately. Previous data regarding sex dif-
ferences in the effect of metabolic syndrome on CIMT are limited.
Iglseder et al. reported that the effect of metabolic syndrome on
CIMT was stronger in women than in men [17]. Nishida et al. showed
that the increase in the number of metabolic syndrome compo-
nents was associated more strongly with CIMT in women than in
men [28], the ﬁndings being in concert with the present results.
Skilton et al. did not ﬁnd sex differences in the associations between
metabolic syndrome and CIMT when the NCEP deﬁnition was used,
although there were sex differences when other deﬁnitions for
metabolic syndrome were used [16]. Empana et al. did not ﬁnd
sex differences in the associations between CIMT and metabolic
syndrome [30]. To sum up the above, some evidence suggests that
metabolic syndrome has a more pronounced inﬂuence on CIMT in
women than in men. The matter has, however, been controversial.
We divided our study population into four risk proﬁle groups
according to FRS and metabolic syndrome. We deﬁned CHD risk to
be low if the risk was less than 10% according to FRS. In men CIMT
was signiﬁcantly higher if FRS was high, regardless of the presence
of metabolic syndrome. In women, however, CIMT was signiﬁcantly
higher if metabolic syndrome was present, regardless of the FRS
category. There are few studies that have elaborated the effects of
metabolic syndrome on CIMT after taking FRS into account. Has-
sinen et al. found in a prospective study of elderly women that
metabolic syndrome was associated with accelerated progression
of CIMT independently of FRS [19]. Teramura et al. recently sug-
gested that metabolic syndrome, as deﬁned by Japanese criteria,
has some additive predictive value on CIMT beyond FRS [20]. How-
ever, Ahluwalia et al. reported that metabolic syndrome was not
associated with CIMT independently of FRS [15]. To the best of our
knowledge, this is the ﬁrst study to report sex differences in the
effects of metabolic syndrome and FRS on CIMT.
There were also certain study limitations. Corresponding to the
majority of Finnish population, our study group consisted of white
Caucasians being racially homogenous. Thus, the present results
may not be applicable to other ethnic groups than white Cau-
casians. Only Hs-CRP was used as a marker of low-grade systemic
inﬂammation in the present study. Including larger set of pro-
and anti-inﬂammatory markers may provide deeper insight into
the role of inﬂammation in the pathophysiology of metabolic syn-
drome. Also measurement of other relevant biochemical indices
such as adhesion molecules and adipokines may provide new infor-
mation about the mechanisms behind the association between
metabolic syndrome and early atherosclerosis.
In conclusion, our ﬁndings suggest that metabolic syndrome is
associated with CIMT independently of other known cardiovascular
risk factors in both sexes in a middle-aged and elderly population.
This association is, however, modiﬁed by sex. Metabolic syndrome
is associated with CIMT independently of its components in women
but not in men. In men, traditional risk factors as deﬁned by FRS
are strong determinants of CIMT, with metabolic syndrome offering
little additional information. In women, however, metabolic syn-
drome is an additional risk factor for subclinical atherosclerosis
beyond FRS. This is the case especially in women with low FRS.
These ﬁndings indicate that metabolic syndrome should be clini-
cally evaluated especially in women with low CVD risk according
to traditional risk factors.
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Objective: Inﬂammatory factors modify the risk of cardiovascular diseases and atherosclerosis. The single
base genetic polymorphism in the promoter region of inﬂammatory cytokine interleukin-6 (IL6 −174 G>C,
rs1800795) is associated with the variation of IL-6 production. The aim of this study was to investigate
whether IL6 −174 G>C is associated with the risk factors and early markers of atherosclerosis.
Methods: As part of Finnish Health 2000 Study, we performed carotid artery ultrasound examinations, IL6
−174 G>C genotyping and cardiovascular risk factor determination for 1334 subjects aged 46–76 years.
Results: In men, serum total cholesterol was higher in IL6 −174 GG (5.70 ± 0.88 mmol/L) than in the
GC (5.51 ± 0.98 mmol/L) or CC (5.38 ± 0.97 mmol/L, mean ± SD, p = 0.0059) groups. The same order was
seen in LDL-C (GG 3.64 ± 0.83 mmol/L, GC 3.41 ± 0.88 mmol/L, CC 3.30 ± 0.91 mmol/L, p = 0.0017). The
opposite association was observed with plasma fasting glucose levels (GG 5.93 ± 0.97, GC 6.11 ± 1.34, CC
6.34 ± 1.59 mmol/L, p = 0.043) and BMI (GG 26.8 ± 3.42, GC 27.5 ± 4.32, CC 28.0 ± 3.81 kg/m2, p = 0.027).
IL6 −174 allele C homozygous men indicated a trend towards higher systolic blood pressure. IL6 −174 G>C
was not associated with carotid artery compliance, intima media thickness or CRP. The effect size of IL6
−174 G>C on cardiovascular risk factors was not signiﬁcant in women. These results suggest that IL6 −174
G>C modiﬁes the levels of several metabolic risk factors of atherosclerosis in men.
© 2009 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Inﬂammation plays a key role in pathogenesis of atherosclero-
sis [1]. Interleukin-6 (IL-6) is a pleiotropic inﬂammatory cytokine
which has been associated with atherosclerosis and cardiovascu-
lar disease [2,3]. A single G>C base exchange polymorphism in the
promoter region of the IL-6 gene (IL6 −174 G>C) is associated with
IL-6 production. In the initial studies IL6 −174 allele G homozygous
and G/C heterozygous subjects have shown a higher expression of
IL-6 protein, higher transcriptional activity and higher inducible IL-
6 responses than subjects homozygous for IL6 allele C [4–6]. The
effect of IL6 −174 G>C on circulating IL-6 is more complex and may
be dependent on the presence of immune challenge, age and BMI of
subjects as well as physiological and psychosocial stress and various
∗ Corresponding author at: Tampere University Hospital, Department of Clinical
Physiology, P.O. Box 2000, FI-33521 Tampere, Finland. Tel.: +358 3 311 67760;
fax: +358 3 311 64329.
E-mail address: janne.hulkkonen@uta.ﬁ (J. Hulkkonen).
metabolic factors [7,8]. IL6 −174 G>C has been associated with the
risk of ischemic cerebrovascular events [9] and coronary heart dis-
ease in men [10,11]. The frequency of IL6 allele C seems to decrease
among old people, suggesting an association with mortality [12,13].
Allele C has also been associated with high blood pressure [11,14]
and high levels of C-reactive protein [11,15]. A recent joint analysis
conducted on the basis of data from 17 studies suggested associa-
tion of IL-6 G>C with fasting glucose levels independently of BMI
[7].
Established cardiovascular risk factors such as serum choles-
terol, blood pressure, obesity and smoking are associated with
increased arterial stiffness [16]. Ultrasonographically measured
carotid artery compliance and common carotid intima media thick-
ness (IMT) are markers of early atherosclerosis [17–19]. IL6 −174
G>C genotypes have been associated with carotid artery compliance
and carotid IMT [14,20].
In spite of intensive research, the role of IL6 −174 G>C as a
risk factor for cardiovascular diseases has remained inconsistent
[15,21], and several authors have expressed a need for further
studies [11,14,21,22]. We have previously found that IL-6 G>C
0021-9150/$ – see front matter © 2009 Elsevier Ireland Ltd. All rights reserved.
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is associated with carotid artery compliance, systolic (SBP) and
diastolic (DBP) blood pressure, serum high-density lipoprotein
cholesterol (HDL-C) in Finnish young male subjects aged 24–39
years (n = 996) [14]. In order to test whether IL6 −174 G>C genotypes
exert inﬂuence on the risk factors and early markers of atherosclero-
sis in the middle-aged to elderly population, we have now analysed
promoter region polymorphism of IL6 −174 G>C in 1334 Finnish
participants of the Health 2000 Study. The age range of subjects in
our study cohort was 46–76 years.
2. Materials and methods
2.1. Subjects
The study sample was drawn from participants of a large Finnish
multidisciplinary epidemiological cross-sectional health examina-
tion survey (the Health 2000 Survey) carried out in Finland from
autumn 2000 to spring 2001 [23]. The overall study cohort was a
two-stage stratiﬁed cluster sample (8028 persons) representing the
entire Finnish population aged 30 years and above. In order to study
cardiovascular diseases and diabetes more thoroughly, a supple-
mental study was carried out (sample size 1867 and participation
rate 82%). The subjects in the supplemental study, a subpopula-
tion of the Health 2000 Survey, were 46 years and older and the
study was executed in the areas located within 150 km from the
ﬁve Finnish University Hospitals, because specialized equipment
was required. A carotid ultrasound examination was included in
this supplemental study. Moreover, current medication data was
collected by questionnaire. There were 1353 subjects (607 men and
746 women; mean age, 58 years; range, 46–76 years) with avail-
able carotid ultrasound data. Genotyping was successful on 1334
of these subjects (98.6%), which formed our study group. For 19
subjects genotyping could not be completed because of signs of
DNA degradation, or protein interference in DNA sample resulting in
poor signal to noise ratio in ﬂuorescence based analysis (see meth-
ods below). The characteristics of the participants are presented in
Table 1.
2.2. Carotid artery studies
High-resolution B-mode carotid ultrasound examination of the
right carotid artery was performed according to a standardized pro-
tocol using a 7.5 MHz linear array transducer. The examinations
were performed by centrally trained and certiﬁed sonographers
at six study locations around Finland. Carotid IMT measurements
Table 1
Clinical and laboratory characteristics for the cases for which interleukin-6 G>C −174
genotype was determined (n = 727 female, n = 607 male). Values were measured at
the time of cross section (during the years 2000–2001).
Parameter Female, mean ± SD Male, mean ± SD
Age (years) 58.7 ± 8.29 58.0 ± 7.78
BMI (kg/m2) 27.1 ± 4.83 27.5 ± 4.03
Carotid IMT (mm) 0.90 ± 0.21 0.97 ± 0.24
Carotid artery compliance (%/10 mmHg) 0.95 ± 0.53 0.88 ± 0.41
SBP (mmHg) 136 ± 22.5 141 ± 20.6
DBP (mmHg) 81.9 ± 9.65 87.3 ± 10.7
Total cholesterol (mmol/L) 5.66 ± 0.92 5.51 ± 0.97
HDL-C (mmol/L) 1.70 ± 0.43 1.43 ± 0.38
LDL-C (mmol/L) 3.38 ± 0.87 3.43 ± 0.88
Triglycerides (mmol/L) 1.29 ± 0.65 1.52 ± 1.16
CRP (mg/L) 3.01 ± 4.63 2.79 ± 4.01
Fasting insulin (mmol/L) 8.99 ± 6.01 10.7 ± 7.84
Fasting glucose (mmol/L) 5.63 ± 0.99 6.14 ± 1.36
Abbreviations: BMI, body mass index; IMT, intima media thickness; SBP, systolic
blood pressure; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein
cholesterol; LDL-C, low-density lipoprotein cholesterol; CRP, C-reactive protein.
were performed off-line with the use of automated imaging pro-
cessing software. One reader was responsible for reading all
ultrasound images. Three summary measures of the carotid IMT
were calculated: (1) the mean of the three average IMTs of the com-
mon carotid artery, (2) the mean of the three average IMTs of the
carotid bulb, and (3) the mean of these two means (mean IMT).
Mean IMT was used in the present study. This method has been
described in detail previously [24]. The intra-reader reproducibility
of the carotid IMT measurements was assessed. The reader mea-
sured the carotid IMT twice from 571 randomly selected images
of 108 study subjects several weeks apart. The mean difference of
the two measurements was 0.001 mm (SD 0.123), the intra-class
correlation 0.934 (p < 0.001) and coefﬁcient of variation 9.2%.
2.3. Laboratory tests
Venous blood samples were drawn from the antecubital vein
after an overnight fast. HDL-C, total cholesterol, triglyceride and
plasma glucose concentrations were determined enzymatically
with a clinical chemistry analyser. Low-density lipoprotein choles-
terol (LDL-C) was calculated with the Friedewald formula. More
detailed description of methodology has been published recently
in this journal [25].
2.4. IL6 genotyping
Genomic DNA was extracted from peripheral blood leukocytes
using a commercially available kit (Qiagen Inc., Hilden, Germany) in
2001. IL6 −174 G>C genotyping was performed by employing the 5′-
nuclease assay and ﬂuorogenic allele-speciﬁc TaqMan probes and
primers [26] as well as the ABI Prism 7900HT Sequence Detection
System (Applied Biosystems, Foster City, CA, USA).
2.5. Statistical analysis
Statistical analyses were initially carried out using Statistica for
Windows 6.0 (StatSoft Inc., Tulsa, OK, USA), and SPSS 12.0 for Win-
dows (SPSS Inc., Chicago, IL, USA), with Kruskall–Wallis analysis
of variance and Mann–Whitney U-test. Hardy–Weinberg equations
were calculated by Arlequin [27]. As the IL6 −174 G>C genetic effect
on carotid artery compliance, blood pressure and HDL-C has pre-
viously been shown to be dependent on sex [14], analyses were
carried out separately for males and females. After nonparametric
analyses, we evaluated the extent of the genetic effect of IL6 −174
G>C on total cholesterol, LDL-C, HDL-C, triglycerides, systolic and
diastolic blood pressure as well as fasting insulin and glucose levels
and BMI. For this purpose we used multivariate linear regression
analysis. In addition to IL6 genotype, known common independent
risk factors and common confounding factors were included in the
model. Lists of these covariates are presented in Table 3. Before the
analysis the regression models were assessed for the multicollinear-
ity. Variance inﬂation factors for covariates in the presented models
were at acceptable level, ranging from 1.023 to 1.735 (tolerances
ranging from 0.576 to 0.988). The skewed distribution of triglyc-
erides was corrected logarithmically before regression analyses. As
the tests in the current study were done under a special hypothe-
ses (post hoc) based on our previous study [14], p values less than
0.05 were considered signiﬁcant. However, the data in Table 2 could
be also referred by multiple alternative signiﬁcance levels after
adjusting with Bonferroni correction (p < 0.0042), Sidak’s correc-
tion (p < 0.0041) or Scheffé’s adjustment (p < 0.0022).
3. Results
The distribution (prevalence given in parenthesis) of IL6 −174
G>C genotypes in our population was as follows: GG, n = 258
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Table 2
The association of IL-6 −174 G>C with the risk factors and early markers of atherosclerosis (n = 727 female, n = 607 male).
Parameter Men, mean ± SD Women, mean ± SD
IL-6 genotype IL-6 genotype
GG GC CC p value* GG GC CC p value*
Total cholesterol (mmol/L) 5.70 ± 0.88 5.51 ± 0.98 5.38 ± 0.97 <0.01 5.75 ± 0.95 5.66 ± 0.93 5.60 ± 0.89 0.33
HDL-C (mmol/L) 1.47 ± 0.34 1.43 ± 0.40 1.38 ± 0.38 0.06 1.70 ± 0.40 1.70 ± 0.45 1.72 ± 0.43 0.76
LDL-C (mmol/L) 3.64 ± 0.83 3.41 ± 0.88 3.30 ± 0.91 <0.01 3.49 ± 0.91 3.38 ± 0.88 3.32 ± 0.83 0.28
Triglycerides (mmol/L) 1.34 ± 0.75 1.56 ± 1.41 1.58 ± 0.87 0.05 1.29 ± 0.70 1.31 ± 0.66 1.24 ± 0.59 0.45
SBP (mmHg) 137 ± 17.2 142 ± 20.2 144 ± 23.2 0.08 135 ± 21.3 136 ± 23.1 137 ± 22.3 0.65
DBP (mmHg) 85.4 ± 9.6 88.0 ± 10.6 87.7 ± 11.5 0.09 81.5 ± 9.6 81.3 ± 9.7 82.9 ± 9.5 0.13
IMT (mm) 0.96 ± 0.23 0.97 ± 0.24 0.97 ± 0.23 0.88 0.89 ± 0.21 0.91 ± 0.22 0.89 ± 0.19 0.51
CAC (%/10 mmHg) 0.95 ± 0.46 0.85 ± 0.38 0.91 ± 0.43 0.30 0.95 ± 0.57 0.98 ± 0.52 0.90 ± 0.51 0.15
CRP (mg/L) 3.03 ± 5.59 2.66 ± 2.93 2.84 ± 4.39 0.49 3.34 ± 5.78 3.01 ± 4.77 2.83 ± 3.54 0.90
Fasting insulin (mmol/L) 9.06 ± 5.24 10.8 ± 8.41 11.6 ± 8.25 0.02 8.63 ± 4.88 9.01 ± 5.71 9.17 ± 7.05 0.70
Fasting glucose (mmol/L) 5.93 ± 0.97 6.11 ± 1.34 6.34 ± 1.59 0.04 5.51 ± 0.73 5.64 ± 1.06 5.69 ± 1.00 0.39
BMI (kg/m2) 26.8 ± 3.42 27.5 ± 4.32 28.0 ± 3.81 0.03 26.9 ± 4.27 27.2 ± 4.60 27.2 ± 5.48 0.82
Abbreviations: BMI, body mass index; IMT, intima media thickness; CAC, carotid artery compliance; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C,
high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; CRP, C-reactive protein.
* Kruskall–Wallis ANOVA test for a trend (2 degrees of freedom).
Table 3
Multivariate model of the relationships between total cholesterol, LDL-C, systolic blood pressure and fasting glucose levels adjusted with common cardiovascular risk factors
in men (n = 727).
Parameter Total cholesterol, coefﬁcient ± SE LDL-C, coefﬁcient ± SE SBP, coefﬁcient ± SE Fasting glucose level, coefﬁcient ± SE
IL6 genotype −0.123 ± 0.056* −0.133 ± 0.051** 2.567 ± 1.167* 0.176 ± 0.077*
Age −0.011 ± 0.005* −0.007 ± 0.005 0.407 ± 0.110*** 0.014 ± 0.007*
BMI 0.012 ± 0.011 0.017 ± 0.011 0.945 ± 0.238*** 0.074 ± 0.014***
Smoking 0.021 ± 0.087 0.016 ± 0.080 −3.344 ± 1.814 0.069 ± 0.121
Fasting glucose level −0.010 ± 0.034 −0.067 ± 0.033* 2.404 ± 0.699***
Fasting insulin level −0.014 ± 0.006* −0.011 ± 0.006 0.054 ± 0.133
Total cholesterol 3.529 ± 0.861***
Statin treatment −0.594 ± 0.116*** −0.643 ± 0.107***
Antihypertensive treatment −0.652 ± 1.986
Whole model R2 9.1% 11.8% 13.7% 6.7%
Abbreviations: For IL6 genotype coefﬁcient is for a 1-unit change in allele G content (null or 1 or 2 copies of allele G). For smoking coefﬁcient is for categorical change from
nonsmoker to smoker and for statin and antihypertensive treatments coefﬁcient is for categorical change of being with or without medication. SE, standard error; LDL-C,
low-density lipoprotein cholesterol; SBP, systolic blood pressure; BMI, body mass index.
* p < 0.05.
** p < 0.01.
*** p < 0.001.
(19.3%); GC, n = 685 (51.3%); CC, n = 391 (29.3%). Allele frequency
for allele G was 0.450 and for allele C 0.550. These ﬁgures are sim-
ilar with previously published ﬁgures on the Finnish population
[6,14] and other European populations [7]. As expected, the dis-
tributions of individual IL6 alleles followed the Hardy–Weinberg
equation (p = 0.21).
In men we found several signiﬁcant associations between IL6
−174 G>C genotype and cardiovascular risk factors. Serum total
cholesterol levels and LDL-C levels increased according to IL6 −174
G>C genotype in the order GG > GC > CC (Table 2). Opposite associa-
tions (GG < GC < CC) were observed with serum triglyceride, fasting
insulin and fasting glucose concentrations as well as BMI (Table 2).
IL6 −174 allele G homozygocity seemed to have beneﬁcial effect on
HDL-C, SBP and DBP, but these ﬁndings were borderline signiﬁcant
(Table 2). We found no signiﬁcant association between IL6 −174 G>C
genotypes and carotid artery compliance, carotid IMT or CRP in this
cohort. In order to evaluate the independent effect of IL6 −174 G>C
on these parameters, linear regression analyses were carried out.
In the multivariate models IL6 −174 G>C remained as an indepen-
dent predictor of serum total cholesterol and LDL-C concentrations
when adjusted by age, BMI, current smoking, fasting plasma glucose
and insulin concentrations and statin treatment (Table 3). More-
over, the trend of effect of IL6 −174 G>C on systolic blood pressure
increased in signiﬁcance (p = 0.028) in the multivariate model when
adjusted by age, BMI, current smoking, fasting plasma glucose and
insulin, total cholesterol and antihypertensive treatment (Table 3).
IL-6 −174 G>C was also associated with fasting glucose concentra-
tions when adjusted with age, BMI and current smoking (Table 3)
and with BMI when adjusted with age, current smoking, fasting glu-
cose and total cholesterol levels (p = 0.043, B 0.470, SE 0.232, whole
model R2 7%). The trends for IL6 −174 G>C effect on HDL-C, plasma
triglyceride levels and diastolic blood pressure could not be reas-
sured (p = 0.139–0.652). When linear regression model R2 values
were calculated with and without the IL6 genotype, the IL6 geno-
type explained 0.7–1.3% of variation observed in total cholesterol,
LDL-C, fasting glucose, BMI and SBP levels. The level of IL6 −174
G>C effect size is thus similar to that which was observed in our
previous study in young male subjects [14]. However, as the overall
R2 values in the current regression models were quite low the true
effect size is expected to be below these rough estimates in the cur-
rent cohort. Among women there were no signiﬁcant association
between IL6 −174 G>C genotypes and cardiovascular risk factors or
the above-mentioned early markers of atherosclerosis (Table 2).
4. Discussion
In this study, we have shown that the IL6 −174 G>C genotype is
an independent predictor of total cholesterol, LDL-C, fasting glucose
levels and BMI in the middle-aged to elderly men.
Several previous studies have found association between IL6
−174 G>C promoter polymorphism, atherosclerosis and cardiovas-
cular risk factors [9–12,14,15,22,28–30]. The data concerning the
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role of IL-6 in lipid metabolism is more limited. Fernandez-Real
et al. reported association between IL6 −174 allele G and high
triglycerides, VLDL, FFA and low HDL-C, but the size of the study
population was very small [31]. Henningsson et al. found asso-
ciation between the IL6 CC genotype and low total cholesterol,
LDL-C and triglycerides in women. There was no association in men
between IL6 −174 G>C genotype polymorphism and lipid pattern,
but IL6 −174 C carriers tended to display elevated triglycerides [32].
In the present study, we observed some similarity with the results
of previous studies in which IL6 −174 C allele carriers was shown
to have higher triglycerides [32], lower HDL-C [14] and higher SBP
[11,14,33], but after adjusting for other risk factors only a trend for
SBP remained in the regression models. This trend for IL6 −174 allele
C and higher SBP is in line with observation by Humphries et al. in
middle-aged men as well as our previous observation in young male
subjects [11,14]. Moreover, our results of association between IL6
−174 G>C and fasting glucose in our current middle-aged to elderly
cohort are in line with the results of the recent joint analysis con-
cluding that IL6 −174 G>C is associated with fasting glucose levels
independent of BMI [7].
IL6 gene is under complex regulation, with many factors known
to exert impact in transcription activity such as glucocorticoids, IL-1
and estrogen (17-beta estradiol) [34,35]. Some studies have shown
that adipose tissue accounts for up to 30% of the total circulating
concentrations of IL-6 in healthy subjects [36,37]. The inhibitory
effect of estrogen (estrogen released from fat tissue or hormone-
producing organs) on IL6 transcription activity may be one of the
reasons why there was no association between IL6 −174 G>C geno-
types and the cardiovascular risk factors in women in this study.
IL6 −174 allele C may mediate a lower transcription peak after
stimulation but a slower decline to baseline than the allele G. This
would result in higher chronic levels of IL-6 in −174 C allele car-
riers compared to GG carriers, but higher levels in GG subjects in
response to acute inﬂammation [38]. Moreover, it has been recently
shown that this kind of genetic effect of IL-6 G>C for circulating IL-
6 is clearly seen in subjects of normal weight (BMI < 24.9 kg/m2)
but not in those who are overweight (BMI > 25) [8]. It is notice-
able in this recent study that the baseline IL-6 were higher in
overweight subjects than in normal subjects supporting the above-
mentioned ideas about these mutual interactions between IL-6,
body composition and inﬂammation [8]. It is also well known that
IL-6 is a key inﬂammatory factor, which stimulates the expression
of acute phase proteins such as CRP in liver [39,40]. In a recent
Rotterdam study consisting 6434 participants, Sie et al. found sig-
niﬁcant association between IL6 −174 allele C carriers and higher
CRP levels compared to subjects without this allele [15]. On the
basis of our current and previous results and observations of oth-
ers concerning IL6 and CRP, it is tempting to speculate whether the
associations with IL6 G>C and plasma lipids, fasting glucose and BMI
are reﬂecting direct effects of IL6 in liver intermediate metabolism
(gluconeogenesis), cholesterol synthesis and acute phase protein
induction. As it is, the metabolic effects of IL-6 should be studied
further.
IL6 −174 G>C has been previously associated with IMT [20] and
our previous results suggested an association of IL6 −174 G>C with
carotid artery compliance among young men in the Cardiovascu-
lar Study of Young Finns cohort [14]. However, among middle-aged
to elderly subjects studied herein, no association with carotid IMT
or carotid artery compliance could be observed. There are several
potential reasons for this, most evident being differences in age,
baseline blood pressure, body mass and body composition as well as
metabolic and pharmacological interference in these study cohorts.
It is also possible that the effect of IL6 in atherosclerosis is differ-
ent in the initiation and development of atherosclerosis and the
subtle allelic effects which can be observed in young populations
are masked by more stronger lifestyle-related covariates in older
cohorts. Unfortunately this subject cannot be reliably analysed in
our cross-sectional study, and intensive long span follow-up studies
are needed to explore these issues further.
In conclusion, we have found association between IL6 −174 G>C
genotypes and total cholesterol levels, LDL-C, fasting glucose levels
as well as BMI in middle-aged to elderly men, and there appears to
be a trend between IL6 −174 G>C genotypes and SBP. It is notewor-
thy that in spite of the relatively low absolute effect size of IL6 −174
genotype for risk factor levels, the genetic determinants studied
here are very common, the prevalence of the IL6 −174 G>C allele C
being 55%. Therefore, at population level, IL6 polymorphism seems
to be an important genetic risk factor for men. Further studies are
needed to explain the metabolic effects of IL6 in men and women.
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Abstract
Aims: The association of diabetes and subclinical atherosclerosis is well established. The eff ect of non-
diabetic glucose intolerance on early atherosclerosis is not as straightforward, and the data regarding sex-
related diff erences in this matter is limited. Therefore, our aim was to investigate these associations in men 
and women separately.
Methods: We studied 1,304 Finnish men and women over 45 years of age who participated in the Finnish 
Health 2000 Survey. Ultrasonically determined carotid artery intima-media thickness and elasticity were 
used as markers of early atherosclerosis. Glucose tolerance was categorized according to the American 
Diabetes Association criteria for diabetes mellitus.
Results: Age-adjusted means for carotid artery intima-media thickness and elasticity indices were 
signiﬁ cantly (p<0.05) associated with glucose tolerance status in both sexes. There was a trend of increasing 
early atherosclerosis with the worsening of glucose tolerance in men and women. These associations were 
weakened in both sexes after further adjustments for other cardiovascular risk factors. In women, but not in 
men, signiﬁ cant (p<0.05) associations between glucose tolerance status and carotid artery elasticity were 
seen even after these further adjustments. 
Conclusions: Diabetes and non-diabetic glucose intolerance are associated with increased early carotid 
atherosclerosis compared to normal glucose tolerance in both sexes. Our results suggest that women with 
glucose intolerance may be in greater risk than men.
Keywords: arteriosclerosis; carotid artery diseases; diabetes; glucose intolerance
2Introduction
Diabetes (DM) is a known risk factor for 
cardiovascular disease (CVD) morbidity and 
mortality. The CVD risk is roughly 2- to 4-fold 
in diabetic subjects in relation to their healthy 
counterparts [1]. The American Diabetes 
Association (ADA) diagnostic criteria for DM 
recognize two intermediate metabolic states 
between normal glucose tolerance (NGT) and DM 
[2]. These pre-diabetic states known as impaired 
fasting glucose (IFG) and impaired glucose 
tolerance (IGT) represent two distinct subgroups 
of  abnormal glucose metabolism. It has been 
shown recently that impaired insulin release is a 
predominant feature in IFG, whereas peripheral 
insulin resistance is characteristic to IGT [3]. 
There is evidence that even these pre-diabetic 
abnormalities in glucose metabolism increase the 
risk for all-cause and CVD mortality [4]. 
 Carotid artery intima-media thickness 
(CIMT) is a well-established marker of  
subclinical atherosclerosis that can be measured 
non-invasively. Increased CIMT has been 
shown to predict coronary heart disease (CHD), 
cerebrovascular disease [5,6] and cardiovascular 
mortality [7]. Carotid artery elasticity as a 
marker of  arterial stiffness has also been used as 
a surrogate in determining early atherosclerosis, 
and it has been related to CVD mortality [8]. 
It is known that subjects with type 2 diabetes 
(T2DM) have increased CIMT [9,10] and carotid 
artery stiffness (CAS) [11,12] in comparison to 
subjects with NGT. Previous reports also suggest 
that CIMT would be increased in subjects with 
IGT as compared to those with NGT [13]. Non-
diabetic glucose intolerance has been linked to 
increased CAS in some [11,14] but not all [12,15] 
of  the studies. There is no convincing evidence 
that IFG alone would be a signifi cant risk factor 
for early carotid atherosclerosis [15,16]. 
DM is a stronger risk factor for CVD events in 
women than in men [17]. Some reports have also 
suggested that the effect of  glucose metabolism 
impairment on early carotid atherosclerosis 
would be more pronounced in women than 
in men [11,18]. Data regarding sex-related 
differences is, however, limited and other studies 
have not confirmed this hypothesis [10,19]. 
Therefore, the objective of  the present study 
was to provide a comprehensive investigation 
of  the associations between impaired glucose 
metabolism and early carotid atherosclerosis 
and to determine whether these associations are 
different in men and women.
Methods 
Study population
Our study population was part of  a large Finnish 
cross-sectional health examination survey (the 
Health 2000 Survey) carried out in 2000–2001. 
The overall study cohort was a two-stage stratifi ed 
cluster sample (8,028 persons) representing the 
entire Finnish population aged 30 years and above. 
In order to study CVD and DM more thoroughly, 
a supplemental study was carried out (sample size 
1,867 and participation rate 82%). Subjects in this 
subpopulation of  the Health 2000 Survey were 45 
years and older. A carotid ultrasound examination 
and an oral glucose tolerance test (OGTT) were 
performed in this population sample. Subjects 
with type 1 DM were excluded from our study. 
After this exclusion there were 1,304 subjects (579 
men and 725 women; mean age, 58 years; range, 
46–76 years) with available ultrasound data. These 
individuals formed the study group of  this report. 
1,173 of  the subjects (523 men and 650 women) 
had available data for carotid artery elasticity 
determination.
The study protocol of  the Health 2000 survey 
was approved by the Epidemiology Ethics 
Committee of  the Helsinki and Uusimaa hospital 
region. The participants of  the survey signed an 
informed consent to participate.
3Smoking and blood pressure 
Current smoking was evaluated with a 
questionnaire. Blood pressure was measured 
from the right arm. The measurement was 
taken three times with 1–2-minute intervals. 
The automatic digital Omron M4 oscillometric 
manometer (Omron Matsusaka Co, Japan, 
Omron Healthcare Europe B.V., Hoofddorp, the 
Netherlands) was used. The average of  the three 
measurements was used in the analysis.
Glucose tolerance
Subjects using insulin were considered to have 
T2DM and they did not participate in OGTT. 
Subjects with oral hypoglycemic medication or 
a previous T2DM diagnosis were considered to 
have T2DM, regardless of  their OGTT results. 
The ADA criteria for DM [2] were used in the 
classification of  subjects with no previously 
diagnosed diabetes as follows: 1) subjects with 
fasting venous plasma glucose of  >7.0 mmol/l 
or 2-h venous plasma glucose of  >11.1 mmol/l 
in an OGTT were considered to have T2DM; 
2) subjects with fasting venous plasma glucose of  
<7.0 mmol/l and 2-h venous plasma glucose of  
7.8–11.0 mmol/l in an OGTT were considered 
to have IGT; 3) subjects with fasting venous 
plasma glucose of  5.6–6.9 mmol/l and 2-h 
venous plasma glucose of  <7.8 mmol/l in an 
OGTT were considered to have IFG; and, fi nally, 
4) subjects with fasting venous plasma glucose of  
<5.6 mmol/l and 2-h venous plasma glucose of  
<7.8 mmol/l in an OGTT were considered to 
have NGT. 
In this classifi cation, subjects with isolated 
IGT (normal fasting glucose) and those with 
both IFG and IGT are categorized into the same 
group (IGT group). IFG and IGT are considered 
as distinct entities and we would have preferred 
to report the results for isolated IFG and isolated 
IGT separately. However, the number of  subjects 
with isolated IGT was very small. Therefore, we 
present the results with four glucose tolerance 
categories, as described above.
Laboratory tests
Venous blood samples were drawn from the 
antecubital vein after an overnight fast. HDL 
cholesterol, total cholesterol and triglyceride 
concentrations were determined enzymatically 
(Roche Diagnostics, GmbH, Mannheim, 
Germany for HDL; Olympus System Reagent, 
Hamburg, Germany for total cholesterol and 
triglycerides) with a clinical chemistry analyser 
(Olympus, AU400, Hamburg, Germany). 
High-sensitivity C-reactive protein (hs-
CRP) concentrations were determined using 
a chemiluminescent immunometric assay 
(Immulite, Diagnostic Products Corporation, 
Los Angeles, CA, USA). LDL cholesterol was 
calculated with the Friedewald formula. In the 
OGTT, subjects were given 75 g of  glucose in a 
10% solution. Venous blood samples for glucose 
determination were taken before and 2 h after the 
glucose load. Plasma glucose was determined by 
the glucose dehydrokinase method (Diagnostica 
Merck, Germany) in a clinical chemistry analyzer 
(Konelab, Finland).
Carotid artery studies
High-resolution B-mode carotid ultrasound 
examination of  the right carotid artery was 
performed according to a standardized protocol 
using 7.5 MHz or 10 MHz linear array transducer. 
Intima-media thickness was measured in the distal 
common carotid artery (CCA) and the carotid bulb 
with commercially available software (PROWIN 
23.1). The mean of  these two measurements was 
used as a measure of  CIMT. This protocol has 
been described in detail earlier [20]. 
We calculated three carotid artery elasticity 
parameters to be used as markers for CAS. For 
the elasticity calculations, the computer software 
PROWIN 23.1 was used to determine the arterial 
4diameter over the distal 1 cm length of  the CCA 
from peak systole and end-diastole images. The 
beginning of  the carotid artery bulb (the site 
where the two parallel walls of  the CCA diverge) 
was used as an anatomical landmark. Systolic and 
diastolic arterial diameters were calculated as the 
mean of  three average systolic and diastolic arterial 
diameters, respectively. The following indices of  
arterial elasticity were calculated:
YEM (mmHg) = [Ep x DAD/(2 x IMT)]
SI = Ln (SBB/DBP)/(ADC/DAD)
CAC (%/10 mmHg) = 100 x 10 x [(ADC/
DAD)/PP]
where YEM = Young’s elastic modulus; Ep = 
Peterson’s elastic modulus = (PP x DAD)/ADC; 
PP = pulse pressure = systolic blood pressure - 
diastolic blood pressure; ADC (arterial diameter 
change) = systolic arterial diameter (SAD) - 
diastolic arterial diameter (DAD); IMT = intima-
media thickness of  the far wall of  the CCA at 
end-diastole; SI = beta stiffness index; SBP = 
systolic blood pressure; DBP = diastolic blood 
pressure; and CAC = carotid artery compliance.
We used several elasticity indices, because they 
measure different aspects of  arterial elasticity. 
CAC refl ects the ability of  the carotid artery to 
expand as a response to PP, caused by cardiac 
contraction and relaxation [21]. SI is a marker 
of  arterial elasticity that is considered to be 
relatively independent of  blood pressure [22]. 
YEM, on the other hand, is a measure of  arterial 
wall stiffness that is independent of  IMT [11]. 
Statistical methods
Statistical analyses were performed using 
SPSS for Windows (version 16.0.1; SPSS Inc., 
Chicago, IL, USA). Interactions were tested 
using the SPSS general linear model. The 
skewed distributions of  triglycerides and hs-CRP 
were corrected logarithmically before statistical 
analyses. Analysis of  variance (ANOVA) was 
used in testing differences between unadjusted 
group means with Dunnett’s T3- correction for 
multiple comparisons. Chi-square test (χ2) was 
employed in the assessment of  the differences in 
prevalence rates. Adjustment for age and other 
cardiovascular risk factors was performed using 
the SPSS general linear model (analysis of  co-
variance = ANCOVA). In the case of  a signifi cant 
ANCOVA p value for glucose tolerance, Fisher’s 
least significant difference test was used to 
evaluate differences between the NGT group and 
the other groups.
Results 
The interaction between sex and glucose 
tolerance, in determining CIMT and carotid 
artery elasticity, was tested. A significant 
interaction (p <0.05) was observed in relation 
to CIMT and CAC and the results are reported 
separately for men and women. 
The clinical characteristics and the unadjusted 
means for the markers of  carotid atherosclerosis 
according to glucose tolerance status are 
presented in Tables 1 and 2 for men and women, 
respectively. Of  the 125 (66 men and 59 women) 
diabetic subjects, 51 (28 men and 23 women) 
had previously diagnosed T2DM. Of  these 51, 
11 (6 men and 5 women) subjects used insulin 
and 31 (20 men and 11 women) were on oral 
hypoglycaemic medication. There was an overall 
tendency for both sexes towards a deteriorating 
trend in various CVD risk factors and in the 
markers of  carotid atherosclerosis with the 
worsening of  glucose tolerance.
Age-adjusted means in the markers of  early 
atherosclerosis according to glucose tolerance 
status are shown in Table 3. In 56 men and 75 
women carotid artery elasticity indices could 
not be determined. Therefore, the amount of  
5subjects in the analysis was smaller in regard to 
these indices as compared to CIMT. Signifi cant 
differences between the groups were seen in all 
variables and in both sexes (ANCOVA p<0.05 for 
all). In men, CIMT was signifi cantly increased 
only in the T2DM group as compared to the 
NGT group. In women, however, mean CIMT 
increased with the worsening of  glucose tolerance, 
and all the other groups had signifi cantly higher 
CIMT than the NGT group. Mean CAC was 
significantly lower in all glucose intolerance 
groups and mean YEM signifi cantly higher in 
the IGT and T2DM groups when compared to 
the NGT group in both sexes. In women, the 
T2DM and IGT groups had signifi cantly higher 
mean SI than the NGT group, while in men only 
the T2DM group differed signifi cantly from the 
NGT group in regard to SI.
The results of  the second ANCOVA model 
with adjustments for age and other CVD risk 
factors are presented in Table 4. Some subjects 
had missing values for some of  the adjusting 
factors. Therefore, slightly smaller number of  
cases was included in this model than in the 
TABLE 1. Clinical characteristics of  the male study subjects
Glucose tolerance
NGT IFG IGT T2DM ANOVA
n = 152-174a n = 215-235 a n = 97-104 a n =58-66 a p-value
Age (years) 57.8±8.1 56.7±7.0 59.5±8.2 61.3±7.8* <0.001
Smoking (%) 30.5 29.4 20.2 24.2 0.230
SBP (mmHg) 135.8±19.2 140.4±18.5 146.2±21.9§ 150.8±23.2¶ <0.001
DBP (mmHg) 84.8±10.0 88.3±9.4§ 88.1±12.0 88.6±13.5 0.004
BMI (kg/m2) 26.0±3.0 27.5±3.9¶ 28.4±3.9¶ 30.1±4.5¶ <0.001
Total cholesterol (mmol/l) 5.5±0.9 5.6±0.9 5.7±1.0 5.3±1.1 0.075
LDL cholesterol (mmol/l) 3.5±0.8 3.5±0.9 3.5±0.9 3.0±1.0* 0.001
HDL cholesterol (mmol/l) 1.5±0.4 1.4±0.4 1.4±0.4 1.3±0.4§ 0.001
Triglycerides (mmol/l) 1.2±0.6 1.4±0.6 1.6±0.9§ 2.3±1.8¶ <0.001
Fasting glucose (mmol/l) 5.2±0.2 6.0±0.3¶ 6.0±0.4¶ 8.3±2.2¶ <0.001
2 h glucose (mmol/l) 5.3±1.2 5.7±1.1* 8.9±0.9¶ 14.3±3.8¶ <0.001
Hs-CRP 2.5±2.9 2.4±2.9 3.4±5.9 4.2±5.9§ 0.001
Antihypertensive med (%) 21.8 20.4 34.6 62.1 <0.001
Statins (%) 12.1 9.4 15.4 25.8 0.005
Previous CVD (%) 11.5 9.8 16.3 27.3 0.002
CIMT (mm) 0.950±0.197 0.934±0.209 0.989±0.261 1.127±0.351§ <0.001
YEM (mmHg) 6591±4146 7008±3951 8575±8681 9402±6207* 0.001
SI 3.59±0.49 3.63±0.43 3.69±0.51 3.84±0.52* 0.005
CAC (%/10 mmHg) 0.98±0.45 0.90±0.40 0.83±0.41 0.71±0.37¶ <0.001
Values are unadjusted means + SD except the prevalence rates which are expressed as %.
a = Variation in n is caused by some missing data. NGT= normal glucose tolerance, IFG= impaired fasting glucose, IGT= 
impaired glucose tolerance, T2DM= type 2 diabetes, SBP= systolic blood pressure, DBP= diastolic blood pressure, BMI= 
body mass index, 2 h glucose= plasma glucose 2 h after glucose load in oral glucose tolerance test, hs-CRP= high sensitivity 
C-reactive protein, antihypertensive med= % of  subjects using antihypertensive medication, statins= % of  subjects using 
statins, previous CVD=  % of  subjects with previous knowledge of  coronary heart disease, stroke, or arterial stenosis, or 
thrombosis in a lower limb, YEM = Young’s elastic modulus, SI = beta stiffness index, CAC = carotid artery compliance. 
*p <0.05, §p < 0.01, ¶p <0.001, pairwise comparison with the NGT group; Dunnett’s T3 correction for multiple comparisons 
in ANOVA.
6age-adjusted model. Among men, none of  the 
parameters differed significantly between the 
groups (ANCOVA p>0.1 for all) after these 
further adjustments. In women, adjusted means 
in CIMT did not signifi cantly differ between 
the groups in this model (p=0.341) but in the 
elasticity indices significant differences were 
observed (ANCOVA p<0.05 for all). In women, 
the T2DM group had signifi cantly higher YEM 
and SI when compared to the NGT group 
(p<0.05 for all). The T2DM and IFG groups had 
TABLE 2. Clinical characteristics of  the female study subjects
Glucose tolerance
NGT IFG IGT T2DM ANOVA
n = 336-371a n =160-176 a n =105-119 a n =49-59 a p-value
Age (years) 56.5±7.6 58.7±8.3* 60.4±8.4¶ 63.8±7.6¶ <0.001
Smoking (%) 20.8 19.9 15.1 13.6 0.373
SBP (mmHg) 129.0±20.8 138.1±19.7¶ 146.6±21.5¶ 155.6±22.2¶ <0.001
DBP (mmHg) 79.7±9.8 83.3±8.4¶ 85.7±9.4¶ 85.6±8.2¶ <0.001
BMI (kg/m2) 25.6±4.3 27.4±4.7¶ 28.9±4.9¶ 30.6±4.5¶ <0.001
Total cholesterol (mmol/l) 5.6±0.9 5.8±0.9 5.8±0.9 5.5±1.0 0.053
LDL cholesterol (mmol/l) 3.3±0.8 3.5±0.9 3.5±0.8 3.3±0.9 0.078
HDL cholesterol (mmol/l) 1.8±0.4 1.7±0.4 1.6±0.4¶ 1.4±0.3¶ <0.001
Triglycerides (mmol/l) 1.1±0.5 1.3±0.6¶ 1.5±0.7¶ 1.8±0.7¶ <0.001
Fasting glucose (mmol/l) 5.1±0.3 5.9±0.3¶ 5.7±0.5¶ 7.3±2.2¶ <0.001
2 h glucose (mmol/l) 5.6±1.1 6.1±1.0¶ 9.0±0.8¶ 14.1±4.0¶ <0.001
Hs-CRP 2.4±4.2 2.3±2.4 5.0±6.8¶ 4.5±4.5¶ <0.001
Antihypertensive med (%) 17.5 29.5 40.3 69.5 <0.001
Statins (%) 6.7 9.7 13.4 23.7 <0.001
Previous CVD (%) 5.4 11.9 12.6 15.3 0.006
CIMT (mm) 0.852±0.175 0.923±0.226§ 0.957±0.227¶ 0.998±0.255¶ <0.001
YEM (mmHg) 5824±3757 6487±3772 7577±4144§ 10424±7142¶ <0.001
SI 3.56±0.46 3.65±0.44 3.75±0.47§ 3.92±0.47¶ <0.001
CAC (%/10 mmHg) 1.10±0.58 0.89±0.39¶ 0.78±0.43¶ 0.61±0.32¶ <0.001
Values are unadjusted means + SD except the prevalence rates which are expressed as %.
a = Variation in n is caused by some missing data. NGT= normal glucose tolerance, IFG= impaired fasting glucose, IGT= 
impaired glucose tolerance, T2DM= type 2 diabetes, SBP= systolic blood pressure, DBP= diastolic blood pressure, BMI= 
body mass index, 2 h glucose= plasma glucose 2 h after glucose load in oral glucose tolerance test, hs-CRP= high sensitivity 
C-reactive protein, antihypertensive med= % of  subjects using antihypertensive medication, statins= % of  subjects using 
statins, previous CVD=  % of  subjects with previous knowledge of  coronary heart disease, stroke, or arterial stenosis, or 
thrombosis in a lower limb, YEM = Young’s elastic modulus, SI = beta stiffness index, CAC = carotid artery compliance.
*p <0.05, §p < 0.01, ¶p <0.001, pairwise comparison with the NGT group; Dunnett’s T3 correction for multiple comparisons 
in ANOVA.
signifi cantly lower CAC than the NGT group. 
In both ANCOVA models the change across the 
groups in women appeared to be larger in the 
elasticity indices than in men.
When the second ANCOVA model was 
further adjusted with subjects’ status in regard 
to antihypertensive and statin medications as 
well previous CVD (previous knowledge of  
CHD, stroke, or arterial stenosis or thrombosis 
in a lower limb) the main fi ndings remained 
essentially similar (data not shown). The only 
7exception was that in regard to SI, the ANCOVA 
p value was borderline (p=0.067 vs. p=0.038 in 
the previous model) signifi cant in women.
Discussion 
In the present study, we have shown that the 
extent of  early carotid atherosclerosis differs in 
men and women according to glucose tolerance 
status. Our findings suggest that impairment 
in glucose metabolism might have stronger 
association with early atherosclerosis in women 
than in men. 
A deteriorating trend in CIMT [19,23,24] 
and CAS [12] according to the worsening of  
glucose tolerance has been reported previously. 
We observed this kind of  trend in both sexes after 
the adjustment for age. It has been shown that 
subjects with T2DM [9,10,25] and, to a lesser 
extent, those with IGT [13] have signifi cantly 
increased early carotid atherosclerosis in 
comparison to those with normal glucose 
metabolism. In regard to T2DM our results were 
comparable in both sexes after the adjustment 
for age. With reference to IGT, however, some 
sex-related differences were seen. In women IGT 
was associated with signifi cant deterioration in all 
the parameters in comparison to NGT, while in 
men this was seen only in YEM and CAC. In the 
present study even IFG was related to decreased 
CAC in both sexes and to increased CIMT in 
women after age had been taken into account. 
In a study by van Popele et al., increased CAS 
was reported in subjects with IFG in comparison 
to those with NGT [14].  However, most of  the 
previous studies have not confi rmed this fi nding 
regarding IFG and early carotid atherosclerosis 
[15,16].
After further adjustment for other CVD risk 
factors, the associations of  impaired glucose 
metabolism and early carotid atherosclerosis 
weakened substantially in both sexes. Statistically 
TABLE 3. Carotid artery intima-media thickness (CIMT) and elasticity indices according to glucose tolerance status in 
men and women, adjusted for age.
Glucose tolerance
NGT IFG IGT T2DM ANCOVA
Men n =152-174a n =215-235 a n =97-104 a n =59-66 a p-value
CIMT (mm) 0.953±0.016 0.953±0.014 0.969±0.021 1.083±0.026¶ <0.001
YEM (mmHg) 6589±437 7191±371 8397±549* 9032±709§ 0.007
SI 3.59±0.04 3.65±0.03 3.66±0.05 3.79±0.06§ 0.045
CAC (%/10 mmHg) 0.98±0.03 0.88±0.03* 0.86±0.04* 0.76±0.05¶ 0.002
Women n=336-371 a n=160-176 a n=105-119 a n=49-59 a
CIMT (mm) 0.875±0.009 0.918±0.014§ 0.930±0.017§ 0.928±0.024* 0.005
YEM (mmHg) 6043±223 6433±320 7257±398§ 9782±586¶ <0.001
SI 3.59±0.02 3.64±0.03 3.70±0.04* 3.83±0.06¶ 0.001
CAC (%/10 mmHg) 1.06±0.03 0.90±0.04¶ 0.84±0.05¶ 0.73±0.07¶ <0.001
Values are age-adjusted means ± SE. a = variation in n is caused by missing elasticity data for some subjects. NGT= normal 
glucose tolerance, IFG= impaired fasting glucose, IGT= impaired glucose tolerance, T2DM= type 2 diabetes, YEM = 
Young’s elastic modulus, SI = beta stiffness index, CAC = carotid artery compliance.
*p <0.05, §p < 0.01, ¶p <0.001, pair wise comparison with the NGT group; Fisher’s least signifi cant difference test was used if  
a signifi cant ANCOVA p value for glucose tolerance was observed.
8signifi cant differences between the groups were 
seen only in women after these adjustments. 
In women, a trend of  worsening carotid artery 
elasticity across the glucose tolerance categories 
(with signifi cant ANCOVA p values) was seen 
even in this model. In the T2DM group all 
the elasticity indices were significantly worse 
compared to the NGT group and even the IFG 
group had significantly lower CAC than the 
NGT group. The weakening of  the observed 
associations after adjusting for CVD risk factors 
leads to the conclusion that these associations 
are partly mediated by the overall risk factor 
profi le. There was indeed a gradual deterioration 
especially in the metabolic risk factors across the 
glucose tolerance groups (Tables 1 and 2). 
The amount of  studies reporting the results 
separately for men and women has been limited 
concerning the association of  glucose tolerance 
and early carotid atherosclerosis. In a study 
TABLE 4. Carotid artery intima-media thickness (CIMT) and elasticity indices according to glucose tolerance status in 
men and women, adjusted for age and other cardiovascular risk factors
Glucose tolerance
NGT IFG IGT T2DM ANCOVA
Men n =149-171a n =213-233 a n =94-100 a n =51-57 a p-value
CIMT (mm) 0.972±0.017 0.965±0.014 0.978±0.022 1.046±0.031 0.101
YEM (mmHg) 6969±457 7062±381 7969±567 8222±783 0.317
SI 3.59±0.04 3.64±0.03 3.64±0.05 3.72±0.07 0.461
CAC (%/10 mmHg) 0.95±0.03 0.89±0.03 0.90±0.04 0.88±0.06 0.587
Women n=335-369 a n=157-173 a n=103-117 a n=48-58 a
CIMT (mm) 0.899±0.011 0.927±0.014 0.923±0.018 0.905±0.026 0.341
YEM (mmHg) 6260±247 6172±321 6448±404 9042±593¶ <0.001
SI 3.59±0.03 3.62±0.04 3.66±0.05 3.80±0.07§ 0.038
CAC (%/10 mmHg) 1.03±0.03 0.93±0.04* 0.94±0.05 0.84±0.07* 0.031
Values are adjusted means ± SE. Adjustments for age, smoking, LDL cholesterol, BMI, SBP, triglycerides, and HDL 
cholesterol. a = variation in n is caused by missing elasticity data in some subjects. There were also few missing covariate 
values. BMI= body mass index, SBP= systolic blood pressure, NGT= normal glucose tolerance, IFG= impaired fasting 
glucose, IGT= impaired glucose tolerance, T2DM= type 2 diabetes, YEM = Young’s elastic modulus, SI = beta stiffness 
index, CAC = carotid artery compliance. 
*p <0.05, §p < 0.01, ¶p <0.001, pair wise comparison with the NGT group; Fisher’s least signifi cant difference test was used if  
a signifi cant ANCOVA p value for glucose tolerance was observed.
by Kawamoto et al., T2DM had a stronger 
association with increased CIMT in women than 
in men [18]. On the other hand, other studies 
have not confi rmed this observation [10,26,27]. 
In these studies, however, only subjects with NGT 
or T2DM were included. Two studies evaluated 
the association between glucose tolerance and 
CIMT in subjects with NGT, IGT or T2DM and 
no signifi cant sex-related differences were found 
[9,19]. In a study by Salomaa et al. fasting blood 
glucose had a stronger association with carotid 
artery elasticity in women than in men [11]. On 
the other hand, no sex-related differences were 
observed in two other studies investigating the 
association of  glucose tolerance and stiffness of  
the carotid arteries [12,14]. These studies by van 
Popele et al. [14] and Henry et al. [12] included 
subjects with NGT, IFG or T2DM and NGT, 
impaired glucose metabolism (i.e. IFG or IGT) 
or T2DM, respectively. All in all, previous results 
9regarding sex-related differences are limited and 
somewhat controversial. Our results support 
the hypothesis that there might be a stronger 
association between glucose intolerance and early 
carotid atherosclerosis in women than in men, 
particularly in relation to carotid artery elasticity.
Although it is beyond the scope of  this 
investigation to evaluate the exact mechanisms 
behind the observed sex-related differences, 
we may speculate some possible explanations. 
Menopause and oestrogenic status are possible 
and commonly suggested mediators for sex-
related differences in cardiovascular risk. Women 
in the present study were mostly postmenopausal 
and it is reasonable to speculate that it might have 
increased their vulnerability to such risk factors 
as glucose intolerance and T2DM. It has also 
been shown that the deteriorating tendency in 
other cardiovascular risk factors such as central 
obesity, adverse lipid profi le, and hypertension 
is stronger in diabetic women than in their 
male counterparts [28]. These risk factors are 
associated with insulin resistance, which has 
also been associated with early atherosclerotic 
changes [29].  It has been suggested that 
insulin resistance is the key element in reversing 
the usually favourable female risk profile in 
diabetic women [28]. These previous reports 
are in agreement with our observation that the 
association between glucose tolerance and early 
carotid atherosclerosis was markedly weakened 
after the adjustments for metabolic and other 
CVD risk factors, although this phenomenon was 
seen in both sexes.
There are some limitations to the present 
study. Our study was cross-sectional, and the 
causality of  the associations cannot be assessed. 
Our population consisted of  middle-aged and 
elderly Caucasians, and the results may not apply 
to other ethnicities. On the other hand, as the 
female subjects were primarily post menopausal 
in the present study, the oestrogen status is not 
a major confounding factor when possible sex 
differences are analysed. Although the size of  the 
overall population was quite large, the subgroups 
of  different stages of  glucose intolerance were 
substantially smaller. The results were, however, 
logical and consistent across the glucose tolerance 
groups.
In conclusion, our results suggest that women 
with glucose intolerance may be at greater risk for 
early atherosclerotic changes than men. There is 
a trend towards increasing carotid atherosclerosis 
with the worsening of  glucose tolerance in 
both sexes. Overall, a deteriorated CVD risk 
factor profi le in subjects with impaired glucose 
metabolism plays an important role in mediating 
the observed associations.
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